Novel benzamide derivative compound and pharmaceutical composition comprising same

A novel benzamide derivative compound addresses the need for effective NAMPT inhibitors by targeting NAMPT to treat NAMPT-related diseases like cancer, showcasing high cytotoxicity and favorable pharmacokinetics.

WO2024246764A1PCT designated stage expired Publication Date: 2024-12-05SAMJIN PHARMA CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/055205
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-30
Filing Date
2024-05-29
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current treatments for diseases related to Nicotinamide phosphoribosyltransferase (NAMPT) lack effective inhibitors, particularly for cancer, where NAMPT plays a crucial role in NAD+ synthesis and is involved in various signaling pathways.

Method used

Development of a novel benzamide derivative compound with specific structural features that inhibit NAMPT, offering a pharmaceutical composition for preventing or treating NAMPT-related diseases such as cancer by administering the compound.

Benefits of technology

The benzamide derivative effectively inhibits NAMPT, demonstrating high cytotoxicity against cancer cells at low concentrations with minimal side effects and excellent pharmacokinetic properties, capable of lowering NAD+ levels in cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000004_0001
    Figure IMGF000004_0001
  • Figure IMGF000009_0001
    Figure IMGF000009_0001
  • Figure IMGF000010_0001
    Figure IMGF000010_0001
Patent Text Reader

Abstract

The present invention relates to a novel benzimide compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof. The novel compound exhibits NAMPT inhibitory activity, can exhibit a preventive or therapeutic effect on diseases that can be treated by inhibiting NAMPT, and can effectively prevent or treat cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]

specification

[0002]

Title of invention

Technical field

[0003]

Technology underlying the invention

[0004] Nicotinamide phosphoribosyl transferase (NAMPT) catalyzes the synthesis of nicotinamide mononucleotide (NMN) from nicotinamide (NAM) and 5' phosphoribosyl-1'-pyrophosphate (PRPP), playing a key role in the cyclic biosynthetic pathway of NAD+ (nicotinamide adenine dinucleotide). NAD is essential for several signaling pathways, including mono-ADP-ribosylation in both the immune system and G-protein-coupled receptor signaling, among other poly-ADP-ribosylation in DNA repair, and NAD is also essential for the deacetylase activity of sirtuins.

[0005] NAD+ is produced by two distinct biosynthetic pathways: the salvage and de novo synthesis pathways. As the rate-limiting enzyme in the NAD+ salvage pathway, NAMPT is biologically essential and may be associated with numerous diverse diseases. Therefore, the development of drugs that more effectively inhibit NAMPT is urgently needed. [Prior Art Literature]

[0006] Patent Document: Republic of Korea Patent Application Publication No. 10-2015-0014250

[0007]

Contents of the invention

[0008]

Problem to be solved

[0009]

Means for Solving the Problem

[0010] 1) The present invention provides a benzamide compound represented by the following Chemical Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof.

[0011] <Chemical Formula 1> In the above Chemical Formula I, R1 is aryl having 6 to 14 members, C2-C8 heterocycloalkenyl or heteroaryl having 5 to 12 members, and one or more of the R1 may be substituted with halogen (F, Cl, Br, or I), -NRaRb, -NO2 or -OH.

[0012] [[ID=ll]]L1 is C1-C6 alkylene.

[0013] L2 is a single bond or C2-C6 alkynylene, and R2 is arylene having 6 to 14 members, C2-C8 heterocycloalkenylene or heteroaryl having 5 to 12 members, and one or more of the R2 may be substituted with Cl-C6 alkyl, CF3, halogen (F, Cl, Br or I), C1-C6 alkoxy, or OH, and -CH2- of the R2 may be substituted with -(C=O)-. Specifically, one or more of the arylene having 6 to 14 members or C2-C8 heterocycloalkenylene of the R2 may be substituted with C1-C6 alkyl, CF3, halogen (F, Cl, Br, or I), C1-C6 alkoxy, or OH, and one or more of -CH2- of the C2-C8 heterocycloalkenylene of the R2 may be independently substituted with -(C=O)-.

[0014] L3 is a single bond, C1-C6 alkylene, C2-C6 alkenylene, C=0, (C=O)NRc, (C=O)NRd- (C1-C6 alkylene), Nry(C=0)-(Cl-C6 alkylene), or 0(C=0)-(Cl- C6 alkylene),

[0015] R2 is H, halogen (F, Cl, Br or I), C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C1-C8 heterocycloalkyl, - NRZIRZ2, 6-14 membered aryl or 5-12 membered heteroaryl, and one or more of R2 may be substituted with C1-C6 alkyl, C1-C6 alkoxy, OH, COOH, (C1-C6 alkylene)- NreRf, NRgRh, NO2, CF3, (C=O)NriRj or halogen (F, Cl, Br, or I), lx is a single bond, C1-C6 alkylene, - NRm-(Cl- C6 alkylene)- or NRn, R3 is H, C1-C6 alkyl, C3-C8 cycloalkyl, 6- to 14-membered aryl, C1-C8 heterocycloalkyl, C2-C8 heterocycloalkenyl, 5- to 12-membered heteroaryl,

[0016] 6 to 14-membered arylene-Cl-C8 heterocycloalkyl, 6 to 14-membered arylene-5 to 12-membered heteroaryl, 5 to 12-membered heteroarylene-6 to 14-membered aryl,

[0017] 5 to 12 membered heteroarylene-Cl- C8 heterocycloalkyl or 5 to 12 membered heteroarylene- 5 to 12 membered heteroaryl, and at least one of R3 is C1-C6 alkyl, C1-C6 alkoxy, phenoxy, OH, (C1-

[0018] C6 alkylene)- OH, COOH, (C1-C6 alkylene)- COOH, (C1-C6 alkylene)- CN, NroRp, (C1-C6 alkylene) -NRqRr, (C=0)-(Cl- C6 alkyl), (C=0)-(C3-C8 cycloalkyl), (C=0)-(6- to 14-membered aryl), 6- to 14-membered aryl, 6- to 14-membered heteroaryl, 6- to 14-membered heterocycloaryl, (C=O)NRsRt which may be substituted with halogen,

[0019] (C=O)-(C1-C6 alkylene)- NruRv, NRwRx, (C=0)0- (Cl- C6 alkyl), N02, CHF2, CF3, 0CF3 or halogen (F, Cl, Br, or I) may be substituted, and at least one - CH2 - of the heterocycloalkenyl of R3 may be substituted with - (C=0)-, and Ra to Rj, Rm to Ry, Rzi and Rz2 may each independently be H or C1-C6 alkyl in each case. For example, Ra, Rb, Rc, Rd, Re, Rf,

[0020] Rg, Rh, Ri, Rj, Rm, Rn, Ro, Rp, Rq, Rr, Rs, Rt, Ru, Rv, Rw, Rx, Ry, Rzi and

[0021] RZ2 can be independently H or C1-C6 alkyl in each case. In the present invention, the term “Cm-Cn” (wherein m and n are each independently an integer greater than or equal to 1) means the number of carbons, for example, “C1-C5 alkyl” means alkyl having 1 to 5 carbons. In the present invention, “substitution” or “substituted with” is defined to include the implicit condition that such substitution depends on the allowable valency of the substituted atom and the substituent, and that the substitution leads to a stable compound, for example, a compound that does not undergo spontaneous modification by rearrangement, cyclization, elimination, etc. In the present invention, “single bond” means a case where adjacent atoms or groups of atoms are directly bonded. In the present invention, “alkyl” means a linear (or straight-chain) saturated hydrocarbon group or a branched (or side-chain) saturated hydrocarbon group, unless otherwise specified. Examples of alkyl include, but are not limited to, one or more selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and n-heptyl, etc. In the present invention, unless otherwise stated, “alkylene” means a divalent functional group derived from alkyl defined as above, and includes, but is not limited to, one or more selected from methylene, ethylene, n-propylene, isopropylene, n-butylene, sec-butylene, isobutylene, tert-butylene, n-pentylene, n-hexylene, and n-heptylene, etc. In the present invention, unless otherwise stated, “alkynylene” means, unless otherwise stated, a divalent functional group derived from alkynyl containing at least one carbon-carbon triple bond in the alkyl. Examples of alkynylene include:

[0022] 4 1— or at least one — I 으- containing hydrocarbons, etc., but are not limited thereto. In the present invention, “alkenyl” means an unsaturated hydrocarbon group including at least one carbon-carbon double bond in the alkyl, unless otherwise specified. In the present invention, “alkenylene” means a divalent functional group derived from the alkenyl defined as above, unless otherwise specified. In the present invention, “alkoxy” means a monovalent group derived from a straight or branched saturated hydrocarbon moiety represented by 0CnH2n+l, unless otherwise specified. Examples of alkoxy include, but are not limited to, one or more selected from methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, and hexoxy. In the present invention, unless otherwise specified, “cycloalkyl” means a saturated hydrocarbon ring having 3 or more carbon atoms, and the saturated hydrocarbon ring includes both monocyclic and polycyclic structures. In addition, it includes both bicyclic structures such as a bridged ring or a spiro structure. Examples of cycloalkyl include, but are not limited to, one or more selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, decahydronaphthalenyl, spiro[4.4]nonanyl, spiro[3.3]heptanyl, bicyclo[3.1.dihexanyl, bicyclo[3.1.1]heptanyl, and bicyclo[2.2.1]heptanyl. In the present invention, unless otherwise specified, “cycloalkenyl” means a cyclic group including at least one carbon-carbon double bond in the cycloalkyl, and the cycloalkenyl is not an aromatic ring.Examples of cycloalkenyl include, but are not limited to, one or more selected from cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. In the present invention, unless otherwise specified, “heterocycloalkyl” means a cyclic group in which at least one carbon atom forming a ring in the cycloalkyl is independently substituted with a heteroatom or functional group selected from the group consisting of N, 0, S, S0, and S02. Examples of heterocycloalkyl include oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiophenyl, oxepanyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, azetidinyl, and aziridinyl. One or more selected from the group consisting of, but not limited to, "heterocycloalkenyl" in the present invention, unless otherwise stated, means a cyclic group in which at least one carbon atom forming the ring in the cycloalkenyl is independently substituted with a heteroatom or functional group selected from the group consisting of N, 0, S, SO and S(》, and heterocycloalkenyl is an aromatic

[0023]

[0024] One or more kinds may be mentioned, but are not limited thereto. In the present invention, “heterocycloalkenylene” means a divalent functional group derived from heterocycloalkenyl as defined above, unless otherwise stated. In the present invention, “aryl” means a monocyclic or polycyclic aromatic cyclic group having one or more aromatic rings, which are fused or non-fused, unless otherwise stated. Examples of aryl include one or more kinds selected from phenyl, naphthalenyl, indenyl, and anthracenyl, but are not limited thereto. In the present invention, “arylene” means a divalent functional group derived from aryl as defined above, unless otherwise stated. In the present invention, “heteroaryl” means a monocyclic or polycyclic aromatic heterocycle, which contains at least one heteroatom selected from the group consisting of N, 0, and has one or more aromatic rings, which are fused or non-fused, unless otherwise stated. Examples of heteroaryl include, but are not limited to, one or more selected from thiazolyl, oxazolyl, thiophenyl, furanyl, pyrrolyl, imidazolyl, isooxazolyl, pyrazolyl, triazolyl, thiadiazolyl, tetrazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, benzothiophenyl, benzofuranyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzthiadiazolyl, benztriazolyl, quinolinyl, isoquinolinyl, and purinyl. In the present invention, unless otherwise stated, “heteroarylene” means a divalent functional group derived from heteroaryl as defined above. In the present invention, unless otherwise stated, “halogen” may be F, Cl, Br, or I.In the present invention, when represented by the divalent functional group -AB-, it includes both -AB- and -BA-. For example, the description of the group - (Cl-C6 alkylene)-NRm- can include both the case of X-(C1-C6 alkylene)-NRm-Y and the case of X-NRm-(C1-C6 alkylene)-Y. In the present invention, C can be represented by CO, C=0 or C(=0), etc., and can be represented by =0 or S(=o), etc. 0 whereas the is SO, S is 0 can be represented by S(=)2, S=02, S(=0)2, etc. In addition, the terms and abbreviations used in this specification have their original meanings unless otherwise defined

[0025] 2) According to the embodiments of the present invention, in the above 1), there is provided a benzamide derivative compound represented by the above formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof

[0026] <Formula 1>

[0027] In the above formula I, R is aryl having 6 to 14 members, C2-C8 heterocycloalkenyl containing at least one heteroatom or heterofunctional group selected from the group consisting of N, O, S, S(=0), and S(=0)2, or heteroaryl having 5 to 12 members containing at least one heteroatom selected from the group consisting of N, O, and S. At this time, the inside of Ri may be unsubstituted or each of one or more may be independently substituted with halogen (F, Cl, Br, or I), -NraRb, -NO2 or -OH.

[0028] Li is C1-C6 alkylene, 匕2 is a single bond or C2-C6 alkenylene, 오 is arylene of 6 to 14 members, or C2-C8 heterocycloalkenylene containing at least one heteroatom or hetero functional group selected from the group consisting of N, O, S, 8(=0), and S(=0)2, or heteroarylene of 5 to 12 members containing at least one heteroatom selected from the group consisting of N, O, and 으, wherein one or more of the -보 of X may be substituted with -C1-C6 alkyl, -CF3, -halogen (F, Cl, Br or I), -C1-C6 alkoxy, or -OH, and one or more of the -CH2- of 오 may each independently be substituted with - (C=0)-. Specifically, the 내 of 오 is unsubstituted, or when X is arylene of 6 to 14 members or C2-C8 heterocycloalkenylene, one or more of the 내 may each independently be substituted with C1-C6 alkyl, -CFs, halog en (F, Cl, Br or I), -C1-C6 alkoxy, or OH. When X is C2-C8 heterocycloalkenylene, -CH2- is unsubstituted or at least one of the -CH2- may each independently be substituted with - (C=0)-.

[0029] L3 is a single bond, C1-C6 alkylene, C2-C6 alkenylene, -C=0, -C(=O)NRc, -C(=O)NRd-(C1-C6 alkylene), -NRyC(=0)-(Cl-C6 alkylene), -NHC(=O), or -OC(=0)-(Cl-C6 alkylene).

[0030] It should be noted that there may be some inaccuracies in the original text due to unclear or incorrect notations (such as "匕", "육", "으" which are not standard chemical notations). This translation is based on the best understanding of the text with the available information.R2 is H, halogen (F, Cl, Br or I), - NRZ1RZ2, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, N, 0, S, SO and S(》 containing one or more heteroatoms or heterofunctional groups selected from the group consisting of C1-C8 heterocycloalkyl, 6-14 membered aryl or 5-12 membered heteroaryl containing one or more heteroatoms selected from the group consisting of N, 0 and wherein the inside of said R2 is unsubstituted or one or more insides of R2 are each independently - C1-C6 alkyl, -C1-C6 alkoxy, -OH, -COOH, -(C1-C6 alkylene)- NReRf, -NRgRh, -N02, -CF3, -C(=O)NRiRj or halogen (F, Cl, Br or can be replaced with I),

[0031] L4 is a single bond, -C1-C6 alkylene-, -NRm-(Cl-C6 alkylene)-, or -NRn-, wherein the inner part of L4 is unsubstituted or one or more inner parts of L4 may be independently substituted with -C1-C6 alkyl,

[0032] R3 is H, C1-C6 alkyl, C3-C8 cycloalkyl, 6-14 membered aryl, C1-C8 heterocycloalkyl containing one or more heteroatoms or heterofunctional groups selected from the group consisting of N, 0, S, SO and S02, C2-C8 heterocycloalkenyl containing one or more heteroatoms or heterofunctional groups selected from the group consisting of N, 0 and , 5-12 membered heteroaryl containing one or more heteroatoms selected from the group consisting of N, 0 and , 6-14 membered arylene-Cl- C8 heterocycloalkyl (wherein the heterocycloalkyl contains one or more heteroatoms or heterofunctional groups selected from the group consisting of N, 0, S, SO and S02), 6-14 membered arylene- 5-12 membered Heteroaryl (wherein the heteroaryl comprises at least one heteroatom selected from the group consisting of N, 0 and ), 5- to 12-membered heteroarylene-6- to 14-membered aryl (wherein the heteroarylene comprises at least one heteroatom selected from the group consisting of N, 0 and ), 5- to 12-membered heteroarylene-Cl-C8 heterocycloalkyl (wherein the heteroarylene may comprise at least one heteroatom selected from the group consisting of N, 0 and S, and the heterocycloalkyl comprises at least one heteroatom or heterofunctional group selected from the group consisting of N, 0, S, S0 and S(》), or 5- to 12-membered heteroarylene-5- to 12-membered heteroaryl (wherein the heteroarylene or heteroaryl is composed of N, 0 and (containing one or more heteroatoms selected from the group),

[0033] R3 is H, C1-C6 alkyl, C3-C8 cycloalkyl, 6-14 membered aryl, C1-C8 heterocycloalkyl containing one or more heteroatoms or heterofunctional groups selected from the group consisting of N, 0, S, SO and S02, C2-C8 heterocycloalkenyl containing one or more heteroatoms or heterofunctional groups selected from the group consisting of N, 0 and , 5-12 membered heteroaryl containing one or more heteroatoms selected from the group consisting of N, 0 and , 6-14 membered arylene-Cl- C8 heterocycloalkyl (wherein the heterocycloalkyl contains one or more heteroatoms or heterofunctional groups selected from the group consisting of N, 0, S, SO and S02), 6-14 membered arylene- 5-12 membered Heteroaryl (wherein the heteroaryl comprises at least one heteroatom selected from the group consisting of N, 0 and ), 5- to 12-membered heteroarylene-6- to 14-membered aryl (wherein the heteroarylene comprises at least one heteroatom selected from the group consisting of N, 0 and ), 5- to 12-membered heteroarylene-Cl-C8 heterocycloalkyl (wherein the heteroarylene may comprise at least one heteroatom selected from the group consisting of N, 0 and S, and the heterocycloalkyl comprises at least one heteroatom or heterofunctional group selected from the group consisting of N, 0, S, S0 and S02) or 5- to 12-membered heteroarylene-5- to 12-membered heteroaryl (wherein the heteroarylene or heteroaryl is composed of N, 0 and and at least one heteroatom selected from the group consisting of ) and wherein - H of R3 is unsubstituted or one or more of R3 is independently - Cl- C6 alkyl, - Cl- C6 alkoxy, phenoxy, -OH, -(C1-C6 alkylene)- OH, -COOH, -(C1-C6 alkylene)- COOH,(C1-C6 alkylene)-CN, -NRoRp, (C1-C6 alkylene)-NRqRr, - C(=0)-(Cl- C6 alkyl), - C(=0)-(C3- C8 cycloalkyl), - C=(0)-(6- to 14-membered aryl), - NO2, -CHF2, -CFs, - OCF3, 6- to 14-membered aryl, 6- to 14-membered heteroaryl including at least one heteroatom selected from the group consisting of N, 0 and , 6- to 14-membered heterocycloaryl including at least one heteroatom or heterofunctional group selected from the group consisting of N, 0, S, S0 and S02, - C(=O)NRsRt (wherein, the inside of - C(=O)NRsRt is unsubstituted or one or more insides are each independently -C(=O)-(C1-C6 alkylene)- NRuRv, -NRwRx, or can be substituted with halogen (F, Cl, Br or I), and when R3 is heterocycloalkenyl, one or more - CH2 - can be independently substituted with -(C=0)-, and Ra to Rj, Rm to Ry, Rzi and Rz' can each independently be H or C1-C6 alkyl in each case. For example, Ra, Rb, Rc, Rd, Re, Rf , Rg, Rh, Ri , Rj , Rm, Rn, Ro, Rp, Rq, Rr , Rs , Rt , Ru, Rv, Rw, Rx, Ry, Rzi and Rz' can each independently be H or C1-C6 alkyl in each case.

[0034] 3) According to embodiments of the present invention, in 1) or 2), Ri is unsubstituted or one or more independently selected from the group consisting of halogens (F, Cl, Br, or

[0035] I), -NRaRb, -N02 or - 0H, wherein Ra and Rb can each independently be -H or Cl- C6 alkyl, and specifically, the - of Ri may be unsubstituted or one or more of the - of Ri may each independently be substituted with halogen (F, C1, Br, or I), - NH2, - NO2, -NHCHs, - N(CH3)2 or -OH.

[0036] 4) According to embodiments of the present invention, in the above 1) to 3), Li is C1-C6 alkylene, and specifically, may be methylene (- CH『 ), ethylene (- CH2CH2- ), n-propylene (- CH2CH2CH2- ), isopropylene (- CHCH3 CH2 ), n-butylene (- CH2CH2CH2CH2- ), sec-butylene (- CHCH3CH2CH2- ), isobutylene (- CH2CHCH3CH2- ), tert-butylene (-CCH3CH3CH2-), n-pentylene (- CH2CH2CH2CH2CH2- ), or n-hexylene (- CH2CH2CH2CH2CH2CH2CH2- ), and specifically, may be methylene (- CH『 ), ethylene (- CH2CH2- ), It can be n-propylene (- CH2CH2CH2-), isopropylene (- CHCH3 CH2), n-butylene (- CH2CH2CH2CH2-), n-pentylene (- CH2CH2CH2CH2CH2-), or n-hexylene (- CH2CH2CH2CH2CH2CH2-).

[0037] 5) According to embodiments of the present invention, in 1) to 4, L2 may be a single bond or C2-C5 alkenylene, and specifically, L' is a single bond.

[0038] . . . . . . or ethynylene (ethynylnene, le s ) may be.

[0039] 6) According to the embodiments of the present invention, in the above 1) to 5), the coming

[0040] may be. At this time, the interior of the coming may not be substituted or one or more of the interiors may each independently be substituted with C1-C6 alkyl, halogen (F, Br, Cl, or I), -OH, -C1-C6 alkoxy, or -CF3, and the -CH2- of the coming may not be substituted or at least one or more of the -CH2- may each independently be substituted with - (C=0)-, specifically when the coming is in the case, the interior may not be substituted or one or more of the interiors may each independently be substituted with C1-C6 alkyl, halogen (F, Br, Cl, or I), -C1-C6 alkoxy,

[0041] -OH, or -CF3, and when the coming is in the case, -〔blood - may not be substituted or at least one or more of the -〔blood - may each independently be substituted with - (C=0)-.

[0042] 7) According to embodiments of the present invention, in 1) to 6), L3 may be a single bond, C1-C6 alkylene, C2-C6 alkenylene, - (C=0)-, - (C=0)- NRc-, - C(=O)NRd- (Cl- C6 alkylene)-, -NRyC(=0)-(Cl- C6 alkylene), -NHC(=O), or - 0(C=0)- (Cl- C6 alkylene), wherein Rc, Rd or Ry may each independently be - H or C1- C6 alkyl. Specifically, L3 can be a single bond, - (CH2)- , - (CH2)2- , -(CH2)S - , - (CH2)4 - , -(CH2)5 - , -(C=0)-NH(CH2)n, -NH(C=0)-, -NH(C=0)-(CH2)m, -(C=O)NH-, - (CH=CH)- CH2- , -0(C=0)CH2- or - (C=0)-, wherein n and m can each independently be 1, 2, 3 or 4.

[0043] 8) According to embodiments of the present invention, in 1) to 7), R2 is

[0044] H, halogen (F, Cl, Br or I), C1-C6 alkyl, C1-C6 alkoxy, -OH, -NH2, When the R2 is unsubstituted or one or more of the R2 can be independently substituted with halogen (F, Cl, Br or I), -C1-C6 alkoxy, -NH2, -OH, -CF3, -N02, - C1-C6 alkyl, -(CH2)2-NH2, -(CH2)3-NH2, -(CH2)-NH2, - (C=0)NH2, -NHCHS, -NHCH(CH3)2, or - COOH. 9) According to embodiments of the present invention, in 1) to 8), the L4 is a single bond, -C1-C6 alkylene-, -NRm-(Cl-C6 alkylene)-, or -NRn-, wherein, Rm and Rn can each independently be -H or Cl-C6 alkyl. Specifically, L4 may be a single bond, - (CH2)- , - (CH2)2- , -(CH2)3 - , - (CH2)4- , - (CH2)5- , ~NH- , -NHCH2- , - NH(CH2)2- , - NH(CH2)3- , -CH(CHs)- , - CH2NH- , -(CH2)2NH- , or - (CHJH- . In this case, the inner portion of L4 may be unsubstituted or at least one inner portion of L4 may be independently substituted with -C1-C6 alkyl.

[0045] 10) According to embodiments of the present invention, in 1) to 9), R3 is

[0046] Or it may be, in which case the inner of R3 is not substituted or

[0047] One or more of R3 are independently selected from -C1-C6 alkyl, -C1-C6 alkoxy, -phenoxy, -

[0048] OH, -(C1-C6 alkylene)- OH, -COOH, -(C1-C6 alkylene)- COOH, -(C1-C6 alkylene) - CN, - NRoRp, (C1-C6 alkylene)- NRqRr, - C(=0)-(Cl- C6 alkyl), - C(=0)-(C3- C8 cycloalkyl), - C=(0)-(6- to 14-membered aryl), - NO2, -CHF2, -CF3, - OCF3, -

[0049] C(=O)NRsRt (wherein, - C(=O)NRsRt may be unsubstituted or one or more of which may be independently substituted with halogen (F, Cl, Br or I)), -C(=O)-(C1-C6 alkylene)- NRuRv, -NRwRx, or may be substituted with halogen (F, Cl, Br or I), and when R3 is heterocycloalkenyl, CH2 - may be unsubstituted or at least one - CH2 - may be independently substituted with - (C=0)-, wherein Ro, Rp, Rq, Rr, Rs, Rt, Ru, Rv, Rw or Rx may each independently be H or C1-C6 alkyl in each case. Specifically, the inner side of R3 is unsubstituted or at least one - of R3 is independently -C1-C6 alkyl (e.g., - Ofc, - CH2CH3, - CH2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, etc.), -C1-C6 alkoxy (e.g., -0CH3, -0CH2CH3, -OCH2CH2CH3, -0CH(CH3)2), -phenoxy, -OH, -CH2F, - CHF2, -CF3, - OCF3, halogen (F, Cl, Br or I), _(C=0)0CH2CH3, -(C=0)CH3, -(C=0)CH(CH3)2, -(C=0)CHCH3NH2, -NH 2I -NHCH3, -N(CH3)2, -COOH, -(C=0)NH2, -(C=0)NHCH3, -(C=0)N(CH3)2, -N0 2I- (C=0)NHCH2CF3, -CH(CH3)OH, -CH2(CH3)OH, -CH2CN, -CH(CH3)CN, -C(CH3)CH2CN, - (CH2)2NH2, - (CH2)3NH2, -(CH2)4NH2, -(CH2)2OH, - (CH2)3OH, - is present, and when R3 is phosphorus, - CH2 - may be unsubstituted or at least one -〔血 - may each independently be substituted with - (C=0).

[0050] 11) According to embodiments of the present invention, in the above 1) to 10), the compound represented by the formula I may be represented by the following formula 1-1.

[0051] <Formula 1-1> In the formula 1-1, R1, Li, X, L3, R2, L4, and R3 may be substantially the same as those in the formula I above.

[0052] 12) According to embodiments of the present invention, in the above 1) to 11), the compound represented by the formula I may be represented by the following 1-2.

[0053] <Formula 1-2> In the formula 1-2, Ri, Li, X, L3, R2, L4, and R3 may be substantially the same as those in the formula I above.

[0054] 13) According to embodiments of the present invention, in the above 1) to 12), it is possible to provide a compound represented by the following formula 1-1, its stereoisomers, its pharmaceutically acceptable salts, or its hydrates or solvates:

[0055] <Formula 1-1> In Formula 1-1 above, Ri, Li, X, L3, R2, L4, and R3 may be substantially the same as those in Formula I above. In embodiments of the present invention, in Formula 1-1, 日 may be a 5- to 12-membered heteroaryl containing one or more heteroatoms selected from the group consisting of N, O, and S, and at this time, the inside of Ri may be unsubstituted or one or more bos may each independently be substituted with halogen (F, Cl, Br, I), -NH2, -NHCHS, -N(CH3)2, -N02, or -OH.

[0056] 14) According to embodiments of the present invention, in 1) to 13) above, in Formula 1-1, Ri is

[0057] unsubstituted or one or more bos may each independently be substituted with halogen (F, Cl, Br, or

[0058] I), -NH2, -NO2, -NHCHs, -N(CH3)2, or -OH.

[0059] 15) According to embodiments of the present invention, in the above 1) to 14), Li in the above chemical formula 1-1 may be C1-C6 alkylene, specifically methylene (- CH2-), ethylene (- CH2CH2-), n-propylene (- CH2CH2CH2-), isopropylene (- CHCH3 CH2), n-butylene (- CH2CH2CH2CH2-), sec-butylene (- CHCH3CH2CH2-), isobutylene (- CH2CHCH3CH2-), tert-butylene (-CCH3CH3CH2-), n-pentylene (- CH2CH2CH2CH2CH2-), or n-hexylene (- CH2CH2CH2CH2CH2CH2-), and specifically methylene (- CH『 ), ethylene (- CH2CH2-), n-propylene (- CH2CH2CH2-), isopropylene (- CHCH3 CH2), n-butylene (- CH2CH2CH2CH2-), n-pentylene (- CH2CH2CH2CH2CH2-), or n-hexylene (-

[0060] It can be CH2CH2CH2CH2CH2CH2CH2- ).

[0061] 16) According to embodiments of the present invention, in the above (1) to (15), it may be arylene having 6 to 14 members derived from Formula 1-1, C2-C8 heterocycloalkenylene containing at least one heteroatom or hetero-functional group selected from the group consisting of N, O, S, S(=O), and S(=O)2, or heteroarylene having 5 to 12 members containing at least one heteroatom selected from the group consisting of N, O, and S. At this time, the above-mentioned - may be unsubstituted, or when the above-mentioned - is arylene having 6 to 14 members or C2-C8 heterocycloalkenylene, each of the one or more - may be independently substituted with C1-C6 alkyl, -CF3, halogen (F, Cl, Br, or I), -C1-C6 alkoxy, or OH. When the above-mentioned - is C2-C8 heterocycloalkenylene, - may be unsubstituted or at least one of the - may be independently substituted with - (C=O)-.

[0062] 17) According to embodiments of the present invention, in the above (1) to (16), derived from Formula 1-1 in the above it may be, and at this time, the above-mentioned - may be unsubstituted or each of the one or more - may be independently substituted with C1-C6 alkyl, halogen (F, Br, Cl, or I), -

[0063] OH, -C1-C6 alkoxy, or -CF3. Specifically, when the above-mentioned - is each of the - may be unsubstituted or each of the one or more - may be independently substituted with C1-C6 alkyl, halogen (F, Br, Cl, or I), -C1-C6 alkoxy, -OH, or -CF3.

[0064] 18) According to embodiments of the present invention, in the above (1) to (17), in Formula 1-1, L3 may be a single bond, C1-C6 alkylene, -(C=O)-, or -C(=O)NRd-(C1-C6 alkylene)-, where Rd may be -H or C1-C6 alkyl. Specifically, L3 may be a single bond, -(CH2)-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(C=O)-NH(CH2)n, -(C=O)NH-, or -(C=O)-, where n may be 0, 1, 2, 3, or 4.

[0065] 19) According to embodiments of the present invention, in the above (1) to (18), in Formula 1-1, R2 may be H, halogen (F, Cl, Br, or I), -NRZ1RZ2, C1-C6 alkyl, C1-C6 alkoxy, or a C1-C8 heterocycloalkyl containing one or more heteroatoms or hetero functional groups selected from the group consisting of N, O, S, SO, and S(=O). At this time, the inside of R2 may be unsubstituted, or one or more insides of R2 may each independently be substituted with -C1-C6 alkyl, -C1-C6 alkoxy, -NRgRh, or halogen (F, Cl, Br, or I), where Rg, Rh, RZ1, and RZ2 may each independently be H or C1-C6 alkyl.

[0066] 20) According to embodiments of the present invention, in the above (1) to (19), in Formula 1-1, R2 may be H, halogen (F, Cl, Br, or I), C1-C6 alkyl, C1-C6 alkoxy, -NH2, may be. At this time, the inside of R2 may be unsubstituted, or one or more insides of R2 may each independently be substituted with halogen (F, Cl, Br, or I), -C1-C6 alkoxy, -NH2, or -C1-C6 alkyl.

[0067] 21) According to embodiments of the present invention, in the above (1) to (20), in Chemical Formula 1-1, L4 is a single bond, -C1-C6 alkylene-, -NRm-(C1-C6 alkylene), or -NRn-, and in this case, the inside of L4 is unsubstituted or at least one of the inside of L4 may be independently substituted with -C1-C6 alkyl, where Rm and Rn may each independently be H or C1-C6 alkyl.

[0068] 22) According to embodiments of the present invention, in the above (1) to (21), in Chemical Formula 1-1, L4 may be a single bond, -(CH2)-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -NH-, -NHCH2-, -NH(CH2)2-, -NH(CH2)3-, and in this case, the inside of L4 is unsubstituted or at least one of the inside of L4 may be independently substituted with -C1-C6 alkyl.

[0069] 23) According to embodiments of the present invention, in 1) to 22), in the chemical formula 1-1, R3 is H, C1-C6 alkyl, 6- to 14-membered aryl, 5- to 12-membered heteroaryl including one or more heteroatoms selected from the group consisting of N, 0 and S, 5- to 12-membered heteroarylene-6- to 14-membered aryl (wherein the heteroarylene or heteroaryl includes one or more heteroatoms selected from the group consisting of N, 0 and S), or 5- to 12-membered heteroarylene-5- to 12-membered heteroaryl (wherein the heteroarylene or heteroaryl includes one or more heteroatoms selected from the group consisting of N, 0 and S), wherein the inside of R3 is unsubstituted or one or more of R3 is each independently -C1-C6 alkyl, -C1-C6 alkoxy, - 6-14 membered heteroaryl containing one or more heteroatoms selected from the group consisting of N, 0 and - NRwRx, or halogen (F, Cl, Br or I), wherein Rw and Rx can each independently be H or Cl-C6 alkyl.

[0070] 24) According to embodiments of the present invention, in the above 1) to 23),

[0071] The inner part of R3 is unsubstituted or at least one inner part of R3 is independently -C1-

[0072] C6 alkyl (e.g., -CHs, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, etc.) - Cl-

[0073] C6 alkoxy (e.g., -0CH3, -OCH2CH3, -OCH2CH2CH3, -0CH(CH3)2), -NH 2I - CF3, -

[0074] 、,N、

[0075] II: qv

[0076] OCF3, halogen (F, Cl, Br or I), or ~ can be substituted. 25) According to embodiments of the present invention, in the above 1) to 11), in the embodiments of the present invention, a compound represented by the following chemical formula 1-2, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof can be provided:

[0077] <Chemical Formula 1-2> In the above chemical formula 1-2, Ri, Li, X, L3, R2, L4, and R3 may be substantially the same as in the chemical formula I above.

[0078] 26) According to embodiments of the present invention, in the above 1) to 11) and 25), Ri in the above chemical formula 1-2 may be a 5- to 12-membered heteroaryl including one or more heteroatoms selected from the group consisting of N, 0 and S, and in this case,

[0079] Ri is unsubstituted or one or more of the halogens are independently selected from the group consisting of F, C1,

[0080] Br, I), -NH2, -NHCHS, -N(CH3)2, -N02 or -OH.

[0081] 27) According to embodiments of the present invention, in 1) to 11), 25) and 26)

[0082] ,、-

[0083] NH In the chemical formula 1-2, Ri is or There is. At this time, the inner part of the above day is not substituted or one or more of the elements are independently halogen (F, Cl, Br, or I), - NH2, -N02, - NHCH3, -

[0084] It can be substituted with N(CH3)2 or -0H.

[0085] 28) According to embodiments of the present invention, in the above 1) to 11) and 25) to 27), Li in the above chemical formula 1-2 may be C1-C6 alkylene, specifically, methylene (- CH2-), ethylene (- CH2CH2-), n-propylene (- CH2CH2CH2-), isopropylene (- CHCH3 CH2), n-butylene (- CH2CH2CH2CH2-), sec-butylene (- CHCH3CH2CH2-), isobutylene (- CH2CHCH3CH2-), tert-butylene (-CCH3CH3CH2-), n-pentylene (- CH2CH2CH2CH2CH2-), or n~ hexylene (- CH2CH2CH2CH2CH2CH2-), and specifically, Methylene (- CH2- ), ethylene (- CH2CH2- ), n-propylene (- CH2CH2CH2- ), isopropylene (- CHCH3 CH2), n-butylene (- CH2CH2CH2CH2- ), n-pentylene (- CH2CH2CH2CH2CH2- ), or n-hexylene (-

[0086] It can be CH2CH2CH2CH2CH2CH2CH2- ).

[0087] 29) According to embodiments of the present invention, in the above 1) to 11) and 25) to 28), in the above chemical formula 1-2, X may be a C2-C8 heterocycloalkenylene including one or more heteroatoms or heterofunctional groups selected from the group consisting of N, 0, S, 8(=0), and S(=0)2, or a 5- to 12-membered heteroarylene including one or more heteroatoms selected from the group consisting of N, 0, and wherein the inner ring is unsubstituted, or when the X is C2-C8 heterocycloalkenylene, one or more inner rings may be independently substituted with C1-C6 alkyl, -CFs, halogen (F, Cl, Br, or I), -C1-C6 alkoxy, or 0H, and when the X is C2-C8 heterocycloalkenylene, - CH2 - may be unsubstituted or at least one - CH2 - may be independently substituted with - (C=0)-.

[0088] 30) According to embodiments of the present invention, in 1) to 11) and 25) to 29), in the chemical formula 1-2, the and in this case, the inner part of the above is unsubstituted or one or more inner parts are each independently C1-C6 alkyl, halogen (F,

[0089] Br, Cl, or I), -OH, -C1-C6 alkoxy, or - CF3, which may be substituted with the above five In case, - CH2 - is unsubstituted or at least one

[0090] - CH2 - can be independently substituted with - (C=0)-

[0091] 31) According to embodiments of the present invention, in 1) to 11) and 25) to 30), L3 in the chemical formula 1-2 may be a single bond or C1-C6 alkylene, and specifically, L3 may be a single bond, - (CH2)-, - (CH2)2-, - (CH2)3-, - (CH2)4-, or - (CH2)5-.

[0092] 32) According to embodiments of the present invention, in 1) to 11) and 25) to 31), in the chemical formula 1-2, R2 may be H, halogen (F, Cl, Br or I), -NRZIRZ2, or 6- to 14-membered aryl, wherein the inside of R2 may be unsubstituted or one or more insides of R2 may be independently substituted with -C1-C6 alkyl, -C1-C6 alkoxy, -NRgRh, or halogen (F, Cl, Br or I), wherein in this, Rg, Rh, Rzi and RZ2 may each independently be H or Cl-C6 alkyl.

[0093] 33) According to embodiments of the present invention, in 1) to 11) and 25) to 32), in the chemical formula 1-2, R2 is H, halogen (F, Cl, Br or I), -NH2, Or it can be. At this time, the inner part of R2 is unsubstituted or one or more - of R2 can be independently substituted with halogen (F, Cl, Br or I), -C1-C6 alkoxy, - NH2, or -C1-C6 alkyl.

[0094] 34) According to embodiments of the present invention, in 1) to 11) and 25) to 32), L4 in the chemical formula 1-2 is a single bond, -Cl- C6 alkylene-, and at this time, the inside of L4 may be unsubstituted or one or more insides of L4 may be independently substituted with -C1-C6 alkyl.

[0095] 35) According to embodiments of the present invention, in the above 1) to 11) and 25) to 33), in Formula 1-2, L4 may be a single bond, -(CH2)-, -(CH2)2-, -(CH2)3-, -(CH2)4-, or -(CH2)5-, and at this time, the -H of L4 is unsubstituted or at least one -H of L4 may be independently substituted with -C1-C6 alkyl respectively. 36) According to embodiments of the present invention, in the above 1) to 11) and 25) to 34), in Formula 1-2, R3 may be a 5- to 12-membered heteroaryl containing at least one heteroatom selected from the group consisting of N, O, and S, and at this time, the -H of R3 is unsubstituted or one or more -H of R3 may be independently substituted with -C1-C6 alkyl, -C1-C6 alkoxy, or halogen (F, Cl, Br, or I) respectively.

[0096] 37) According to embodiments of the present invention, in the above 1) to 11) and 25) to 35)

[0097] ...N

[0098] ’Y "[MH wherein, in Formula 1-2, R3 is — J and at this time

[0099] the -H of R3 is unsubstituted or at least one -H of R3 may be independently substituted with -C1-C6 alkyl (e.g., -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, etc.), -C1-C6 alkoxy (e.g., -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2), or halogen (F, Cl, Br, or I) respectively.

[0100] 38) According to embodiments of the present invention, in 1) to 37), the present invention provides a compound described in Table 1 below, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

[0101] [Table 1]

[0102]

[0103]

[0104]

[0105]

[0106]

[0107]

[0108]

[0109]

[0110]

[0111]

[0112]

[0113]

[0114] 39) According to embodiments of the present invention, in 1 to 38), the benzamide compound represented by the chemical formula I of the present invention, the benzamide compound represented by the chemical formula 1-1, the benzamide compound represented by the chemical formula 1-2, the benzamide compounds 1 to 249 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof exhibit NAMPT inhibitory activity.

[0115] 40) According to embodiments of the present invention, in 1 to 39), the benzamide compound represented by the chemical formula I of the present invention, the benzamide compound represented by the chemical formula 1-1, the benzamide compound represented by the chemical formula 1-2, the benzamide compounds 1 to 249 of Table 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof can effectively inhibit NAMPT at a low concentration, and can effectively prevent or treat a disease that can be treated by inhibiting NAMPT.

[0116] 41) According to embodiments of the present invention, in 1 to 40), the benzamide compound represented by the chemical formula I of the present invention, the benzamide compound represented by the chemical formula 1-1, the benzamide compound represented by the chemical formula 1-2, the benzamide compounds 1 to 249 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof can sufficiently lower the NAD concentration in cells.

[0117] 42) According to embodiments of the present invention, in 1 to 41), the benzamide compound represented by the chemical formula I of the present invention, the benzamide compound represented by the chemical formula 1-1, the benzamide compound represented by the chemical formula 1-2, the benzamide compounds 1 to 249 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof exhibit high cytotoxicity against cancer cells and can sufficiently kill cancer cells at low concentrations.

[0118] 43) According to embodiments of the present invention, in 1 to 42, the benzamide compound represented by the chemical formula I of the present invention, the benzamide compound represented by the chemical formula 1-1, the benzamide compound represented by the chemical formula 1-2, the benzamide compounds 1 to 249 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof exhibit high cytotoxicity against gastric cancer cells or colon cancer cells, and can sufficiently kill gastric cancer cells or colon cancer cells at low concentrations.

[0119] 44) According to embodiments of the present invention, in 1 to 43), the benzamide compound represented by the chemical formula I of the present invention, the benzamide compound represented by the chemical formula 1-1, the benzamide compound represented by the chemical formula 1-2, the benzamide compounds 1 to 249 of Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof may have little or no side effects and exhibit excellent pharmacodynamic properties. For example, the benzamide compound represented by the above chemical formula I, the benzamide compound represented by the above chemical formula 1-1, the benzamide compound represented by the above chemical formula 1-2, the benzamide compounds 1 to 249 of the above Table 1, their stereoisomers, their pharmaceutically acceptable salts or their hydrates or solvates can exhibit excellent absorption rates (e.g., high bioavailability), can be appropriately distributed to each tissue upon administration and can exhibit a desired pharmacological effect (e.g., a preventive or therapeutic effect for a disease that can be treated by inhibiting NAMPT) in each tissue, and can be effectively metabolized in the body. In the present invention, "stereoisomer" includes diastereomers and optical isomers, and optical isomers include not only enantiomers but also mixtures of enantiomers and racemates. In the present invention, “pharmaceutically acceptable” may mean physiologically acceptable and not typically causing allergic reactions such as gastrointestinal upset or dizziness or similar reactions when administered to a subject.

[0120] 45) According to embodiments of the present invention, in the above 1 to 44), in the present invention, “pharmaceutically acceptable salt” means a salt commonly used in the pharmaceutical industry, for example, an inorganic ion salt manufactured with calcium, potassium, sodium or magnesium; an inorganic acid salt manufactured with hydrochloric acid, nitric acid, phosphoric acid, hydrobromic acid, iodic acid, perchloric acid or sulfuric acid; an organic acid salt manufactured with acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, sparse acid, ascorbic acid, carbonic acid or vanillic acid; There are sulfonic acid salts manufactured from methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, or naphthalenesulfonic acid; amino acid salts manufactured from glycine, arginine, or lysine; and amine salts manufactured from trimethylamine, triethylamine, ammonia, pyridine, or picoline, but the types of salts meant in the present invention are not limited by these listed salts.

[0121] 46) According to embodiments of the present invention, in 1 to 45), the pharmaceutically acceptable salt may be a hydrochloride salt, and for example, the pharmaceutically acceptable salt may be a hydrochloride salt of a benzamide compound represented by the chemical formula I, a benzamide compound represented by the chemical formula 1-1, a benzamide compound represented by the chemical formula 1-2, benzamide compounds 1 to 249 of Table 1, or a stereoisomer thereof. The pharmaceutically acceptable salt of the present invention can be prepared by a conventional method known to those skilled in the art. The "hydrate" of the present invention is a compound represented by the chemical formula I or a pharmaceutically acceptable salt thereof, and water are bound by non-covalent intermolecular forces, and may contain a stoichiometric or non-stoichiometric amount of water. Specifically, the hydrate may contain water in a ratio of about 0.25 mol to about 10 mol based on 1 mol of the active ingredient, and more specifically, may contain about 0.5 mol, about 1 mol, about 1.5 mol, about 2 mol, about 2.5 mol, about 3 mol, about 5 mol, etc. The "solvate" of the present invention is a compound represented by Chemical Formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a solvent other than water are bound by non-covalent intermolecular forces, and may contain the solvent in a stoichiometric or non-stoichiometric amount. Specifically, the solvate may contain solvent molecules in a ratio of about 0.25 mol to about 10 mol based on 1 mol of the active ingredient, and more specifically, may contain about 0.5 mol, about 1 mol, about 1.5 mol, about 2 mol, about 2.5 mol, about 3 mol, about 5 mol, etc. A pharmaceutical composition comprising a compound represented by Chemical Formula I

[0122] 47) The present invention provides a pharmaceutical composition comprising, as an active ingredient, a benzamide compound represented by the chemical formula I according to 1) to 46), a benzamide compound represented by the chemical formula 1-1, a benzamide compound represented by the chemical formula I-2, benzamide compounds 1 to 249 of Table 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof.

[0123] 48) According to embodiments of the present invention, in the above 33), a pharmaceutical composition comprising a benzamide compound represented by the above chemical formula I, a benzamide compound represented by the above chemical formula 1-1, a benzamide compound represented by the above chemical formula 1-2, benzamide compounds 1 to 249 of the above Table 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient exhibits NAMPT inhibitory activity and can be used for the prevention or treatment of a NAMPT enzyme-related disease.

[0124] 49) According to embodiments of the present invention, in 47) or 48), a pharmaceutical composition comprising as an active ingredient a benzamide compound represented by the chemical formula I of the present invention, a compound represented by the chemical formula 1-1, compounds 1 to 245 of the above Table 14, stereoisomers thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof can sufficiently lower the NAD concentration in a cell.

[0125] 50) According to embodiments of the present invention, in the above 47) to 49), a pharmaceutical composition comprising a benzamide compound represented by the above chemical formula I of the present invention, a benzamide compound represented by the above chemical formula 1-1, a benzamide compound represented by the above chemical formula 1-2, benzamide compounds 1 to 249 of the above Table 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient may exhibit a preventive or therapeutic effect on cancer.

[0126] 51) According to embodiments of the present invention, in the above 47) to 50), in the embodiments of the present invention, the cancer may be a solid cancer or a blood cancer, and the cancer may be skin cancer (e.g., melanoma), lymph node cancer, breast cancer, cervical cancer, uterine cancer, gastrointestinal cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, rectal cancer, oral cancer, brain cancer, head and neck cancer, throat cancer, testicular cancer, kidney cancer, pancreatic cancer, bone cancer, spleen cancer, liver cancer, bladder cancer, laryngeal cancer, nasal cancer, AIDS-related cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, colorectal cancer, virus-related cancer (one selected from nasopharyngeal cancer, vaginal cancer, vulvar cancer, penile cancer, Kaposi's sarcoma, Burkitt's lymphoma, T-cell lymphoma, and Merkel cell carcinoma), multiple myeloma, acute and chronic leukemia, for example, lymphoblastic leukemia. , cancers of the blood and bone marrow, such as myeloid leukemia, lymphocytic leukemia, and myelocytic leukemia.

[0127] 52) According to embodiments of the present invention, in the above 47) to 51), the pharmaceutical composition of the present invention may additionally include one or more pharmaceutically acceptable carriers in addition to the benzamide compound represented by the above chemical formula I, the benzamide compound represented by the above chemical formula 1-1, the benzamide compound represented by the above chemical formula 1-2, the benzamide compounds 1 to 249 of the above Table 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof. At this time, the pharmaceutically acceptable carrier is one commonly used in the art at the time of formulation, and may be at least one selected from lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, but is not limited thereto. In addition, the pharmaceutical composition of the present invention may additionally include a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, or a preservative in addition to the above components. In addition, the pharmaceutical composition of the present invention may be formulated in the form of oral dosage forms such as tablets, powders, granules, pills, capsules, suspensions, emulsions, oral solutions, emulsions, syrups, etc., external preparations, suppositories, or sterile injectable solutions using pharmaceutically acceptable carriers and excipients, and may be manufactured in unit dose form or may be manufactured by placing the composition in a multi-dose container. The formulation may be manufactured by a conventional method used in formulation in the art or by a method disclosed in Remington's Pharmaceutical Science (19th ed., 1995), and may be formulated into various formulations depending on each disease or ingredient.The pharmaceutical composition of the present invention can be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally, or topically) depending on the intended method, and the dosage varies depending on the patient's condition and weight, the degree of the disease, the drug form, the administration route, and the time, but can be appropriately selected by those skilled in the art. Specifically, the daily dosage of the benzamide compound represented by the above chemical formula I of the present invention, the benzamide compound represented by the above chemical formula 1-1, the benzamide compound represented by the above chemical formula 1-2, the benzamide compounds 1 to 249 of the above Table 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof can be about 0.1 to about 1000 mg / kg based on the weight of the compound represented by the above chemical formula I, and can be administered once or several times a day in divided doses. The pharmaceutical composition of the present invention may further include one or more components that exhibit the same or similar effect or can bring about synergy in efficacy when used in combination, in addition to the benzamide compound represented by the above chemical formula I, the benzamide compound represented by the above chemical formula 1-1, the benzamide compound represented by the above chemical formula 1-2, the benzamide compounds 1 to 249 of the above Table 1, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof.

[0128] 53) According to embodiments of the present invention, in 47) to 51), the present invention provides a method for preventing or treating a NAMPT enzyme-related disease, comprising a step of administering to a subject a benzamide compound represented by the chemical formula I, a benzamide compound represented by the chemical formula 1-1, a benzamide compound represented by the chemical formula 1-2, benzamide compounds 1 to 249 of Table 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a pharmaceutical composition comprising the same.

[0129] 54) According to embodiments of the present invention, in the above 53), the method for preventing or treating a disease related to NAMPT enzyme of the present invention may include administering a therapeutically effective amount of a benzamide compound represented by the above chemical formula I, a benzamide compound represented by the above chemical formula 1-1, a benzamide compound represented by the above chemical formula 1-2, benzamide compounds 1 to 249 of the above Table 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a pharmaceutical composition comprising the same.

[0130] 55) According to embodiments of the present invention, in the above 53) or 54), in the present invention, the “therapeutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dosage level can be determined according to the type and severity of the patient’s disease, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the excretion rate, the treatment period, the concurrently used drugs, and other factors well known in the medical field. Specifically, it may mean an amount effective in the prevention or treatment of a disease (e.g., cancer) that can be treated by inhibiting NAMPT. In the present invention, “subject” means a subject for which the prevention or treatment of a disease is to be performed, and more specifically, may mean mammals such as humans, monkeys, mice, dogs, cats, horses, cows, etc., but is not limited thereto.

[0131] 56) According to embodiments of the present invention, in the above 53) to 55), “prevention” in the present invention means all acts of inhibiting or delaying the onset of a NAMPT enzyme-related disease by administering a benzamide derivative compound represented by the chemical formula I of the present invention, a benzamide compound, a benzamide compound represented by the chemical formula 1-1, a benzamide compound represented by the chemical formula 1-2, benzamide compounds 1 to 249 of Table 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof.

[0132] 57) According to embodiments of the present invention, in 53) to 56), “treatment” in the present invention means all acts in which symptoms of a NAMPT-related disease are improved or beneficially changed by administration of a benzamide derivative compound represented by the chemical formula I of the present invention, a benzamide compound, a benzamide compound represented by the chemical formula 1-1, a benzamide compound represented by the chemical formula 1-2, benzamide compounds 1 to 249 of Table 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof.

[0133] 58) The present invention provides the use of a benzamide derivative compound represented by the chemical formula I according to the above 47) to 51), a benzamide compound, a benzamide compound represented by the above chemical formula 1-1, a benzamide compound represented by the above chemical formula 1-2, benzamide compounds 1 to 249 of the above Table 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a pharmaceutical composition comprising the same for the prevention or treatment of a NAMPT enzyme-related disease.

[0134] 59) The present invention provides the use of a benzamide derivative compound represented by the above chemical formula I according to 47) to 51), a benzamide compound represented by the above chemical formula 1-1, a benzamide compound represented by the above chemical formula I-2, benzamide compounds 1 to 249 of Table 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a pharmaceutical composition comprising the same, for the manufacture of a medicament for the prevention or treatment of a NAMPT enzyme-related disease. The matters mentioned in each item of the present invention, that is, the benzamide compound, the use, the composition, and the treatment method, are equally applicable unless they are contradictory to each other, and terms and abbreviations used in the present specification have their original meanings unless otherwise defined.

[0135]

Effect of the invention

[0136]

Specific details for carrying out the invention

[0137] <Example> Example 1: Synthesis of compound 1 Reagents and conditions. (a) Na2S, DMF, room temperature (rt), 16 h (16 h) (b) 3-(chloromethyl)- 1-methyl- 1H-pyrazole (3- (chloromethyl)- 1-methyl-

[0138] (IH-pyr azole), K2CO3, DMF, rt, 16 h (c) mCPBA, DCM, room temperature (rt), 16 h (16 h) (d) Fe, AcOH, 80 °C, 2 h (2 h) (e) HC1, NaN02, KI, H2O, 0 °C to room temperature (0 °C- rt), 1 h (l h) (f) PdC12[PPh3]2, Cui, TEA, ACN, room temperature (rt), 16 h (16 h) (g) NaOH, H2O, MeOH, 55 °C, 2 h (2 h) (h) 3-(1H-pyrazol- 4-yl)propan-l-amine dihydrochloride,

[0139] TBTU, TEA, DCM, 12 h (12 h) Step 1) Synthesis of methyl 4-mercapto-3-nitrobenzoate Methyl 4-fluoro-3-nitrobenzoate (10 g, 46.4 mmol, 1 eq) was dissolved in DMF (80 ml) and sodium disulfide (4.32 g, 55.3 mmol, 1.2 eq) was added and stirred at room temperature for 16 h. After the reaction was completed, 200 ml of water was added to the reaction mass and the pH was adjusted to 5 with IN HC1 while stirring. The yellow solid formed during stirring was filtered and washed with 25% EA / HX suspension to obtain the target compound (6.13 g, 28.7 mmol, 62%). Step 2) Synthesis of methyl 4-(((1-methyl- 1H-pyrazol- 3-yl)methyl)thio)-3-nitrobenzoate Methyl 4-mercapto-3-nitrobenzoate (4 g, 18.8 mmol, 1 eq) was dissolved in DMF (40 ml) and K2CO3 (5.18 g, 37.52 mmol, 2 eq) was added and stirred. When the color of the reaction product turned dark red, 3-(chloromethyl)-1-methyl-IH-pyrazole (2.45 g, 18.8 mmol, 1 eq) was added to the reaction product and stirred for 16 hours. The reaction was confirmed by TLC, and when the reaction was completed, water was added to the reaction product and the resulting precipitate was filtered to obtain the target compound (5.14 g, 16.7 mmol, 89%).Step 3) Synthesis of methyl 4-(((1-methyl- 1H-pyrazol- 3-yl)methyl)sulfonyl)-3-nitrobenzoate.

[0140] (methyl 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl ) thio )-3-ni trobenzoate, 5.14 g, 16.7 mmol , 1 eq) was dissolved in DCM (100 ml), mCPBA (12.2 g, 50.2 mmol , 3 eq) was added, and the mixture was stirred for 16 hours. The reaction was confirmed by TLC, and when the reaction was complete, water was added to dilute, saturated NaHC03 aqueous solution was neutralized, and DCM was extracted several times. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure to obtain the crude target compound. Step 4) Synthesis of methyl 3-amino-4-(((l-methyl-lH-pyrazol-3- yl)methyl)sulfonyl)benzoate

[0141] (methyl 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )-3-ni trobenzoate,

[0142] To a solution of AcOH (100 ml) and iron (9.32 g, 16.7 mmol, 10 eq) was added and stirred at 80°C for 2 hours. The catalyst was removed through celite filtration, and the filtrate was concentrated under reduced pressure. The residue was basified with aqueous potassium carbonate solution, extracted with ethyl acetate, and the organic layer was concentrated under reduced pressure. The target compound was obtained as a crude product. Step 5) Synthesis of methyl 3-iodo-4-(((l-methyl-lH-pyrazol-3- yl)methyl)sulfonyl)benzoate A solution of sodium nitrite (1.73 g, 1.5 eq) dissolved in water (40 ml) was added to methyl 3-amino-4-(((1-methyl-lH-pyrazol-3-yl)methyl)sulfonyl)benzoate (1 g, 4.65 mmol, 1 eq).

[0143] (16.7 mmol) was slowly added dropwise to a suspension of concentrated hydrochloric acid aqueous solution (40 mL) and water (40 mL) at 0°C. The mixture was stirred in an ice bath for 30 minutes, and a solution of potassium iodide (8.3 g, 3 eq) dissolved in water (40 mL) was added to the mixture at 0°C. The reaction mixture was stirred at room temperature for 1 hour, treated with saturated aqueous potassium carbonate solution (pH>8), and extracted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 30-50% EA / HX) to obtain the target compound (3.24 g, 3 steps [(c), (d), (e)] yield 46%). Step 6) Synthesis of methyl 3-((4-fluorophenyl)ethynyl)-4-(((1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl)benzoate

[0144] (methyl 3— iodo— 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )benzoate)

[0145] (0.84 g, 2 mmol, 1 eq) was added MeCN (10 ml, 0.2 M) and TEA (0.84 ml, 6 mmol, 3 eq). PdC12[PPhs]2 (42 mg, 3 mol%) and Cul (11 mg, 3 mol%) were added to the reaction mixture and stirred at room temperature for 5 minutes under a nitrogen atmosphere. Then, 4-fluorophenyl-acetylene (0.29 g, 1.2 eq) was added. The reaction mixture was stirred at room temperature for 16 hours and concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 40-50% EA / HX) to obtain the target compound (1.7 mmol, 85%). Step 7) Synthesis of 3-((4-fluorophenyl)ethynyl)-4-(((1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid (3-((4-f luorophenyl)ethynyl)-4-( ((1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid) Methyl 3-((4-fluorophenyl)ethynyl)-4-( ((1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl)benzoate (methyl 3-((4-f luorophenyl)ethynyl 1 )-4-( ((1-methyl— 1H— pyrazol— 3— yl)methyl )sulfonyl )benzoate, 0.7 g, 1.7 mmol , 1 eq) to MeOH (17 ml, 0.1 M), H2O (8.5 ml, 0.2 M), NaOH (0.17 g, 4.3 mmol, 2.5 eq) and 55。Stirred for 2 hours at 0. The reaction was confirmed by TLC, and when the reaction was completed, the pH of the reactant was adjusted to 1 with IN HC1 aqueous solution, and extracted with Toyo. The organic layer was washed with water, dried over magnesium sulfate, and concentrated under reduced pressure to obtain the target compound (0.62 g, 92%). Step 8) Synthesis of N-(3-(1H-pyrazol-4-yl)propyl)-3-((4-fluorophenyl)ethynyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (>(3-(1H-pyrazol-4-yl)propyl)-3-((4-fluorophenyl)ethynyl)— 4—(((1— methyl— 1H— pyrazol— 3— yl)methyl)sulfonyl)benzamide)。

[0146] 3-((4-fluorophenyl)ethynyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid (3-((4-f luorophenyl)ethynyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid) (0.12 g, 0.3 mmol, 1 eq) was added to DCM (5 ml) and TBTU (0.14 g, 0.45 mmol, 1.5 eq) was stirred at room temperature for 50 min. Then, TEA (0.15 ml, 1.11 mmol, 3.7 eq) and 3-(1H-pyrazol-4-yl)propan-1-amine dihydrochloride (3-(1H-pyrazol-4-yl)propan-1-amine dihydrochloride, 71 mg, 0.36 mmol, 1.2 eq) were added to the reaction mixture and stirred for 12 hours. Water was added to the reaction mixture and the mixture was extracted with a solvent. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 3-4% MeOH / DCM) to obtain the target compound (0.1 g, 0. 20 mmol, 66%). iH NMR (400 MHz, CDC13) 6 8.01 (d, J = 1.6 Hz, 1H), 7.94 (d, J = 8.2

[0147] Hz, IH), 7.73 — 7.66 (m, 3H), 7.49 (s, 2H), 7.23 (d, J = 2.2 Hz, IH), 7.13

[0148] (t, J= 8.7 Hz, 2H), 6.35 — 6.32 (m, IH), 6.17 (d, J= 2.2 Hz, IH), 4.79 (s,

[0149] 2H), 3.79 (s, 3H), 3.55 (q, J = 6.4 Hz, 2H), 2.66 (t, J = 7.4 Hz, 2H), 1.97

[0150] (p, J = 7.4 Hz, 2H).

[0151] MS(ESI) m / e MH + 506.2 Compounds 11, 13, 18, 21, 23, 24, 26 to 28, 30 to 43, and 48 to 70 can be synthesized by changing the reactants in a method substantially the same as the synthetic method of Example 1. Example 2: Synthesis of Compound 2

[0152]

[0153] Synthesis of 3-((4-fluorophenyl)ethynyl)-N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide

[0154] The target compound was synthesized in the same manner as in step 8) of Example 1 using 1-{imidazo[l,2-a]pyridin-7-yl}methanamine dihydrochloride. iH NMR (400 MHz, DMS0) 6 9.47 — 9.44 (m, 1H), 8.52 (d, J = 7.1 Hz,

[0155] 1H), 8.33 (s, IH), 8.05 (d, J = 8.2 Hz, IH), 7.97 — 7.88 (m, 2H), 7.82 —

[0156] 7.76 (m, 2H), 7.60 (s, IH), 7.54 (s, IH), 7.46 (s, IH), 7.39 (t, J= 8.4 Hz,

[0157] 2H), 6.89 (d, J = 6.7 Hz, IH), 6.10 (s, IH), 4.88 (s, 2H), 4.55 (d, J = 5.4

[0158] Hz, 2H), 3.72 (s, 3H).

[0159] MS(ESI) m / e MH + 528.4 The compound was prepared by changing the reactants in substantially the same manner as in Example 2.

[0160] Compounds 220, 221, 222, and 227 can be synthesized. Example 3: Synthesis of Compound 3

[0161] N-(2-(1H-pyrrolo[3,2-c]pyridin-3-yl)ethyl)-3-((4-fluorophenyl)ethynyl)-

[0162] Synthesis of 4-(((1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (N-(2-(lH-pyrrolo[3,2- c]pyr idin-3-yl )ethyl )-3-( (4- f luoropheny 1 )ethynyl )— 4— (((1— methyl— IH—pyr azol— 3-yl )methyl )sulfonyl )benzamide)

[0163] The target compound was synthesized in the same manner as in step 8 of Example 1 using 1-{1H-pyrrolo[3,2-c]pyridin-2-yl}methanamine dihydrochloride. iH NMR (400 MHz, MeOD) 6 8.91 (s, 1H), 8.15 (d, J = 5.8 Hz, 1H), 8.10

[0164] (s, IH), 7.90 (d, J = 8.3 Hz, IH), 7.82 (d, J = 8.3 Hz, IH), 7.78 — 7.72i

[0165] (m, 2H), 7.45 (m, 2H), 7.32 (s, IH), 7.24 (t, J= 8.3 Hz, 2H), 6.17 (s, IH),

[0166] 4.83 (s, 2H), 3.78 — 3.72 (m, 5H), 3.19 (t, J = 7.1 Hz, 2H).

[0167] MS(ESI) m / e [M- H]“ 540.4 Example 4: Synthesis of 3-(chloromethyl)-1-(4-(trifluoromethyl)phenyl)-IH-pyrazole (3-(chloromethyl )— 1—(4— (tri f luoromethyl )phenyl )— IH— pyrazole) Reagents and conditions. (a) l-iodo-4-

[0168] ( tr if luoromethyl ) benzene , Cui , K3PO4 , (1S,2S)- (+)- N, N'-dimethylcyclohexane- 1,2-diamine ((IS, 2S)-(+)- N, N '-Di methyl cyclohexane- 1,2- diamine) , 110°C, 16 h (16h)

[0169] (b) L1AIH4, THF, 0°C to room temperature (0°C - rt), 1 hour (Ih) (c) SOC12, DCM, room temperature (rt),

[0170] 12 hours (12h) Step 1) Methyl 1-(4-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxylate

[0171] Synthesis of (methyl 1— (4— (tr if luoromethyl ) phenyl )—lH—pyrazole— 3— carboxylate) Methyl 1H-pyrazole- 3 -carboxylate (1 g, 7.9 mmol, 1 eq), 1-iodo-4- ( tr if luoromethyl )benzene (2.15 g, 1 eq), Cui (0.24 g, 1.27 mmol , 0.16 eq), (1S,2S)- (+)- N,N'-dimethylcyclohexane- 1,2 -diamine ((1S,2S)- (+)- N,N'-

[0172] Dimethyl eye 1 ohexane- 1 , 2-di am i ne ) (0.28 ml , 1.7 mmol , 0.22 eq), K3PO4 (4 g, 19 mmol , 2.4 eq), and toluene (10 ml , 0.8 M) were placed in a pressure tube and stirred at 110°C for 16 hours. The reaction mixture was cooled to room temperature, water and ethanol were added, and the mixture was separated. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel, 10% EA / HX) to obtain the target compound (1.4 g, 5.2 mmol, 65%). Step 2) Synthesis of (1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methanol Methyl i—(4—(trifluoromethyl)phenyl)—lH— pyrazole-3-carboxylate (1 g, 3.7 mmol, 1 eq) was dissolved in anhydrous THF, and lithium aluminum hydride solution (3.7 ml, 1.0 M in THF solution) was added dropwise at 0°C. After stirring at room temperature for 1 hour, the reaction mass was cooled to 0°C. Water (1 ml), IN NaOH aqueous solution (1 ml), and water (2 ml) were added sequentially to the reaction mixture to terminate the reaction, and then filtered through Celite. The filtrate was concentrated under reduced pressure to obtain the crude target compound. Step 3) Synthesis of 3-(chloromethyl)-1-(4-(trifluoromethyl)phenyl)-1H-pyrazole

[0173] (1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methanol ((1-(4-

[0174] (trifluoromethyl)phenyl)—lH— pyrazol— 3— yl) methanol) was dissolved in DCM (20 ml), SOC12 (0.54 ml, 2 eq) was added, stirred at room temperature for 12 hours, and concentrated under reduced pressure to obtain the crude target compound. Example 5: Synthesis of compound 4

[0175] Reagents and conditions .. (a) Na2S, DMF, reflux,

[0176] 2 h (2 h) (b) 3-(chloromethyl)-1-(4-(trifluoromethyl)phenyl)-1H-pyrazole (3-(chloromethyl)— 1—(4—(tri f luoromethyl)phenyl)-1H-pyrazole), K2CO3, DMF, room temperature (rt), 0.5 h (0.5 h) (c) mCPBA, DCM, room temperature (rt), 16 h (16 h) (d) PdChfPPhsh, Cui, TEA, ACN, room temperature (rt), 16 h (16 h) (e) NaOH, H2O, MeOH, 60°C, 12 h (12 h) (f) 3-(1H-pyrazol-4-yl)propan-1-amine dihydrochloride (3-(1H-pyrazol-4-yl )propan—l—amine dihydrochloride) , TBTU, TEA, DCM, 12 h (12 h) Step 1) Synthesis of methyl 3-iodo-4-mercaptobenzoate Methyl 4-fluoro-3-iodobenzoate (5 g, 17.8 mmol, 1 eq) was dissolved in DMF (20 ml) and sodium disulfide (1.53 g, 19.6 mmol, 1.1 eq) was added, followed by refluxing for 2 h. Water was added to the reaction mixture, acidified with IN HC1, and extracted several times with distilled water. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure to obtain the target compound as a crude residue. Step 2) Synthesis of methyl 3-iodo-4-(((1-(4-(trifluoromethyl)phenyl)- 1H-pyrazol-3-yl)methyl)thio)benzoate

[0177] 3-(chloromethyl )— 1—(4— (tri f luoromethyl ) phenyl )-lH-pyrazole (94 mg) was dissolved in DMF (2 ml) and K2C03 (0.098 g, 0.71 mmol, 2 eq) was added. Methyl 3-iodo-4-mercaptobenzoate (0.1 g) was added to the reaction mixture and stirred for 30 minutes. Water was added to the reaction mixture and the mixture was extracted several times with oil. The organic layer was washed with a saturated NH4C1 aqueous solution, separated, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EA / HX) to obtain the target compound (78 mg, 0.15 mmol, 42%). Step 3) Methyl 3-iodo-4-(((1-(4- (trifluoromethyl)phenyl)- 1H-pyrazol-3-yl)methyl)sulfonyl)benzoate (methyl 3- iodo-4- (((1-(4-

[0178] Synthesis of (trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzoate Methyl 3-iodo-4-(((1-(4- (trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methyl)thio)benzoate (methyl 3-iodo-4-(((1-(4- (trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methyl)thio)benzoate, 0.1 g, 0.61 mmol, 1 eq) was dissolved in DCM (30 ml), and mCPBA (0.45 g, 1.83 mmol, 3 eq) was added and stirred for 16 h. The reaction was confirmed by TLC, and when the reaction was complete, water was added to dilute, neutralized with saturated NaHCOs aqueous solution, and extracted several times with DCM. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure, and the resulting residue was purified by column chromatography (silica gel, 25% EA / HX) to obtain the target compound (0.19 g, 0.34 mmol, 57%). Step 4) Synthesis of methyl 3-((4-fluorophenyl)ethynyl)-4-(((1-(4- (trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzoate (methyl 3-((4- f 1 fluorophenyl)ethynyl 1 )-4- (((1— (4— (trifl uf uromethy 1 ) pheny 1 )—1H— pyr azol-3- yl )methyl )sulfonyl )benzoate) Methyl 3-iodo-4-( ( (1-(4- (trifluoromethyl)phenyl )-1H-pyrazol-3-yl )methyl)sulfonyl )benzoate (methyl 3-iodo-4-( ( (1-(4- (trifluoromethyl)phenyl )-1H-pyrazol-3-yl )methyl)sulfonyl )benzoate) )-lH- pyrazol-3-yl )methyl )sulfonyl )benzoate, 0.1 g, 0.19 mmol , leq) was added to MeCN (1 ml , 0.2 M) and TEA (0.078 ml, 0.56 mmol, 3 eq) was added. PdCMPPh^ (4 mg, 3 mol%) and Cul (l mg, 3 mol%) were added to the reaction mixture and stirred at room temperature for 5 minutes under a nitrogen atmosphere. Then, 4-fluorophenyl-acetylene (27 mg, 0.22 mmol, 1.2 eq) was added. The reaction mixture was stirred at room temperature for 16 hours and concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 30% EA / HX) to obtain the target compound (86 mg, 0.16 mmol, 85%). Step 5) Synthesis of 3-((4-fluorophenyl)ethynyl)-4-(((1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid (3-((4-f luorophenyl)ethynyl)-4-(((l-(4-(trif luoromethyl)phenyl)—1H—pyrazol—3—yl)methyl)sulfonyl)benzoic acid) Methyl 3-((4-fluorophenyl)ethynyl)-4-(((1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzoate (methyl 3-((4-f luorophenyl)ethynyl)-4-( ((l-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzoate ) phenyl )—lH— pyrazol— 3— yl )methyl )sulfonyl )benzoate, 0.085 g, 0.16 mmol, 1 eq) was added MeOH (1 ml, 0.1 M), H2O (0.5 ml, 0.2 M), NaOH (0.016 g, 0.4 mmol, 2.5 eq) and stirred at 60°C for 2 hours. NaOH (0.016 g, 0.4 mmol, 2.5 eq) was additionally added and stirred for 12 hours. The reaction was confirmed by TLC, and when the reaction was completed, the pH of the reaction product was adjusted to 1 with IN HC1 aqueous solution and extracted with EA. The organic layer was washed with water, separated, dried over magnesium sulfate and concentrated under reduced pressure to give the target compound (0.075 g, 90%) was obtained. Step 6) Synthesis of compound 4: N-(3-(1H-pyrazol-4-yl)propyl)-3-((4-fluorophenyl)ethynyl)-4-( ((1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (N-(3-(1H-pyr azol -4-yl)propyl)-3-((4-f luorophenyl)ethynyl)-4-.

[0179] Synthesis of (((l-(4-(trifluoromethyl)phenyl)— 1H— pyrazol— 3— yl)methyl)sulfonyl)benzoic acid (3- ( (4- f luorophenyl)ethynyl)-4-(((l-(4-

[0180] (tri fluoromethyl ) phenyl )— 1H— pyrazol— 3— yl )methyl )sulfonyl )benzoic acid,

[0181] DCM (2.5 ml) and TBTU (0.037 g, 0.21 mmol, 1.5 eq) were added to 0.075 g, 0.14 mmol, 1 eq) and stirred at room temperature for 50 min. Then, TEA (0.072 ml, 0.52 mmol, 3.7 eq) and 3-(1H-pyrazol-4-yl)propan-1-amine dihydrochloride (3-(111-pyrazol— 4— yl )propan—l— amine dihydrochloride, 0.034 g, 0.17 mmol , 1.2 eq) were added to the reaction mixture and stirred for 12 h. Water was added to the reaction mixture and extracted with a tungsten nitrate. After drying the organic layer with magnesium sulfate and concentrating under reduced pressure, the residue obtained was purified by column chromatography (silica gel, 2% MeOH / DCM) to obtain the target compound. iH NMR (400 MHz, MeOD) 5 8.25 - 8.22 (m, 2H), 7.98 (d, J = 8.1 Hz, 1H), 7.87 (d, J = 8.1 Hz, IH), 7.73 (m, 6H), 7.49 (m, 2H), 7.20 (t, J = 8.5 Hz, 2H), 6.53 (s, IH), 4.99 (s, 2H), 3.45 (d, J = 6.8 Hz, 2H), 2.63 (t, J = 7.4 Hz, 2H), 1.98 - 1.92 (m, 2H).

[0182] MS(ESI) m / e [MH]“ 634.4 The compound was prepared by changing the reactants in substantially the same manner as in Example 5

[0183] 111,112, 113, 114, 116, 117, 118, 120, 121, 123, 124, 125, 126, 127, 128,

[0184] 129, 130, 132, 135, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 149,

[0185] 219, 157, 158, 209, 210, 201, 212, 213, 223, 225, 169, 170, 171, 218, 172,

[0186] 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187,

[0187] Compounds 188, 189, 190, 217, 191, 192, 204, 205, 206, 207, 208, and 214 can be synthesized. Reagents and Conditions (a) 1-(bromomethyl)-2,3-dimethylbenzene, K2CO3, DMF, room temperature (rt), 0.5 h (0.5 h) (b) mCPBA, DCM, room temperature (rt), 16 h (16 h) (c) PdChfPPhsh, Cui, TEA, ACN, room temperature (rt), 16 h (16 h) (d) NaOH, H2O, MeOH, 55°C, 12 h (12 h) (e) 3-(1H-pyrazol-4-yl)propan-1-amine dihydrochloride, TBTU, TEA, DCM, 12 hours (12h) Step 1) Synthesis of methyl 4-((2,3-dimethylbenzyl)thio)-3-iodobenzoate

[0188] 1-(Bromomethyl)-2,3-dimethylbenzene (0.07 g, 0.36 mmol, 1 eq) was dissolved in DMF (2 ml) and K2C03 (0.098 g, 0.71 mmol, 2 eq) was added. Methyl 3-iodo-4-mercaptobenzoate (0.1 g) was added to the reaction mixture and stirred for 30 minutes. Water was added to the reaction mixture and extracted several times with EA. The organic layer was washed with a saturated NH4C1 aqueous solution, separated, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% EA / HX) to obtain the target compound. Step 2) Synthesis of methyl 4-((2, 3-dimethylbenzyl)sulfonyl)-3-iodobenzoate Methyl 4-((2, 3-dimethylbenzyl)thio)-3-iodobenzoate (0.31 g, 0.75 mmol, 1 eq) was dissolved in DCM (30 ml), mCPBA (0.55 g, 2.3 mmol, 3 eq) was added, and the mixture was stirred for 16 h. The reaction was confirmed by TLC, and when the reaction was completed, water was added to dilute, saturated NaHCOs aqueous solution was neutralized, and DCM was extracted several times. After drying the organic layer with magnesium sulfate and concentrating under reduced pressure, the residue obtained was purified by column chromatography (silica gel, 20% EA / HX) to obtain the target compound (0.17 g, 0.39 mmol, 52%).Step 3) Synthesis of methyl 4-((2, 3-dimethylbenzyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzoate To methyl 4-((2, 3-dimethylbenzyl)sulfonyl)-3-iodobenzoate (0.17 g, 0.38 mmol, leq) was added MeCN (2 ml, 0.2 M) and TEA (0.16 ml, 1.15 mmol, 3 eq). PdC12[PPh3]2 (8 mg, 3 mol%) and Cui (2 mg, 3 mol%) were added to the reaction mixture and stirred at room temperature for 5 minutes under a nitrogen atmosphere. Then, 4-fluorophenyl-acetylene (55 mg, 0.45 mmol, 1.2 eq) was added. The reaction mixture was stirred at room temperature for 16 hours and concentrated under reduced pressure. The obtained residue was purified by column chromatography to obtain the target compound (0.165 g, 0.38 mmol, 99%). Step 4) Synthesis of 4-((2, 3-dimethylbenzyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzoic acid 4-( ((2, 3-dimethyIbenzy1)sulfonyl)-3-((4-f luorophenyl)ethynyl)benzoic acid) Methyl 4-((2, 3-dimethylbenzyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzoate (0.165 g, 0.38 mmol, 1 eq) was added to MeOH (1 ml, 0.1 M), H2O (0.5 ml, 0.2 M), NaOH (0.016 g, 0.4 mmol, 2.5 eq) was added and stirred at 85°C for 12 hours.The reaction was confirmed by TLC, and when the reaction was completed, the pH of the reactant was adjusted to 1 with IN HC1 aqueous solution and extracted with distilled water. The organic layer was washed with water, separated, dried over magnesium sulfate, and concentrated under reduced pressure to obtain the target compound as a crude product. Step 5) Synthesis of compound 5: Synthesis of N-(3-(1H-pyrazol-4-yl)propyl)-4-((2,3-dimethylbenzyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzamide.

[0189] 4-((2, 3-dimethylbenzyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzoic acid (4-

[0190] ( (2, 3-dimethy Ibenzy 1 )sulfonyl )-3-( ( 4-f luorophenyl )ethynyl )benzoic acid)

[0191] (0.15 g, 0.35 mmol, 1 eq) was added to DCM (5 ml) and TBTU (0.17 g, 0.53 mmol, 1.5 eq) and stirred at room temperature for 50 min. Then, TEA (0.18 ml, 1.3 mmol, 3.7 eq) and 3—(1H—pyrazol—4—yl)propan—l—amine dihydrochloride (0.083 g, 0.42 mmol, 1.2 eq) were added to the reaction mixture and stirred for 12 h. Water was added to the reaction mixture and extracted with ethanol. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 3-5% MeOH / DCM) to obtain the target compound (0.07 g, 0.13 mmol, 38%). iH NMR (400 MHz, DMSO) 6 12.51 (s, 1H), 8.83 (m, 1H), 8.27 (s, 1H), 8.00 (d, J = 8.3 Hz, IH), 7.91 (d, J = 8.1 Hz, IH), 7.77 — 7.70 (m, 2H), 7.52 (br, IH), 7.37 (d, J = 8.5 Hz, 2H), 7.10 (d, J = 7.4 Hz, IH), 6.95 (t, J = 7.5 Hz, IH), 6.85 (d, J = 7.6 Hz, IH), 4.91 (s, 2H), 3.32 (m, 2H), 2.48 (m, 2H), 2.19 (s, 6H), 1.80 (p, J = 7.0 Hz, 2H).

[0192] MS(ESI) m / e [M- H]' 528.4 Example 7: Synthesis of compound 6 Scheme Reagent and Condition (a) Na2S, DMF, room temperature (rt),

[0193] 16 h (16 h) (b) n-chlorosuccinimide, 2N HC 1 ( aq . ), MeCN, room temperature (rt), 16 h (16 h) (c) methylamine, EtOH, MeCN, room temperature (rt), 1 h (I h) (d) Fe, AcOH, 80°C, 1 h (I h) (e) HC 1, NaN 0 2 , KI, H 0, 0°C room temperature (rt),

[0194] 1 hour (Ih) (f) PdChfPPhsh, Cui, TEA, ACN, room temperature (rt), 1 hour (Ih) (g) NaOH, H20,

[0195] MeOH, 55°C, 4 h (4h) (h) 3-(IH-pyrazol-4-yl)propan-l-amine dihydrochloride, TBTU, TEA, DCM, 12 h (12h) Step 1) Synthesis of methyl 4-mercapto-3-nitrobenzoate Methyl 4-fluoro-3-nitrobenzoate,

[0196] Dissolve 10 g, 46.4 mmol, 1 eq) in DMF (80 ml) and add sodium disulfide (4.32 g, 55.3 mmol, 1.2 eq) and stir at room temperature for 16 hours. After the reaction was completed, 200 ml of water was added to the reaction mixture and the pH was adjusted to 5 with IN HC1 and stirred. The yellow solid formed during stirring was filtered and washed with a suspension of 25% EA / HX to obtain the target compound (6.13 g, 28.7 mmol, 62%). Step 2) Preparation of methyl 4-(chlorosulfonyl)-3-nitrobenzoate (methyl 4-

[0197] Synthesis of (chlorosulfonyl)-3-nitrobenzoate To a reaction mixture of n-chlorosuccinimide (3.3 g, 24.5 mmol, 5 eq), 2N HC1 aqueous solution (5.2 ml, 2 eq), and MeCN (50 ml) in an ice bath, methyl 4-mercapto-3-nitrobenzoate (1 g, 4.9 mmol, 1 eq) was added and stirred at room temperature for 16 h. After the reaction was completed, 20 ml of water was added and MeCN was concentrated under reduced pressure. The residue was extracted several times with a distilled water bath and washed several times with a saturated aqueous solution of NaHCOs and brine. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure to obtain the target compound as a crude residue. Step 3) Synthesis of methyl 4-(N-methylsulfamoyl)-3-nitrobenzoate Methyl 4-(chlorosulfonyl)-3-nitrobenzoate (0.2 g, 0.71 mmol, 1 eq) was dissolved in MeCN, and methylamine solution (33 wt. % in absolute ethanol) was added and stirred at room temperature for 1 hour. Water was added to the reaction mixture, and the residue, which was concentrated under reduced pressure with MeCN, was extracted several times with a tungsten nitrate. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue obtained was purified by column chromatography (silica gel, 20-50% EA / HX) to obtain the target compound (0.13 g, 0.47 mmol, 66%).Step 4) Synthesis of methyl 3 -amino-4- (N- methylsulfamoyl )benzoate Methyl 4- (N- methylsulfamoyl )- 3 -nitrobenzoate (0.128 g, 0.47 mmol, 1 eq) was added to AcOH (5 ml) and iron (0.26 g, 4.67 mmol, 10 eq), and the mixture was stirred at 80 °C for 1 hour. The catalyst was removed by filtration through celite, and the filtrate was concentrated under reduced pressure. The residue was basified with an aqueous potassium carbonate solution and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure to obtain the target compound as a crude product. Step 5) Synthesis of methyl 3 -iodo-4- (N- methylsulfamoyl )benzoate A solution of sodium nitrite (0.03 g, 0.4 mmol, 1.5 eq) dissolved in water (1 ml) was slowly added dropwise to a suspension of methyl 3 -amino-4- (N- methylsulfamoyl )benzoate (0.065 g, 0.27 mmol, 1 eq), concentrated hydrochloric acid aqueous solution (1 ml) and water (1 ml) at 0 °C. The mixture was stirred in an ice bath for 30 minutes, and a solution of potassium iodide (0.13 g, 0.8 mmol, 3 eq) dissolved in water (1 mL) was added to the mixture at 0 °C. The reaction mixture was stirred at room temperature for 1 - 2 hours, treated with saturated aqueous potassium carbonate solution (pH > �), and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue obtained was purified by column chromatography (silica gel, 20 - 60% EA / HX) to obtain the target compound (0.06 g, 0.17 mmol, 63%).Step 6) Synthesis of methyl 3-((4-fluorophenyl)ethynyl)-4-(N-methylsulfamoyl)benzoate To methyl 3-iodo-4-(N-methylsulfamoyl)benzoate (0.06 g, 0.17 mmol, 1 eq) add MeCN (1 ml) and then TEA (0.071 ml, 0.51 mol, 3 eq). PdCMPPhzh (0.0036 mg, 3 mol%) and Cui (0.001 mg, 3 mol%) were added to the reaction mixture, and the mixture was stirred at room temperature for 5 minutes under a nitrogen atmosphere. Then, 4-fluorophenyl-acetylene (0.024 g, 0.2 mmol, 1.2 eq) was added. The reaction mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 40% EA / HX) to obtain the target compound (0.059 g, 0.17 mmol, 99%). Step 7) Synthesis of 3-((4-fluorophenyl)ethynyl)-4-(N-methylsulfamoyl)benzoic acid To methyl 3-((4-fluorophenyl)ethynyl)-4-(N-methylsulfamoyl)benzoate (0.089 g, 0.26 mmol, 1 eq) was added MeOH (2.6 ml, 0.1 M), H2O (1.3 ml, 0.2 M), and NaOH (0.026 g, 0.64 mmol, 2.5 eq), and stirred at 55°C for 4 h. The reaction was confirmed by TLC, and when the reaction was completed, the pH of the reaction product was adjusted to 1 with an IN HC1 aqueous solution and extracted with water.The organic layer was washed with water, separated, dried over magnesium sulfate, and concentrated under reduced pressure to obtain the target compound as a crude product. Step 8) Synthesis of compound 6: N-(3-(1H-pyrazol-4-yl)propyl)-3-((4-fluorophenyl)ethynyl)-4-(N-methylsulfamoyl)benzamide (N-(3-(1H-pyrazol-4-yl)propyl)-3-.

[0198] Synthesis of ((4-fluorophenyl)ethynyl)-4-(N-methylsulfamoyl)benzamide To 3-((4-fluorophenyl)ethynyl)-4-(N-methylsulfamoyl)benzoic acid (3-((4- f luorophenyl)ethynyl)-4-(N-methyl sulfamoyl)benzoic acid) (0.084 g, 0.25 mmol, 1 eq) were added DCM (5 ml) and TBTU (0.12 g, 0.38 mmol, 1.5 eq), and the mixture was stirred at room temperature for 50 min. Then, TEA (0.13 ml, 0.93 mmol, 3.7 eq), 3-(lH-pyrazol— 4— yl )propan— 1— amine dihydrochi or ide (0.060 g, 0.3 mmol , 1.2 eq) were added to the reaction mixture and stirred for 12 hours. Water was added to the reaction mixture and extracted with a distilled water. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (C18 Aq, 40% ACN / 0.1% formic acid in water) to obtain the target compound (0.02 g, 0.045 mmol, 18%). iH NMR (400 MHz, MeOD) 5 8.42 (s, 1H), 8.05 - 7.92 (m, 2H), 7.56 - 7.48 (m, 4H), 7.18 (t, J = 8.8 Hz, 2H), 6.95 (s, IH), 3.47 (t, J = 7.1 Hz, 2H), 2.94 (s, 3H), 2.63 (t, J = 7.5 Hz, 2H), 1.94 (p, J = 7.3 Hz, 2H).

[0199] MS(ESI) m / e MH + 441.2 Compounds 12, 14, 19, 20, 22, 29, 71-74, 215, and 216 can be synthesized by changing the reactants in a manner substantially identical to Example 7. Example 8: Synthesis of Compound 7 3-((4-fluorophenyl)ethynyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-N-

[0200] (2-(6-nitropyridin-3-yl)ethyl)benzamide (3-((4-f luorophenyl)ethynyl)-4-

[0201] Synthesis of (((1— methyl— IH—pyr azol— 3— yl )methyl)sulfonyl )— N— (2— (6— nitropy idin— 3— yl )ethyl )benzamide) Scheme Reagent and Condition (a) Potassium tert-butyl N-[2-(trifluoroboranuidyl)ethyl]carbamate, Pd(dppf)C12 • CH2CI2, CS2CO3, H2O, toluene, 80 °C, overnight); (b) 4N HC1 in dioxane, room temperature (rt), overnight; (c) TBTU, TEA, DCM, room temperature (rt), overnight Step 1) tert-Butyl (2-(6-nitropyridin-3-yl)ethyl)carbamate Synthesis of 3- yl )ethyl )carbamate)

[0202] 5-Bromo-2-nitropyridine (1 g, 4.93 mmol, 1.0 eq) was dissolved in toluene (20 ml, 0.25 M), and then potassium tert-butyl N-[2-(trifluoroboranuidyl)ethyl]carbamate (1.36 g, 5.41 mmol, 1.1 eq) was added to form [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) coordinated with dichloromethane.

[0203] [1,1' -Bis (diphenylphosphino) ferrocene] di chloro opal ladium(II) , complex with dichloromethane (0.302 g, 0.369 mmol , 0.07 eq), CS2CO3 (4.815 g, 14.8 mmol , 3 eq), H20 (5 ml) were added and heated to 80 °C and stirred overnight. After cooling to room temperature, water and toluene were added and the organic layer was extracted. The organic layer was dried over MgS04, filtered, concentrated, and purified by column chromatography (silica gel, EA / HX). (0.842 g, 64%) Step 2) Synthesis of 2-(6-nitropyridin-3-yl)ethan-l-amine Tert-butyl (2-(6-nitropyridin-3-yl)ethyl)carbamate (0.842 g, 3.15 mmol, 1 eq) was dissolved in 4N HC1 in dioxane (4N HC1 in dioxane, 8 ml, 31.5 mmol, 10 eq) and stirred at room temperature overnight. The reaction mixture was concentrated, and diethyl ether was added to precipitate. The precipitated solid was washed with diethyl ether and filtered under reduced pressure. (0.507 g, 79%) Step 3) Synthesis of compound 7: 3-((4-fluorophenyl)ethynyl)-4-(((1-methyl- 1H-pyrazol- 3-yl)methyl)sulfonyl)-N- (2- (6-nitropyridin- 3-yl)ethyl)benzamide Synthesis of 3-((4- f luorophenyl )ethynyl )— 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )—N—(2— (6- nitropyridin- 3- yl )ethyl )benzamide

[0204] 3-( (4-fluorophenyl )ethynyl )-4- ( ( (1-methyl- 1H-pyrazol-3-yl )methyl)sulfonyl )benzoic acid (3- ( (4- f luorophenyl )ethynyl )-4- ( ( (1-methyl 1H-pyrazol-3-yl )methyl )sulfonyl )benzoic acid, 0.1 g, 0.25 mmol , 1 eq) was dissolved in DCM (0.5 ml, 0.5 MH], and 2-(6-nitropyridin- 3 -yl )ethan-1-amine (2-(6-nitropyr idin— 3— yl )ethan—l— amine, 0.057 g, 0.28 mmol , 1.1 eq), TBTU (0.12 g,

[0205] 0.375 mmol, 1.5 eq), TEA (0.076 ml, 0.55 mmol, 2.2 eq) were added and stirred at room temperature overnight. The reaction mixture was diluted with DCM, and the organic layer was extracted by adding saturated aqueous NaHCOs solution, H2O, and brine. The organic layer was dried over MgSO4, filtered, concentrated, and then precipitated by adding Sun. The precipitated solid was washed with MC and filtered under reduced pressure. (0.052 g, 38%) iH NMR (400 MHz, MeOD) 5 8.51 (s, 1H), 8.27 (d, J = 8.3 Hz, 1H), 8.10 (d, J = 12.5 Hz, 2H), 7.88 (d, J = 8.2 Hz, IH), 7.79 (d, J = 8.2 Hz, IH), 7.75 - 7.69 (m, 2H), 7.43 (s, IH), 7.21 (t, J = 8.4 Hz, 2H), 6.15 (s, IH), 4.81 (s, 2H), 3.76 - 3.70 (m, 5H), 3.14 (t, J) = 6.8 Hz, 2H). ; MS(ESI) m / e MH + 548.4 Example 9: Synthesis of Compound 8

[0206] Synthesis of N-(2-(6-aminopyridin-3-yl)ethyl)-3-((4-fluorophenyl)ethynyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide Scheme Reagent and Condition (a) Zn, NH4Cl, 1,4-dioxane, H2O, room temperature (rt), overnight

[0207] 3-( (4-fluorophenyl)ethynyl )-4- ( ( (1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl )- N- (2- (6-nitropyridin-3-yl)ethyl )benzamide 3- ( (4-f luorophenyl )ethynyl )-4-

[0208] (((1— methyl— IH— pyr azol— 3— yl )methyl)sulfonyl )— N— (2— (6— nitropyr idin— 3— yl )ethyl )benzamide (0.046 g, 0.084 mmol , 1 eq) was dissolved in 1,4-dioxane: water (H2O) (3:1 (V / V) (1 ml, 0.084 MH]), then Zinc (0.055 g, 0.84 mmol, 10 eq) and NH4CI (0.045 g, 0.84 mmol, 10 eq) were added and stirred at room temperature overnight. The reaction mixture was washed with MeOH and filtered under reduced pressure through celite. The filtrate was concentrated and purified by reverse phase column chromatography (0.1% formic acid in IfeO / Acetonitrile). Purified. (0.021 g, 47%) iH NMR (400 MHz, MeOD) 5 8.13 (s, 1H), 7.90 (d, J= 8.6 Hz, 2H), 7.83

[0209] (d, J= 8.3 Hz, IH), 7.78 - 7.73 (m, 2H), 7.63 (d, J= 8.6 Hz, IH), 7.45 (s,

[0210] IH), 7.23 (t, J = 8.3 Hz, 2H), 6.74 (d, J = 8.8 Hz, IH), 6.16 (s, IH), 4.84

[0211] (s, 2H), 3.74 (s, 3H), 3.60 (t, J = 6.7 Hz, 2H), 2.82 (t, J = 6.7 Hz, 2H).

[0212] MS(ESI) m / e MH + 518.4 Example 10: Synthesis of compound 9

[0213] Synthesis of N-(3-(1H-pyrazol-4-yl)propyl)-3-((4-fluorophenyl)ethynyl)-4-((3-(trifluoromethyl)benzyl)sulfonyl)benzamide

[0214] Scheme Reagent and Condition (a) 1-(chloromethyl)-4-(trifluoromethyl)benzene, TEA, ACN, reflux, 1 h (Ih); (b) mCPBA, MC, room temperature (RT), overnight; (c) Fe, NH4C1, EtOH, water (H2O), reflux, 1 h (Ih); (d) Sodium nitrite (NaNO'), potassium iodide (KI), pTSA, ACN, 0°C, 1 h (1 h); (e) 1-ethynyl-4-fluorobenzene, TEA, Cui, PdC12(PPh3)2, ACN, Reflux, 1 h (Ih); (f) NaOH, EtOH, H2O, reflux, 1 h (Ih); (g) 3-(IH-pyrazol-4-yl)propan-l-amine dihydrochloride, TBTU, TEA, MC, room temperature (rt), overnight Step 1) Synthesis of methyl 3-nitro-4-((4-(trifluoromethyl)benzyl)thio)benzoate Methyl 4-mercapto-3-nitrobenzoate, 0.1 g, 0.469 mmol , 1 eq) was dissolved in ACN (5 ml , 0.1 M) to give 1-(chloromethyl)-4-(trifluoromethyl)benzene (l-(chloromethyl)-4-

[0215] ( tr if fluoromethy 1 )benzene , 0.07 ml , 0.469 mmol , leq) and TEA (0.09 ml , 0.61 mmol , 1.3 eq) were added and refluxed for 1 hour. After completion of the reaction, the mixture was concentrated, water was added, and extraction was performed using a distilled water bath. The organic layer was dried over MgS04, filtered, concentrated, and obtained as a crude product. (0.15g, 85%) iH NMR (400 MHz, CDC13) 8 8.90 (s, 1H), 8.19 (d, J = 8.4 Hz, 1H) , 7.71 (s, IH), 7.64 (dd, J = 16.9, 7.6 Hz, 2H), 7.52 (t, J = 8.6 Hz, 2H), 4.32 (s, 2H), 3.99 (s, 3H). Step 2) Synthesis of methyl 3-nitro-4-((4-(trifluoromethyl)benzyl)sulfonyl)benzoate Methyl 3-nitro-4-((4-(trifluoromethyl)benzyl)thio)benzoate (methyl 3-nitro-4-((4-(trifluoromethyl)benzyl)sulfonyl)benzoate, 0.15 g, 0.4 mmol, leq) was dissolved in MC (2 ml, 0.2 M), mCPBA (0.68 g, 3.96 mmol, 10 eq) was added, and the mixture was stirred overnight. After completion of the reaction, saturated aqueous NaHCOs was added, and the mixture was extracted with MC. The organic layer was dried over MgS04, filtered, concentrated, and obtained as a crude product. (0.138g, 86%) iH NMR (400 MHz, CDCI3) 8 8.43 (s, IH), 8.16 (d, J = 8.0 Hz, IH) , 7.69 (d, J = 8.1 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.56 - 7.51 (m, 2H), 7.45 (t, J = 7.6 Hz, 1H), 4.89 (s, 2H), 4.00 (s, 3H).Step 3) Synthesis of methyl 3-amino-4-((4-(trifluoromethyl)benzyl)sulfonyl)benzoate Methyl 3-nitro-4-((4-(trifluoromethyl)benzyl)sulfonyl)benzoate (methyl 3— nitro— 4— ((4— (trifluoromethyl)benzyl)sulfonyl)benzoate, 0.14 g, 0.342 mmol, 1 eq) was dissolved in ethanol (EtOH) : water (H2O) (7 ml, 4:l(v: v) , 0.05 M), and then Fe (0.1 g, 1.71 mmol, 5 eq) and NH4CI (0.091 g, 1.71 mmol, 5 eq) were added. After adding, it was refluxed and stirred for 1 hour. After cooling to room temperature, it was filtered through Celite, water was added to the filtrate, and extracted with a toyo. The organic layer was dried over MgS04, filtered, and concentrated to obtain a crude product. (0.12 g, 93.8%) iH NMR (400 MHz, CDC13) 8 7.57 (d, J = 7.4 Hz, 1H), 7.44 - 7.32 (m, 4H), 7.28 (d, J = 6.1 Hz, 2H), 5.12 (s, 2H), 4.43 (s, 2H), 3.92 (s, 3H). Step 4) Synthesis of methyl 3-iodo-4-((4-(trifluoromethyl)benzyl)sulfonyl)benzoate Methyl 3-amino-4-((4-(trifluoromethyl)benzyl)sulfonyl)benzoate (0.373 g, 1 mmol, 1 eq) was dissolved in ACN (10 ml, 0.1 M), pTSA (0.517 g, 3 mmol, 3 eq) was added, and then sodium nitrite (0.Add KI (0.169 g, 1.02 mmol, 1.02 eq) dissolved in 1 ml of water and stir at room temperature for 1 hour. After neutralizing to pH 8 or higher with saturated aqueous NaHCOs solution, extract with distilled water. The organic layer was dried over MgSO4, filtered, concentrated, and purified by column chromatography (silica gel, EA / HX). (0.175 g, 36%) iH NMR (400 MHz, CDCls) 8 8.77 (s, 1H), 8.01 (d, J = 8.2 Hz, 1H).

[0216] 7.86 (d, J= 8.1 Hz, IH), 7.59 (d, J= 5.0 Hz, IH), 7.44 (d, J= 6.3 Hz, 3H), 4.75 (s, 2H), 3.99 (s, 3H). Step 5) Methyl 3-((4-fluorophenyl)ethynyl)-4-((4-(trifluoromethyl)benzyl)sulfonyl)benzoate (methyl 3-( (4-f luoropheny 1 )ethyny 1 )-4-( (4-

[0217] Synthesis of (trifluoromethyl)benzyl)sulfonyl)benzoate Methyl 3-iodo-4-((4-(trifluoromethyl)benzyl)sulfonyl)benzoate (methyl 3— iodo— 4— ((4— (tri fluoromethyl)benzyl)sulfonyl)benzoate, 0.194 g, 0.4 mmol, 1 eq) was dissolved in ACN (4 nil, 0.1 M), then TEA (0.12 ml, 0.88 mmol, 2.2 eq), PdC12(PPhs)2 (8.4 rag, 0.012 nmol, 3 mol%), and Cui (3 mg, 0.016 mmol, 4 mol%) were added and stirred at room temperature for 5 min. 1-ethynyl-4-fluorobenzene (1- ethynyl-4-f luorobenzene) ?0.07 ml, 0.6 mmol, 1.5 eq) was added and stirred at 90°C for 1 hour. After cooling to room temperature, the residue was concentrated and purified by column chromatography (silica gel, EA / HX). (0.183 g, 96.3%) iH NMR (400 MHz, CDC13) 8 8.40 (s, IH), 8.01 (d, J = 8.1 Hz, IH),

[0218] 7.87 (d, J= 8.3 Hz, IH), 7.71 (t, J= 6.1 Hz, 2H), 7.57 (d, J= 7.1 Hz, IH), 7.47 - 7.38 (m, 3H), 7.17 (t, J = 7.9 Hz, 2H), 4.76 (s, 2H), 4.01 (s, 3H). Step 6) 3- ((4-fluorophenyl)ethynyl)-4- ((4-(trifluoromethyl)benzyl)sulfonyl)benzoic acid (3- ( (4- f luorophenyl )ethynyl )-4- ( (4-

[0219] Synthesis of methyl 3-((4-fluorophenyl)ethynyl)-4-((4-(trifluoromethyl)benzyl)sulfonyl)benzoate (methyl 3-((4-f luorophenyl)ethynyl)— 4—((4—

[0220] (trifluoromethyl)benzyl)sulfonyl)benzoate (0.183 g, 0.396 mmol, 1 eq) was dissolved in EtOH (8 ml, 0.05 M), then NaOH (0.079 g, 1.98 mmol, 5 eq) dissolved in H2O (0.8 ml) was added and refluxed for 1 hour. After cooling to room temperature, concentrated, and diluted with water. After adjusting the pH to 5-6 with IN HC1, the resulting solid was filtered, washed with water, and dried. (0.14 g, 76.5%) iH NMR (400 MHz, DMSO) 5 8.28 (s, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.84 (d, J = 8.3 Hz, IH), 7.80 - 7.73 (m, 2H), 7.68 (d, J = 7.6 Hz, IH), 7.58 - 7.51 (m, IH), 7.51 - 7.47 (m, IH), 7.45 (s, IH), 7.38 (t, J = 8.5 Hz, 2H), 5.03 (s, 2H). Step 7) Synthesis of N-(3-(IH-pyrazol-4-yl)propyl)-3-((4-fluorophenyl)ethynyl)-4-((3-(trifluoromethyl)benzyl)sulfonyl)benzamide

[0221] 3-((4-fluorophenyl)ethynyl)-4-((4-(trifluoromethyl)benzyl)sulfonyl)benzoic acid (3— ((4— f luorophenyl)ethynyl)-4-( (4-

[0222] (trifluoromethyl)benzyl)sulfonyl)benzoic acid, 0.046 g, 0.1 mmol, 1 eq) was dissolved in MC, then TBTU (0.048 g, 0.15 mmol, 1.5 eq), TEA (0.03 ml, 0.22 mmol, 2.2 eq), and 3-(IH-pyrazol-4-yl)propan-1-amine dihydrochloride (3-(IH-pyrazol-4-yl)propan-1-amine dihydrochloride, 0.022 g, 0.11 mmol, 1.1 eq) were added and stirred at room temperature overnight. After completion of the reaction, saturated NaHCOs aqueous solution was added, neutralized, and extracted with MC. The organic layer was dried over MgS04, filtered, concentrated, and purified by column chromatography (silica gel, EA 100%). (35.7 mg, 62.7%) iH NMR (400 MHz, CDCls) 8 8.05 (s, 1H), 7.78 (d, J = 8.1 Hz, 1H),

[0223] 7.69 - 7.63 (m, 2H), 7.61 (d, J = 8.0 Hz, IH), 7.54 (d, J = 6.4 Hz, IH), 7.45 (s, 2H), 7.41 - 7.34 (m, 3H), 7.13 (t, J = 8.1 Hz, 2H), 6.35 (s, IH),

[0224] 4.70 (s, 2H), 3.51 (dd, J = 12.6, 6.3 Hz, 2H), 2.62 (t, J = 7.2 Hz, 2Hff), 1.99 - 1.89 (m, 2H). m / e MH + 570.1 Example 11: Synthesis of compound 10

[0225] N-(3-(1H-pyrazol-4-yl)propyl)-3-((4-fluorophenyl)ethynyl)-4-(((1-

[0226] (pyridin-4-yl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide N- (3-(IH-pyr azo 1-4- yl)propyl)-3-((4- f luoropheny 1 )ethynyl )— 4— (((1— (pyr idin— 4— yl )— IH— pyrazol— 3— yl )methyl )sulfonyl ) benz am ide

[0227] Scheme Reagent and Condition (a) 4-iodopyridine, K3PO4, Cui, 1,2-transdimethylaminocyclohexane, 110°C, 16 h; (b) 1.0 M L1AIH4 in THF, THF, 0°C, 1 h; (c) SOCI2, MC, 0°C —reflux; (d) methyl 4-mercapto-3-nitrobenzoate, K2CO3, DMF, room temperature (rt), overnight; (e) mCPBA, MC, room temperature (RT), overnight; (f) Fe, NH4CI , ethanol (EtOH), water (H2O), reflux, 1 h (Ih); (g) sodium nitrite (NaN02), KI, pTSA, ACN, 0°C, 1 h (1 h); (h) l-ethynyl-4-fluorobenzene, TEA, Cui, PdCl2(PPh3)2, ACN, reflux, 1 h (Ih); (i) NaOH, EtOH, H2O, reflux, 1 h (Ih); (j) 3-(IH-pyrazol-4-yl)propan-l-amine dihydrochloride, TBTU, TEA, MC, room temperature (rt), overnight 1) Ethyl 1-(pyridin-4-yl)-1H-pyrazole-3-carboxylate ethyl 1-

[0228] Synthesis of (pyr idin-4-yl)-lH-pyrazole-3-carboxylate Put ethyl 1H-pyrazole-3-carboxylate (lg, 7.2 mmol, leq) in a pressure tube and dissolve it in toluene (30 ml, 0.2 M), then add 4-iodopyridine (1.54 g, 7.56 mmol, 1.05 eq), K3PO4 (3.8 g, 18 mmol, 2.5 eq), Cui (0.14 g, 0.72 mmol, 0.1 eq), 1,2- trans dimethylaminocyclohexane (1,2- trans dimethyl ami nocyclohexane, 0.22 ml, 1.44 mmol, 0.2 eq) was added and stirred at 110°C for 16 hours. After the reaction was completed, it was cooled to room temperature, water was added, and extraction was performed with ethanol. The organic layer was dried over MgSO, filtered, concentrated, and purified by column chromatography (silica gel, EA / HX). (1.1 g, 70.5%) Na NMR (400 MHz, CDCI3) 6 8.71 (d, J = 4.9 Hz, 2H), 8.06 (s, 1H), 7.72 (d, J = 4.9 Hz, 2H), 7.04 (s, 1H), 4.46 (q, J = 6.8 Hz, 2H), 1.43 (t, J = 6.9 Hz, 3H). Step 2) Synthesis of (l-(pyridin-4-yl)- lH-pyrazole-3-yl)methanol Ethyl l-(pyridin-4-yl)- lH-pyrazole-3-carboxylate (ethyl l-(pyridin-4- yl)—lH—pyrazole— 3— carboxylate, 1.1 g, 5.06 mmol, 1 eq) was dissolved in anhydrous THF (50 ml, 0.1 M) and then stirred at 0°C in 1.0 M L1AIH4 in THF (7.6 ml, 7.60 mmol, 1.5 eq) was slowly added dropwise and stirred for 1 hour. After completion of the reaction, water and oil were added, the solid was filtered, and the filtrate was concentrated to obtain a crude product. (0.89 g, 100%) iH NMR (400 MHz, MeOD) 5 8.59 (d, J= 5.3 Hz, 2H), 8.42 (s, 1H), 7.87 (d, J = 5.4 Hz, 2H), 6.63 (s, IH), 4.70 (s, 2H). Step 3) 4-(3-(chloromethyl)- IH-pyrazol-1-yl)pyridine (4-(3-.

[0229] Synthesis of ( chloromethyl ) - IH-py r az o 1 - 1-y 1 )pyr idine)

[0230] (1-(pyridin-4-yl)-IH-pyrazol-3-yl)methanol ((1-(pyridin-4-yl)-IH-pyrazol-3-yl)methanol, 0.89g, 5.06mmol, leq) was dissolved in MC (25ml, 0.2M), and SOC12 (1.1ml, 15.2mmol, 3eq) was slowly added dropwise at 0°C, followed by reflux stirring overnight. After completion of the reaction, the mixture was concentrated under reduced pressure and obtained as a crude product. (1.42 g, 100%) iH NMR (400 MHz, MeOD) 5 8.62 (d, J= 5.3 Hz, 2H), 8.45 (s, IH), 7.89 (d, J = 5.4 Hz, 2H), 6.69 (s, IH), 4.73 (s, 2H). Step 4) Synthesis of methyl 3-nitro-4- (((1-(pyridin-4-yl)- IH-pyrazol-3-yl)methyl)thio)benzoate

[0231] 4-(3-(chloromethyl)-1H-pyrazol-1-yl)pyridine (4-(3-(chloromethyl)-lH-pyrazol-l-yl)pyr idine, 0.091g, 0.47mmol, leq) was dissolved in DMF (5ml, 0.1M), and then K2CO3 (0.13g, 0.94mmol, 2eq) was added. Methyl 4-mercapto-3-nitrobenzoate (0.1g, 0.47mmol, leq) dissolved in DMF (5ml, 0.1MH) was slowly added, and the mixture was stirred at room temperature overnight. After completion of the reaction, water was added, and the resulting solid was filtered and dried to obtain a crude product. (0.09g, 52%) iH NMR (400 MHz, MeOD) 5 8.77 (s, IH), 8.60 (d, J= 5.3 Hz, 2H), 8.42 (s, 1H), 8.21 (d, J = 8.6 Hz, 1H), 7.98 (d, J = 8.6 Hz, 1H), 7.87 (d, J = 5.5 Hz, 2H), 6.67 (s, 1H), 4.49 (s, 2H), 3.96 (s, 3H). Step 5) Methyl 3-nitro-4-(((1-(pyridin-4-yl)- 1H-pyrazol-3-yl)methyl)sulfonyl)benzoate (methyl 3-nitro-4-( ( (1-(pyridin-4- y 1 Synthesis of methyl 3-nitro-4-( ( (1-(pyridin-4-yl)-1H-pyrazol-3-yl)methyl)thio)benzoate) Methyl 3-nitr o-4- (((1-(pyridin-4-yl)-1H-pyrazol-3-yl)methyl)thio)benzoate (0.61 g, 1.65 mmol, 1 eq) was dissolved in MC (8 ml, 0.2 M), mCPBA (2.8 g, 16.46 mmol, 10 eq) was added, and the mixture was stirred overnight.After completion of the reaction, saturated NaHCOs aqueous solution was added and extracted with MC. The organic layer was dried over MgSO, filtered, concentrated, and obtained as a crude product. (0.685g, 100%) iH NMR (400 MHz, MeOD) 5 8.50 (s, 1H), 8.43 (s, 1H) , 8.36 (d, J= 6.5 Hz, 2H), 8.28 (d, J = 7.9 Hz, IH), 7.99 (s, IH), 7.95 (d, J = 7.9 Hz, 2H), 7.86 (d, J= 6.6 Hz, 2H), 7.60 (d, J= 7.8 Hz, IH), 7.47 (t, J= 7.9 Hz, IH), 6.72 (s, IH), 5.11 (s, 2H), 4.00 (s, 3H). Step 6) Synthesis of methyl 3-amino-4-(((1-(pyridin-4-yl)-lH-pyrazol-3-yl)methyl)sulfonyl)benzoate Methyl 3-nitro-4-( ((1-(pyridin-4-yl)-lH-pyrazol-3-yl)methyl)sulfonyl)benzoate, 0.385g, 0.96mmol, 1 eq) was dissolved in ethanol (EtOH): water (H2O) (10 ml, 4:l(v:v), 0.1 MH], then Fe (0.27 g, 4.78 mmol, 5 eq) and NH4C1 (0.26 g, 4.78 mmol, 5 eq) were added and refluxed for 1 hour. After cooling to room temperature, Celite filtered, water was added to the filtrate, and extraction was performed with a toyo. The organic layer was dried over MgS04, filtered, concentrated, and purified by column chromatography (silica gel, EA / HX). (0.085 g, 24%) iH NMR (400 MHz, MeOD) 5 8.55 (d, J = 4.9 Hz, 2H), 8.38 (s, 1H), 7.71 (d, J = 5.1 Hz, 2H), 7.51 (s, IH), 7.46 (d, J = 8.2 Hz, IH), 7.16 (d, J = 8.2 Hz, IH), 6.53 (s, IH), 4.68 (s, 2H), 3.90 (s, 3H). Step 7) Synthesis of methyl 3-amino-4-( ((1-(pyridin-4-yl)-IH-pyrazol-3-yl)methyl)sulfonyl)benzoate (methyl 3-amino-4-( ((1-(pyridin-4-yl MH-pyrazol-3-yl)methyl)sulfonyl)benzoate, 0.159 g, 0.427 mmol, 1 eq) was added to ACN (4 ml, 0.1 M) and add pTSA (0.22 g, 1.28 mmol, 3 eq), then add sodium nitrite NaN02 (0.03 g, 0.436 mmol, 1.02 eq) dissolved in 0.4 ml of water at 0°C and KI (0.142 g, 0.854 mmol, 2 eq) dissolved in 0.8 ml of water. After reacting at room temperature for 1 hour, add saturated NaHCOs aqueous solution, neutralize to pH 8 or higher, and extract with a solvent. The organic layer was dried over MgS04, filtered, and concentrated to obtain a crude product. (0.2 g, 100%) iH NMR (400 MHz, CDCI3) 8 8.75 (s, IH), 8.61 (d, J = 4.9 Hz, 2H) , 8.00 (s, 2H), 7.92 (s, IH), 7.43 (d, J= 4.9 Hz, 2H), 6.55 (s, IH), 4.88 (s,.

[0232] 2H), 3.95 (s, 3H). Step 8) Synthesis of ethyl 3-((4-fluorophenyl)ethynyl)-4-(((1-(pyridin-4-yl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzoate (ethyl 3-((4-f luorophenyl )ethynyl )-4- ( ( (l-(pyr idin-4-y 1 ) -IH-pyr azo 1 -3-yl )methyl )sulfonyl )benzoate) (methyl 3 - iodo-4-( ( (1-(pyridin-4-yl )-1H-pyrazol-3-yl )methyl )sulfonyl )benzoate) )sulfonyl )benzoate, 0.2 g, 0.414 mmol, 1 eq) was dissolved in ACN (4 nil, 0.1 M), then TEA (0.13 ml, 0.92 mmol, 2.2 eq), PdC12(PPh3)2 (8.7 nig, 0.012 mmol, 3 mol%), and Cui (3.2 mg, 0.017 ranio 1, 4 rao 1%) were added and stirred at room temperature for 5 minutes. After adding 1-ethynyl-4-f luorobenzene (0.071 ml, 0.62 mmol, 1.5 eq), the mixture was stirred at 90°C for 1 hour, cooled to room temperature, concentrated, and purified by column chromatography (silica gel, EA / HX). (0.104 g, 51.5%) I NMR (400 MHz, CDC13) 6 8.61 (s, 2H), 8.38 (s, 1H), 8.01 (s, 2H), 7.91 (s, 1H), 7.73 - 7.65 (m, 3H), 7.43 (s, 2H), 7.11 (t, J = 8.2 Hz, 2H), 6.55 (s, 1H), 4.89 (s, 2H), 3.98 (s, 3H).Step 9) Synthesis of 3-((4-fluorophenyl)ethynyl)-4-(((1-(pyridin-4-yl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid (3-((4-f luorophenyl)ethyny 1)-4-( ((l-(pyridin-4-yl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid) Ethyl 3-((4-fluorophenyl)ethynyl)-4-(((1-(pyridin-4-yl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzoate (ethyl 3-((4-f luorophenyl)ethyny 1)-4-( (1-(pyridin— 4— yl)— 1H— pyrazol— 3— yl )methyl )sulfonyl )benzoate, 0.104 g, 0.212 mmol , 1 eq) was dissolved in EtOH (4 ml, 0.05 M), then NaOH (0.042 g, 1.062 mmol, 5 eq) dissolved in H2O (0.4 ml) was added and refluxed for 1 hour. After cooling to room temperature, the mixture was concentrated and diluted with water. After adjusting the pH to 5 to 6 with IN HC1, the resulting solid was filtered, washed with water, and dried. (0.039 g, 40%) Step 10) Synthesis of N-(3-(1H-pyrazol-4-yl)propyl)-3-((4-fluorophenyl)ethynyl)-4-(((1-(pyridin-4-yl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide.

[0233] 3-((4-fluorophenyl)ethynyl)-4-(((1-(pyridin-4-yl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid (3-((4-f luorophenyl)ethynyl)-4-(((1-(pyridin-4-y1)-IH-pyr azo 1-3-yl)methyl)sulfonyl)benzoic acid, 0.039g, 0.08mmol, 1 eq) was dissolved in MC, and then TBTU (0.039g, 0.12mmol, 1.5 eq), TEA (0.025 ml, 0.176mmol, 2.2 eq), 3-(1H-pyrazol-4-yl)propan-1-amine dihydrochloride (3-( IH-pyr azo 1-4- yl )propan-l-amine dihydrochloride, 0.0174 g, 0.088 mmol , 1.1 eq) was added and stirred at room temperature overnight. After completion of the reaction, saturated aqueous NaHCOs was added, neutralized, and extracted with MC. The organic layer was dried over MgSO 4 , filtered, concentrated, and purified by column chromatography (silica gel, MeOH / MC). (16.2 mg, 35.6 %) iH NMR (400 MHz, MeOD) 5 8.53 (d, J = 5.2 Hz, 2H), 8.35 (s, 1H), 8.21

[0234] (s, IH), 7.98 (d, J= 8.3 Hz, IH), 7.86 (d, J= 8.3 Hz, IH), 7.77 - 7.70 (m, 2H), 7.64 (d, J = 5.3 Hz, 2H), 7.49 (s, 2H), 7.21 (t, J = 8.2 Hz, 2H), 6.57

[0235] (s, IH), 4.99 (s, 2H), 3.45 (t, J = 7.2 Hz, 2H), 2.62 (t, J = 7.2 Hz, 2H),

[0236] 1.93 (p, J = 6.8 Hz, 2H). MS(ESI) m / e MH +569.2 Compounds 15, 16, 17, and 25 can be synthesized by changing the reactants in a method substantially the same as that of Example 11. Example 12: Compound 245 (Synthesis of hydrochloride of Compound 47)

[0237] Synthesis of N-(3-(1H-pyrazol-4-yl)propyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((4-(piperidin-4-yl)phenyl)ethynyl)benzamide hydrochloride N-(3-(1H-pyrazol-4-yl)propyl)— 4— (((1— methyl— 1H— pyrazol— 3— yl)methyl)sulfonyl)-3-( (4-(piperidin-4-yl)phenyl)ethynyl)benzamide hydrochloride

[0238] Reaction Scheme 10. (a) Trimethylsilylacetylene,

[0239] PdC12[PPh3k Cui, TEA, Toluene, 100°C, 12 h (12h); (b) K2CO3, MeOH, room temperature (rt). 1 h (Ih); (c) PdChfPPhsh, Cui, TEA, ACN, reflux, 12 h (12h); (d) NaOH, H2O, MeOH, 55°C; 2 h (2h); (e) (IH—pyrazol— 4— yl )propan—l— amine dihydrochloride, TBTU, TEA, DCM, room temperature (rt), 12 h (12h); (f) 4N HC1 in dioxane, 1,4-dioxane, room temperature (r . t ) . 12 hours (12h) Step 1) Synthesis of tert-butyl 4-(4-((trimethylsilyl)ethynyl)phenyl)piper idine-1-carboxylate Tert-butyl 4-(4-((trimethylsilyl)ethynyl)phenyl)piper idine-1-carboxylate (0.34g, 1mmol, leq) and trimethylsilylacetylene (0.24ml, 1.5mmol, 1.5eq) were added to toluene (0.1M, After dissolving in 10 ml of PdC12[PPh3]2 (0.07 g, 0.1 mmol, O.leq), Cui (0.019 g, 0.1 mmol, O.leq), and triethylamine (0.6 ml, 4 mmol, 4 eq) in water, the mixture was stirred at 100°C for 12 h. The reaction mixture was extracted with DCM. The organic layer was dried over MgS04 and concentrated under reduced pressure. The resulting residue was used in the next reaction without purification.Step 2) Synthesis of tert-butyl 4-(4-ethynylphenyl)piperidine-1-carboxylate Tert-butyl 4-(4-((trimethylsilyl)ethynyl)phenyl)piperidine-1-carboxylate (0.31 g, 0.87 mmol, leq) was dissolved in methanol (0.2 M), and then K2C03 (0.6 g, 4.33 mmol, 5 eq) was added and stirred at room temperature for 1 hour. After the reaction was completed, the product was filtered, concentrated, and purified by column chromatography (silica gel, 10% EA / HX) to obtain the target compound (0.266 g). Step 3) Synthesis of tert-butyl 4-(4-((5-(methoxycarbonyl)-2-(((1-methyl- 1H-pyrazol- 3-yl)methyl)sulfonyl)phenyl)ethynyl)phenyl)piperidine- 1-carboxylate (tert-butyl 4-(4- ( (5-(methoxycarbony 1 )— 2—( ( (1— methyl— IH—pyrazol— 3— yl )methyl )sulfonyl )phenyl )ethynyl )phenyl )piperidine—l— carboxylate) methyl 3 -iodo- 4-( ( (1-methyl- 1H-pyrazol- 3 -yl )methyl )sulfonyl )benzoate.

[0240] To (methyl 3— iodo— 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )benzoate, 0.1 g, 0.24 mmol, leq) was added MeCN (2 ml, 0.1 M) and TEA (0.074 ml, 0.53 mmol, 2.2 eq). PdC12[PPh3]2 (5 mg, 3 mol%) and Cul (2 mg, 4 ol%) were added to the reaction mixture, and the mixture was stirred for 5 minutes at room temperature under a nitrogen atmosphere. Then, tert-butyl 4- (4-ethynylphenyl) piperidine- 1-carboxylate (0.1 g, 1.5 eq) was added. The reaction mixture was stirred at 90°C.The mixture was stirred for 12 hours at 0°C and concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel, 40-50% EA / HX) to obtain the target compound (0.1 g). iH NMR (400 MHz, CDCls) 68.35 (d, J = 1.1 Hz, 1H), 7.97 (dd, J = 11.4, 4.8 Hz, 3H), 7.63 (d, J = 8.1 Hz, 2H), 7.20 (d, J = 2.0 Hz, 2H), 6.13 (d, J = 2.1 Hz, IH), 4.81 (s, 2H), 4.26 (s, 2H), 3.98 (s, 3H), 3.76 (s, 3H), 2.81 (t, J = 12.2 Hz, 2H), 2.69 (t, J = 12.2 Hz, IH), 1.83 (d, J = 13.0 Hz, 2H), 1.65 (d, J = 12.4 Hz, 2H), 1.49 (s, 9H). Step 4) Synthesis of 3- ((4-(1- (tert-butoxycarbonyl)piperidin- 4-yl)phenyl)ethynyl)- 4- (((1-methyl- 1H-pyrazol- 3-yl)methyl)sulfonyl)benzoic acid (3- ((4-(1- (tert-butoxycarbonyl )piper idin— 4— yl )phenyl )ethynyl )— 4— (((1— methyl— IH— pyrazol— 3— yl )methyl )sulfonyl )benzoic acid) tert-butyl 4- (4-( (5-(methoxycarbonyl )- 2- ( ( (1-methyl- 1H-pyrazol- 3-yl )methyl)sulfonyl)phenyl)piperidine- 1-carboxylate (tert- butyl 4- (4-((5-。

[0241] (met hoxy car bony 1 )— 2— (((1— methyl— IH— pyrazol— 3— yl )methyl )sulfonyl ) phenyl )ethynyl ) phenyl )piper idine— 1— carboxylate, 0.1g,

[0242] Ethanol (3 ml, 0.05 M), H2O (0.5 ml), and NaOH (0.035 g, 0.87 mmol, 5 eq) were added to a solution of 0.173 mmol, leq) and stirred at 100°C for 1 hour. The reaction was confirmed by TLC, and when the reaction was completed, the pH of the reaction product was adjusted to 1 with IN HC1 aqueous solution and extracted with ethanol. The organic layer was washed with water, dried over magnesium sulfate, and concentrated under reduced pressure to obtain the target compound (0.082 g, 84%). Step 5) Synthesis of tert-butyl 4- (4- ((5- ((3- (1H-pyrazol- 4 -yl)propyl)carbamoyl)-2- (((1-methyl- 1H-pyrazol- 3 -yl)methyl)sulfonyl)phenyl)ethynyl)phenyl)piperidine-1-carboxylate

[0243] 3- ((4-(1- (tert-butoxycarbonyl)piperidin-4-yl)phenyl)ethynyl)-4- (((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid (3- ((4-(1- (tert-butoxycarbonyl)piper idin-4-yl)phenyl)ethynyl)— 4— (((1— methyl— 1H— pyrazol— 3— yl)methyl )sulfonyl )benzoic acid, 0.082 g, 0.145 mmol , 1 eq) was added to DCM (2 ml) TBTU (0.071 g, 0.22 mmol , 1.5 eq), TEA (0.045 ml , 0.32 mmol , 2.2 eq), 3— (1H—pyrazol-4-yl)propan-1-amine dihydrochloride (3-(1H-pyrazol-4-yl)propan-l-amine dihydrochloride, 32 mg, 0.16 mmol, 1.1 eq) was added and stirred for 2 hours. Water was added to the reaction mixture and extracted with oil. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 100% EA) to obtain the target compound (0.02 g, 21%).Step 6) Synthesis of N-(3-(1H-pyrazol-4-yl)propyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((4-(piperidin-4-yl)phenyl)ethynyl)benzamide hydrochloride (N-(3-(1H-pyrazol-4-yl)propyl)— 4—(((1— methyl— 1H— pyrazol— 3— yl)methyl)sulfonyl)— 3—((4— (piperidin-4-yl)phenyl)ethynyl)benzamide hydrochloride) tert-butyl 4-(4-((5-((3-(1H-pyrazol-4-yl)propyl)carbamoyl)-2-(((1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl)phenyl)ethynyl)phenyl)piperidine-1-carboxylate (tert-butyl 4— (4— ((5— ((3— (1H— pyrazol— 4— yl )propyl )carbamoyl )—2—(((l—methyl— IH-pyr azo 1-3-yl )methyl )sulfonyl )phenyl )ethynyl )phenyl )piperidine—l— carboxylate, 0.02g, 0.03mmol , leq) was dissolved in 1,4-dioxane (1,4-dioxane, 1ml, 0.03M) and then 4N HC1 in 1,4-di oxane, 0.015ml, 0.06 mmol, 2 eq) was added and stirred at room temperature for 12 hours. After the reaction was completed, the resulting solid was filtered and washed with 1,4-dioxane to obtain the target compound (0.0066 g, 39%). iH NMR (400 MHz, MeOD) 68.20 (s, 3H), 7.96 — 7.86 (m, 3H), 7.70 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 1.9 Hz, IH), 7.42 (d, J = 8.1 Hz, 2H), 6.18 (d, J = 2.0 Hz, IH), 4.86 (s, 2H), 3.74 (s, 3H), 3.55 (d, J= 12.5 Hz, 2H), 3.51 — 3.44 (m, 3H), 3.19 (t, J = 12.6 Hz, 2H), 3.09 — 2.98 (m, 2H), 2.73 (dd, J = 14.4, 7.3 Hz, 3H), 2.14 (d, J = 14.3 Hz, 2H), 2.02 — 1.97 (m, 3H). Compound 83, was obtained by changing the reactants in substantially the same manner as in Example 12.

[0244] Compounds 84, 85, 86, 87, 88, 89, 90, 91, 105, and 249 can be synthesized. Example 13: 4-ethynyl-N-(2-(piperidin-1-yl)ethyl)benzamide _£4-ethynyl-

[0245] Synthesis of N-(2-(piper idin-1-yl)ethyl)benzamide)

[0246] 4-ethynyl benzoic acid (2.0 g, 13.7 mmol, 1 eq) was added DMF (20 ml), HATU (07.8 g, 20.5 mmol, 1.5 eq), DI PEA (7 ml, 41.1 mmol, 3), 2-(piper idin—l—yl )ethan—l— amine (2.7 ml, 15.4 mmol, 1.1 eq), and stirred for 12 h. Water was added to the reaction mixture, and the organic layer, extracted three times with a Toyo, was washed with an aqueous solution of NH4Cl, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, 10% MeOH / DCM) to obtain the target compound. iH NMR (400 MHz, CDCls) 6 7.81 (d, J = 7.9 Hz, 2H), 7.58 (d, J = 7.8 Hz, 2H), 7.39 (s, IH), 3.68 (m, 2H), 3.23 (s, IH), 2.89-2.99 (m, 6H), 1.80 (m, 4H), 1.62 (s, 2H). Example 14: Synthesis of compound 115

[0247] 3-((4-fluorophenyl)ethynyl)- N-(imidazo[l,2-a]pyridin-7-ylmethyl)- 4-(N-((1-methyl- 1H-pyrazol-3-yl)methyl)sulfamoyl)benzamide (3-((4-f luorophenyl)ethynyl)— N— ( imidazo[l,2— a]pyr idin— 7— ylmethyl )— 4— (N—((l— methyl—

[0248] Synthesis of IH-pyr azo 1-3-yl )methyl )sulfamoyl )benzamide)

[0249] Reagents and conditions: (a) NCS, 2N HCl (aq), ACN, 0 °C to rt, overnight; (b) ACN, 4 h, rt; (c) Zn, NH4Cl, 1,4-dioxane, H2O, rt, overnight; (d) NaNO2, KI, HCl, H2O, 0 °C to rt, 2 h; (e) PdCl2(PPh3)2, CuI, TEA, ACN, 60 °C, 4 h; (f) 1N NaOH, EtOH, 60 °C, overnight; (g) 1-{imidazo[1,2-a]pyridin-7-yl}methanamine dihydrochloride, TBTU, TEA, DCM, rt, overnight. Step 1) Synthesis of methyl 4-(chlorosulfonyl)-3-nitrobenzoate

[0250] NCS (3.131 g, 23.45 mmol, 5 eq) and 2N HC1 aqueous solution (4.69 ml, 9.38 mmol, 2 eq) were added to ACN (46 ml, 0.1 M) and stirred at 0°C for 30 minutes. Methyl 4-mercapto-3-nitrobenzoate (1 g, 4.69 mmol, 1 eq) was added and stirred at room temperature overnight. After completion of the reaction, the mixture was concentrated, diluted with distilled water, and sequentially extracted with NaHC03 aqueous solution and NaCl aqueous solution. The organic layer was dried over MgSO, filtered, and concentrated to obtain the target compound as a crude product. Step 2) Synthesis of methyl 4-(N-((l-methyl- 1H-pyrazol-3-yl)methyl)sulfamoyl)-3-nitrobenzoate

[0251] (1—methyl— 1H—pyrazol— 3—yl)methanamine (1.042 g, 9.38 mmol, 2 eq) was dissolved in ACN (20 ml, 0.23 M), and methyl 4-(chlorosulfonyl)-3-nitrobenzoate (1.311 g, 4.69 mmol, 1 eq) dissolved in ACN (26 ml, 0.18 M) was added dropwise to the reaction mixture. After completion of the reaction, the mixture was extracted with EA and water. The organic layer was dried over MgSO, filtered, concentrated, and purified by column chromatography (silica gel, EA / HEX) to obtain the target compound (0.3 g, 18.4%). Step 3) Synthesis of methyl 3-amino-4-(N-((l-methyl-lH-pyr azo 1-3- yl )methyl )sulfamoyl )benzoate (methyl 4-(N-((l-methyl- 1H-pyrazol- 3 -yl)methyl)sulfamoyl )benzoate) (methyl 4— (N— ((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfamoyl )—3— nitrobenzoate, 0.296 g, 0.835 mmol , 1 eq) was added to 1,4-dioxane: H20(3:l(v / v))(8.3 ml,

[0252] After dissolving in 0.1 M), Zn (0.546 g, 8.35 mmol, 10 eq) and NH4C1 (0.447 g, 8.35 mmol, 10 eq) were added and stirred at room temperature overnight. The mixture was washed with MeOH, filtered under reduced pressure, and concentrated to obtain the target compound as a crude product. Step 4) Synthesis of methyl 3-iodo-4-(N-((l-methyl- 1H-pyrazol- 3-yl)methyl)sulfamoyl)benzoate (methyl 3-iodo-4-(N-((1-methyl- 1H-pyrazol- 3-yl)methyl)sulfamoyl)benzoate) Methyl 3-amino-4-(N-((1-methyl- 1H-pyrazol- 3-yl)methyl)sulfamoyl)benzoate (methyl 3— amino— 4— (N—((l— methyl— 1H— pyrazol— 3— yl)methyl )sulfamoyl )benzoate, 0.255 g, 0.79 mmol, 1 eq), HC1 (7 ml, 0.1 M) was added to H2O (7 ml, After dissolving in 0.1M, 0。Stirred in In. NaN02 (0.082 g, 1.185 mmol, 1.5 eq) dissolved in H20 (7 ml, 0.1 M H) was added dropwise. The reaction solution was stirred at 0 °C for 30 minutes, and then KI (0.393 g, 2.37 mmol, 3 eq) dissolved in H20 (7 ml, 0.1 M) was added dropwise. The reaction solution was stirred at room temperature for 2 hours, neutralized to pH 8 or higher with aqueous NaHCOs solution, and extracted with EA and water. The organic layer was dried over MgS04, filtered, concentrated, and purified by column chromatography (silica gel, EA / HEX) to obtain the target compound (0.167 g, 48.6%). Step 5) Preparation of methyl 3-((4-fluorophenyl)ethynyl)-4-(N-((l-methyl- 1H-pyrazole- Synthesis of methyl 3-((4-fluorophenyl)-1)ethyny-1)-4-(N-((1-methyl-1H-pyrazol-3-yl)methyl)sulfamoyl)benzoate Methyl 3-iodo-4-(N-((1-methyl-1H-pyrazol-3-yl)methyl)sulfamoyl)benzoate (methyl 3— iodo— 4— (N—((l— methyl— 1H— pyrazol— 3— yl)methyl )sulfamoyl )benzoate, 0.167 g, 0.38 mmol, 1 eq) was dissolved in ACN (7.6 ml, 0.05 MH], and then 1-ethynyl-4-fluorobenzene (l-ethynyl-4-f luorobenzene, 0.068 g, 0.57 mmol, 1.5 eq),。

[0253] PdC12(PPh3)2 (0.008 g, 0.01 mmol, 0.03 eq), Cui (0.002 g, 0.01 mmol, 0.03 eq), and TEA (0.077 g, 0.76 mmol, 2 eq) were added and degassed with nitrogen gas (N2 gas). The reaction solution was heated to 60 °C and stirred for 4 hours. After completion of the reaction, it was filtered through celite and extracted with distilled water. The organic layer was washed with water, separated, dried over MgSO, filtered, and concentrated to obtain the target compound as a crude product. Step 6) Synthesis of 3-((4-fluorophenyl)ethynyl)-4-(N-((l-methyl-1H-pyrazol-3-yl)methyl)sulfamoyl)benzoic acid (3-((4-f luoropheny 1 )ethynyl )-4-(N-((l-methyl-1H-pyrazol-3-yl )methyl )sulfamoyl )benzoic acid) Methyl 3-((4-fluorophenyl)ethynyl)-4-(N-((l-methyl-1H-pyrazol-3-yl)methyl)sulfamoyl)benzoate, 0.187 g, EtOH (8 ml, 0.05 M), H2O (4.38 ml, 0.1 M), NaOH (0.175 g, 4.38 mmol, 10 eq) were added to a solution of 0.438 mmol, 1 eq) and stirred at 60°C overnight. After completion of the reaction, the pH of the reaction mixture was adjusted to 1 with IN HC1 aqueous solution and extracted with distilled water. The organic layer was washed with water, separated, dried over MgSO, filtered, and concentrated to obtain the target compound as a crude product.Step 7) Synthesis of 3-((4-fluorophenyl)ethynyl)-N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-(N-((1-methyl-1H-pyrazol-3-yl)methyl)sulfamoyl)benzamide (3-((4-f luorophenyl)ethynyl)—N—(imidazo[l,2—a]pyridin—7—ylmethyl)—4—(N—((l—methyl—IH-pyr azo 1-3-yl)methyl)sulfamoyl)benz am ide).

[0254] To 3-((4-fluorophenyl)ethynyl)-4-(N-((l-methyl-1H-pyrazol-3-yl)methyl)sulfamoyl)benzoic acid (3-((4-f luorophenyl)ethynyl)-4-(N-((l-methyl-1H-pyrazol-3-yl)methyl)sulfamoyl)benzoic acid) (0.131 g, 0.32 mmol, 1 eq) were added DCM (3.2 ml, 0.1 M) and TBTU (0.154 g, 0.48 mmol, 1.5 eq) and stirred at room temperature for 30 min. Then, TEA (0.070 g, 0.7 mmol, 2.2 eq) and 1-{imidazo[l,2- a]pyridin-7-yl}methanamine dihydrochloride (1-{imidazo[l,2- a]pyridin-7-ylLhnethanamine dihydrochloride, 0.077 g, 0.352 mmol, 1.1 eq) were added to the reaction mixture and stirred for 12 hours. Water was added to the reaction mixture and extracted with DCM. The organic layer was dried over MgS04, filtered, concentrated, and purified by column chromatography (silica gel, MeOH / DCM) to obtain the title compound (0.03 g, 17.3%). iH NMR (400 MHz, DMSO) 6 9.36 (s, 1H), 8.54 (s, 1H), 8.51 (d, J = 6.9 Hz, IH), 8.12 (dd, J = 19.3, 8.1 Hz, 2H), 7.90 (s, IH), 7.55 (dd, J = 8.3, 5.7 Hz, 3H), 7.47 (s, IH), 7.42 (d, J = 1.8 Hz, IH), 7.24 (t, J = 8.8 Hz, 2H), 7.10 (s, IH), 6.89 (d, J = 6.2 Hz, IH), 5.81 (d, J = 1.9 Hz, IH), 4.57 (s, 2H), 3.62 (s, 3H); MS MH + 543.6 Example 15: Synthesis of compound 193

[0255] Synthesis of N-(imidazo[l,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((4-((2-(piperazin-1-yl)ethyl)carbamoyl)phenyl)ethynyl)benzamide

[0256] Reagents and conditions: (a) PdC12(PPh3)2, Cui, TEA,

[0257] ACN, 60 °C, 1 hour (1 h); (b) IN NaOH, EtOH, 60 °C, 1 hour (1 h); (c) TBTU, TEA,

[0258] DCM, room temperature (rt), overnight; (d) TFA, DCM, room temperature (rt), overnight Step 1) Synthesis of tert-butyl 4- (2- (4- ((5-(methoxycarbonyl)- 2- (((1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl)phenyl)ethynyl)benzamido)ethyl)piperazine- 1-carboxylate (tert-butyl 4— (2— (4— ((5— (methoxycarbonyl )— 2— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )phenyl )ethynyl )benzamido)ethyl )piperazine—l— carboxylate) Methyl 3 -iodo- 4- ( (1-methyl- 1H-pyrazol- 3 -methyl sulfonyl benzoate

[0259] (methyl 3— iodo— 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )benzoate,

[0260] After dissolving 0.26 g, 0.52 mmol, 1 eq) in ACN (3 ml, 0.2 MH], tert-butyl 4-(2-(4-ethynylbenzamido)ethyl)piperazine-1-carboxylate (0.336 g, 0.84 mmol, 1.5 eq), PdC12(PPhs)2 (0.013 g, 0.0186 mmol, 0.03 eq), Cui (0.0035 g, 0.0186 mmol, 0.03 eq), TEA (0.125 g, 1.24 mmol, 2 eq) were added, and then degassed with nitrogen gas. The reaction mixture was heated to 60 °C and stirred for 1 hour. After completion of the reaction, the mixture was filtered through Celite and extracted with a distilled water. The organic layer was washed with water, separated, dried over MgSO4, filtered, and concentrated to obtain the target compound as a crude product.Step 2) Synthesis of 3-((4-((2-(4-(tert-butoxycarbonyl)piperazin-1-yl)ethyl)carbamoyl)phenyl)ethynyl)-4-(((1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid (3-((4-((2-(4-(tert-butoxycarbonyl)piperazin— 1— yl)ethyl)carbamoyl)phenyl)ethynyl)-4-(((1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid) tert-butyl 4-(2-(4-((5-(methoxycarbonyl)-2-(((1-methyl- 1H-pyrazol-3-yl)methoxy) To (tert-butyl 4— (2— (4— ((5— (methoxycarbonyl )— 2— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )phenyl )ethynyl )benzamido)ethyl )piperazine—l— carboxylate, 0.403 g, 0.62 mmol, 1 eq) were added EtOH (12 ml, 0.05 M), H2O (3.1 ml, 0.2 M), NaOH (0.120 g, 3.1 mmol, 5 eq) and stirred at 60°C for 1 hour. When the reaction was confirmed by TLC and the reaction was completed, the pH of the reaction product was adjusted to 1 with IN HC1 aqueous solution and purified by EA. The organic layer was washed with water, separated, dried over MgS04, filtered, and concentrated to obtain the target compound as a crude product.Step 3) Synthesis of tert-butyl 4- (2- (4- ((5-((imidazo[1,2- a]pyridin- 7 -ylmethyl)carbamoyl)- 2-(( (1-methyl- 1H-pyrazol- 3 -yl)methyl)sulfonyl)phenyl)ethynyl)benzamido)ethyl)piperazine- 1-carboxylate (tert- butyl 4- (2- (4- ((5- ((imidazo[l,2- a]pyr idin- 7-ylmethyl)carbamoyl)— 2— (((1— methyl— 1H— pyrazol— 3— yl)methyl )sulfonyl )phenyl )ethynyl )benzamido)ethyl )piperazine—l— carboxylate).

[0261] 3-( (4-( (2- (4- (tert-butoxycarbonyl)piperazin- 1-yl )ethyl)carbamoyl)phenyl )ethynyl)-4-(( (1-methyl- 1H-pyrazol- 3 -yl)methyl)sulfonyl)benzoic acid (3- ((4- ((2- (4- (tert-butoxycarbonyl )piperazin— 1— yl )ethyl )carbamoyl )phenyl )ethynyl )—4—(((l— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )benzoic acid, 0.394 g, 0.62 mmol, 1 eq) was added to DCM (3 ml, 0.2 M) and TBTU (0.298 g, 0.93 mmol, 1.5 eq) was added and stirred at room temperature for 50 minutes. Then, TEA (0.137 g, 1.36 mmol, 2.2 eq) and l-{imidazo[l,2-a]pyridin-7-yl}methanamine dihydrochloride (l-{imidazo[l,2-a]pyridin-7-yl}me than amine dihydrochloride, 0.150 g, 0.682 mmol, 1.1 eq) were added to the reaction mixture and stirred for 12 hours. Water was added to the reaction mixture and extracted with DCM. The organic layer was dried over MgS04, filtered, concentrated, and purified by column chromatography (silica gel, MeOH / DCM) to obtain the title compound (0.27 g, 56.4%).Step 4) Synthesis of N-(imidazo[l,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((4-((2-(piperazin-1-yl)ethyl)carbamoyl)phenyl)ethynyl)benzamide (N-( imidazo[l,2-a]pyr idin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-3-( (4-( (2-(piperazin-1-yl)ethyl)carbamoyl)phenyl)ethynyl)benzamide) tert-butyl 4-(2-(4-((5-((imidazo[1,2-a]pyridin- 7-ylmethyl)carbamoyl)- 2- (((1-methyl- 1H-pyrazol- 3-yl )methyl)sulfonyl)phenyl)ethynyl)benzamido)ethyl)piperazine- 1-carboxylate (tert- butyl 4- (2- (4- ((5- ((imidazo[l,2- a]pyridin- 7- ylmethyl ) carbamoyl )— 2— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl ) phenyl )ethynyl )benzamido)ethyl )piperazine—l— carboxylate, 0.150 g, 0.196 mmol, leq) was dissolved in DCM (2 ml, 0.1 M H], then TFA (0.223 g, 1.96 mmol, 10 eq) was added and stirred at room temperature overnight. The mixture was stirred. After completion of the reaction, the mixture was concentrated and purified by reverse-phase column chromatography (0.1% formic acid in H2O / ACN) to obtain the title compound (0.067 g, 51.5%). iH NMR (400 MHz, MeOD) 6 8.51 (s, 1H), 8.28 (s, 1H), 8.23 ​​(s, 1H),.

[0262] 7.96 (s, IH), 7.91 (d, J = 5.1 Hz, 3H), 7.78 (d, J = 7.5 Hz, 2H), 7.66 (s,

[0263] IH), 7.59 (s, IH), 7.44 (s, IH), 7.10 (d, J = 6.7 Hz, IH), 6.17 (s, IH),

[0264] 4.85 — 4.83 (m, 2H), 4.70 (s, 2H), 3.72 (s, 3H), 3.57 (s, 3H), 3.50 (s, IH),

[0265] 3.22 (s, 2H), 2.79 (s, 2H), 2.75 — 2.57 (m, 4H); MS MH + 665.58 Compounds 119, 131, 133, 134, and 136 can be synthesized by changing the reactants in substantially the same manner as in Example 15. Example 16: Synthesis of Compound 228

[0266] 3—((4-aminophenyl)ethynyl)-N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide ( 3-((4-aminopheny 1 )ethynyl )-N-

[0267] Synthesis of (imidazo[l,2— a]pyr idin— 7— ylmethyl )— 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )benzamide) Reagents and conditions: 4-ethynylaniline, TEA, Cui, PdC12(PPh3)2, ACN, reflux, 1 hour (Ih);

[0268] N-(Imidazo[1,2-a]pyridin-7-ylmethyl)-3-iodo-4-(((1-methyl-IH-pyrazole-

[0269] 3-yl)methyl)sulfonyl)benzamide N-( imidazo[l ,2- a]pyr idin- 7- ylmethyl )-3-iodo-4- (((1— methyl— IH— pyrazol— 3— yl)methyl)sulfonyl)benzamide, 0.535 g, 1 mmol , 1 eq) was dissolved in ACN (10 ml, 0.1 M), then TEA (0.3 ml, 2.2 mmol, 2.2 eq), PdCl2(PPh3)2 (21 mg, 0.03 mmol , 3 mol%), and Cui (8 mg, 0.04 mmol , 4 mol%) were added and stirred at room temperature for 5 min. 4-Ethynylaniline (4-ethynylani 1 ine, 0.14 g, 1.2 mmol, 1.5 eq) was added and stirred at 90°C for 1 hour. After cooling to room temperature, the mixture was concentrated and purified by column chromatography (silica gel, EA / HX). (0.193 g, 37%) iH NMR (400 MHz, CD30D) 6 8.41 (d, J = 7.0 Hz, 1H), 8.16 — 8.12 (m, 1H), 7.87 (d, J = 8.3 Hz, IH), 7.84 — 7.79 (m, 2H), 7.53 (s, IH), 7.48 (s, IH), 7.44 — 7.37 (m, 3H), 6.95 (dd, J = 7.1, 1.5 Hz, IH), 6.69 (d, J = 8.7 Hz, 2H), 6.12 (d, J= 2.2 Hz, IH), 4.85 (s, 2H), 4.64 (s, 2H), 3.72 (s, 3H). Compound 105 can be synthesized by changing the reactants in substantially the same manner as in Example 16. Example 17: Synthesis of Compound 229

[0270] Synthesis of 3-((3-aminophenyl)ethynyl)-N-(imidazo[l,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide Reagents and conditions: (a) 3-ethylnylaniline, PdCl2(PPh3)2, Cu, TEA, ACN, 60°C, 4 h

[0271] N-(imidazo[l,2-a]pyridin-7-ylmethyl)-3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (N-(imidazo[l,2-a]pyr idin-7-ylmethyl)-3-iodo-4- (((1— methyl— IH—pyrazol— 3— yl)methyl)sulfonyl)benzamide, 0.050 g, 0.093 mmol, 1 eq) was dissolved in ACN (1 ml, 0.1 MH], and 3-ethylnylaniline (3-ethylnylani 1 ine) (0.016 g, 0.139 mmol, 1.5 eq), PdC12(PPhs)2 (0.006 g, 0.01 mmol, 0.1 eq), Cui (0.002 g, 0.01 mmol, 0.1 eq), TEA (0.037 g, 0.37 mmol, 4 eq) were added and degassed with nitrogen gas. The reaction solution was heated to 60°C and stirred for 4 hours. After completion of the reaction, it was filtered through celite and extracted with a toyo. The organic layer was washed with water, separated, dried over MgS04, filtered, concentrated, and purified by column chromatography (silica gel, MeOH / DCM) to obtain the title compound (0.002 g, 4%).

[0272] 1H NMR (400 MHz, MeOD) 68.43 (d, J = 7.0 Hz, 1H), 8.23 ​​(s, 1H), 7.92 (d, J = 0.7 Hz, 2H), 7.82 (s, 1H), 7.56 (s, 1H), 7.51 (s, 1H), 7.44 (d, J = 2.2 Hz, 1H), 7.17 (t, J = 7.8 Hz, 1H), 7.02 (d, J = 1.8 Hz, 1H), 6.98 (dd, J = 11.8, 4.6 Hz, 2H), 6.81 (dd, J = 8.1, 1.5 Hz, 1H), 6.15 (d, J = 2.2 Hz,

[0273] 1H), 4.67 (s, 2H), 3.74 (s, 3H). Compounds 102, 103, 104, 106, 107, 108, 109, 110, 153, 154, 155, 156, 193, 224, 226 can be synthesized by changing the reactants in substantially the same manner as in Example 17. Example 18: Synthesis of Compound 230

[0274] Synthesis of N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((3-(piperazine-1-carbonyl)phenyl)ethynyl)benzamide (cis-6-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((3-(piperazine-1-carbonyl)phenyl)ethynyl)benzamide) Reagents and conditions: (a) N-Boc piperazine, EDOHC1, HOBt, TEA, DCM, room temperature (rt), overnight; (b) PdC12(PPh3)2, Cui, TEA, ACN, reflux, 1 h; (c) TFA, DCM, room temperature (rt),

[0275] Step 1) Synthesis of tert-butyl 4-(3-ethynylbenzoyl)piperazine-1-carboxylate

[0276] 3—ethynylbenzoic acid (0.2 g, 1.37 mmol, 1 eq), EDOHCl (0.393 g, 2.05 mmol, 1.5 eq), HOBt (0.296 g, 2.192 mmol, 1.6 eq) were added to DCM (13 ml, 0.1 M) and stirred at room temperature for 15 minutes. N-Boc-piperazine (0.331 g, 1.781 mmol, 1.3 eq) and TEA (0.416 g, 4.11 mmol, 3 eq) were added and stirred at room temperature overnight. After completion of the reaction, the reaction solution was concentrated under reduced pressure and purified by column chromatography (silica gel, EA / HEX) to obtain the target compound (0.25 g, 58%). Step 2) Synthesis of tert-butyl 4- (3- ((5-((imidazo[1,2- a]pyridin- 7 -ylmethyl)carbamoyl)- 2- (((1-methyl- 1H-pyrazol- 3 -yl)methyl)sulfonyl)phenyl)ethynyl)benzoyl)piperazine-1-carboxylate

[0277] N-(imidazo[1,2-a]pyridin-7-ylmethyl)-3-iodo-4-(((1-methyl-IH-pyrazol-3-yl)methyl)sulfonyl)benzamide (N-( imidazo[l ,2- a]pyridin-7-ylmethyl )-3-iodo-4-

[0278] (((1— methyl— IH— pyrazol— 3— yl)methyl)sulfonyl)benzamide, 0.1 g, 0.19 mmol, 1 eq) was dissolved in ACN (1.9 ml, 0.1 M), and then tert-butyl 4- (3- ethynylbenzoyl)piperazine-l- carboxylate (0.089 g, 0.285 mmol, 1.5 eq), PdC12(PPhs)2 (0.013 g, 0.02 mmol, 0.1 eq), Cui (0.004 g, 0.02 mmol, 0.1 eq), TEA (0.077 g, 0.76 mmol, 4 eq) were added under nitrogen gas. (Degassed with gas). The reaction mixture was stirred under reflux for 1 hour. After completion of the reaction, it was filtered through celite and extracted with a toyo. The organic layer was washed with water, separated, dried over MgSO4, filtered, concentrated, and purified by column chromatography (silica gel, MeOH / DCM) to obtain the target compound (0.052 g, 37.9%). Step 3) N-(Imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((3-(piperazine-1-carbonyl)phenyl)ethynyl)benzamide (N-

[0279] Synthesis of ( imidazo[l ,2— a]pyr idin— 7— ylmethyl )— 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )—3— ((3— (piperazine— 1— carbonyl ) phenyl )ethynyl ) benz am ide) tert-butyl 4- (3- ((5-((imidazo [1,2- a]pyridin- 7 -ylmethyl)carbamoyl)- 2-

[0280] (((1-methyl- 1H-pyrazol- 3-yl)methyl)sulfonyl)phenyl)ethynyl)benzoyl)piperazine-1-carboxylate (tert- butyl 4- (3- ((5- ((imidazo[l,2- a]pyridin- 7- ylmethyl ) carbamoyl )— 2— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl ) phenyl )ethynyl )benzoyl )piperazine—l— carboxylate, 0.050 g, 0.069 mmol, leq) was dissolved in DCM (1 ml, 0.07 M), TFA (0.079 g, 0.69 mmol, 10 eq) was added, and the mixture was stirred at room temperature overnight. After completion of the reaction, the mixture was concentrated and purified by reverse phase column chromatography (0.1% formic acid in H2O / ACN) to obtain the title compound (0.013 g, 32.5%). iH NMR (400 MHz, DMSO) 69.45 (d, J = 5.5 Hz, 1H), 8.51 (d, J = 6.6 Hz, 1H), 8.34 (s, 1H), 8.16 (s, 1H), 8.06 (d, J = 8.2 Hz, 1H), 7.97 — 7.88 (m, 2H), 7.79 (d, J = 7.5 Hz, 1H), 7.75 (s, 1H), 7.60 (t, J = 7.4 Hz, 2H), 7.55 (d, J = 7.2 Hz, 2H), 7.46 (s, 1H), 6.89 (d, J = 6.9 Hz, 1H) , 6.09 (s, 1H), 4.88 (s, 2H), 4.54 (d, J = 5.3 Hz, 2H), 3.70 (s, 3H), 3.43 (s, 4H), 2.96 (s, 4H). Example 19: Synthesis of compound 231

[0281] N-(Imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzamide (N-

[0282] ( imidazo[l ,2— a]pyr idin— 7— ylmethyl )— 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )— 3—( (1,2, 3, 4— tetr ahydro isoquinol in— 6— Reagents and conditions: (a) dimethyl (1-diazo-2-oxopropyl)phosphate, K2CO3, MeOH, room temperature (rt), overnight; (b) PdC12(PPh3)2, Cui, TEA, ACN, reflux, 1 h; (c) TFA, 4N HC1 in 1,4-di oxane, DCM, room temperature (rt), overnight. Step 1) Synthesis of tert-butyl 6-ethynyl-3,4-dihydroisoquinoline-2(1H)-carboxylate tert-Butyl 6-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (0.25 g, 0.96 mmol, 1 eq) was diluted in MeOH (4 ml, 0.24 M) and dimethyl (1-diazo-2-oxopropyl)phosphate (0.221 g, 1.152 mmol, 1.2 eq), K2CO3 (0.265 g, 1.92 mmol, 2 eq) were added and stirred at room temperature overnight. After completion of the reaction, the mixture was extracted with DCM and water. The organic layer was washed with aqueous NaCl solution, separated, dried over MgSO, filtered, and concentrated to obtain the target compound as a crude product.Step 2) Synthesis of tert-butyl 6- ((5-((imidazo[1,2- a]pyridin- 7 -ylmethyl)carbamoyl)- 2- (((1-methyl- 1H-pyrazol- 3 -yl)methyl)sulfonyl)phenyl)ethynyl)- 3,4-dihydroisoquinoline- 2(1H)-carboxylate (tert- butyl 6- ((5- ((imidazo[l,2- a]pyridin- 7- ylmethyl)carbamoyl)— 2— (((1— methyl— 1H— pyrazol— 3— yl)methyl)sulfonyl)phenyl)ethynyl)-3 , 4-dihydro isoquinoline- 2(lH)-carboxylate).

[0283] N-(imidazo[1,2-a]pyridin-7-ylmethyl)-3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (N-( imidazo[l ,2- a]pyr idin-7- ylmethyl )-3-iodo-4-

[0284] (((1— methyl— IH— pyrazol— 3— yl)methyl)sulfonyl)benzamide, 0.1 g, 0.19 mmol, 1 eq) was dissolved in ACN (1.9 ml, 0.1 M), and tert-butyl 6-ethynyl- 3, 4-dihydroisoquinoline- 2(1H)-carboxylate (tert- butyl 6- ethynyl 1-3,4- dihydro isoquinol ine- 2(1H)- carboxylate, 0.072 g, 0.281 mmol, 1.5 eq), PdC12(PPh3)2 (0.013 g, 0.02 mmol, 0.1 eq), Cui (0.004 g, 0.02 mmol, 0.1 eq), TEA (0.076 g, After adding 0.75 mmol, 4 eq) to the reaction mixture, degassing was performed with nitrogen gas (N2 gas). The reaction mixture was stirred under reflux for 1 hour. After completion of the reaction, the mixture was filtered through celite and extracted with distilled water. The organic layer was washed with water, separated, dried over MgSO, filtered, concentrated, and purified by column chromatography (silica gel, MeOH / DCM) to obtain the target compound (0.046 g, 36.9%).Step 3) Synthesis of N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((1,2,3,4-tetrahydroisoquinolin-6-yl)ethynyl)benzamide (N-(imidazo[l,2— a]pyridin—7— ylmethyl )— 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )— 3—( (1,2, 3, 4— tetr ahydro isoquinolin— 6— yl )ethynyl )benzamide) tert-butyl 6-((5-((imidazo[1,2-a]pyridin-7-ylmethyl)carbamoyl)- 2- (((1-methyl- 1H-pyrazol- 3-yl)methyl)sulfonyl)phenyl )ethynyl)- 3,4-dihydroisoquinoline-2(1H)- carboxylate (tert- butyl 6- ((5- ((imidazo[l,2- a]pyridin- 7- ylmethyl ) carbamoyl )— 2— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )phenyl )ethynyl )-3 ,4-dihydro isoquinol ine-2(lH)- carboxylate, 0.046 g, 0.069 mmol , leq) was dissolved in DCM (1 ml , 0.07 M), then TFA (0.079 g, 0.69 mmol, 10 eq) was added and stirred at room temperature overnight. The mixture was stirred. After the reaction mixture was concentrated, 4N HC1 in 1,4-dioxane (0.34 ml, 1.38 mmol, 20 eq) was added and stirred at room temperature for 3 hours. After the reaction was completed, the mixture was concentrated and purified by reverse-phase column chromatography (0.1% formic acid in H2O / ACN) to obtain the title compound (0.013 g, 33%). iH NMR (400 MHz, DMSO) 69.47 (s, 1H), 8.67 (s, 1H), 8.32 (s, 1H), 8.05.

[0285] (d, J = 8.0 Hz, IH), 7.93 (d, J = 8.0 Hz, IH), 7.61 (s, IH), 7.52 (d, J =

[0286] 13.1 Hz, 3H), 7.28 (s, IH), 6.90 (d, J = 6.3 Hz, IH), 6.10 (s, IH), 4.90 (s,

[0287] 2H), 4.53 (s, 2H), 3.90 (s, 3H), 3.72 (s, 3H), 2.92 (s, 3H). Example 20: Synthesis of compound 232

[0288] 3—((3- (aminomethyl)phenyl)ethynyl)- N- (imidazo [1,2- a]pyridin- 7 -ylmethyl)- 4-

[0289] ( ( (1-methyl- 1H-pyrazol- 3 -yl )methyl)sulfonyl )benzamide (3- ((3-

[0290] Synthesis of (aminomethyl )phenyl )ethynyl )— N— (imidazo[l,2— a]pyr idin— 7— ylmethyl )—4—(((l— methyl - IH-py r az 01 -3-y 1 )methyl )sulfonyl )benzamide)

[0291] Reagents and conditions: (a) B0C2O, DCM, 0 °C to rt, overnight; (b) PdC12(PPh3)2, Cui, TEA, ACN, reflux, 4 h; (c) 4N HC1 in dioxane, rt, overnight. Step 1) Synthesis of tert-butyl (3-ethynyl benzyl)carbamate

[0292] (3-Ethynylphenyl)methanamine ((3—ethynylphenyl)methanamine, 0.1 g, 0.76 mmol, 1 eq) was diluted in DCM (1.4 ml, 0.5 M), and di-tert-butyl dicarbonate (Di-tertbutyl di carbonate, 0.183 g, 0.84 mmol, 1.1 eq) was added at 0 °C and gradually warmed to room temperature and stirred overnight. After completion of the reaction, it was extracted with DCM and water. The organic layer was dried over MgSO₄, filtered, concentrated and purified by column chromatography (silica gel, EA / HEX) to obtain the target compound (0.15 g, 85%). Step 2) tert-Butyl (3-((5-((imidazo[1,2-a]pyridin-7-ylmethyl)carbamoyl)-2-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)phenyl)ethynyl)benzyl)carbamate

[0293] (Synthesis of tert-butyl (3-((5-((imidazo[1,2-a]pyridin-7-ylmethyl)carbamoyl)-2-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)phenyl)ethynyl)benzyl)carbamate)

[0294] N-(Imidazo[1,2-a]pyridin-7-ylmethyl)-3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (N-(imidazo[1,2-a]pyridin-7-ylmethyl)-3-iodo-4-

[0295] (((1— methyl— IH— pyrazol— 3— yl) methyl) sulfonyl) benzamide, 0.2 g, 0.37 mmol, 1 eq) was dissolved in ACN (3.7 ml, 0.1 M), and tert-butyl (3-ethynylbenzyl) carbamate (0.128 g, 0.56 mmol, 1.5 eq), PdC12(PPh3)2 (0.007 g, 0.01 mmol, 0.03 eq), Cui (0.002 g, 0.01 mmol, 0.03 eq), TEA (0.075 g, 0.74 mmol, 2 eq) were added, followed by degassing with nitrogen gas (N gas). The reaction mixture was stirred for 4 hours under reflux. After completion of the reaction, it was filtered through celite and extracted with ethanol. The organic layer was washed with water, separated, dried over MgSO, filtered, concentrated and purified by column chromatography (silica gel, MeOH / DCM) to obtain the target compound (0.15 g, 63.5%). Step 3) 3-((3-(aminomethyl)phenyl)ethynyl)- N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (3-((3-

[0296] Synthesis of tert-butyl (3- ((5-((imidazo [1,2- a]pyridin- 7 -ylmethyl)carbamoyl)- 2- (((1-methyl- 1H-pyrazol- 3 -yl)methyl)sulfonyl)phenyl)ethynyl)carbamate (tert- butyl (3— ((5— ((imidazo [l,2— a]pyridin- 7 -ylmethyl)carbamoyl)- 2— (((1— methyl— 1H— pyr azo 1-3-yl)methyl )sulfonyl )phenyl )ethynyl )benzyl )carbamate, 0.05 g, 0.078 mmol , leq) was dissolved in 1,4-dioxane (1 ml, 0.07 M), and 4N HCK4N HC1 in 1,4-dioxane (0.58 ml, 2.34 mmol, 30 eq) was added and stirred at room temperature overnight. After completion of the reaction, the reaction product was concentrated and purified by reverse phase column chromatography (0.1% formic acid in H2O / ACN). The purified product was added 4N HCK4N HC1 in 1,4-dioxane (0.058 ml, 0.3 M) at room temperature and stirred overnight. The resulting solid was washed with diethyl ether and filtered under reduced pressure to obtain the title compound (0.017 g, 42.3%). iH NMR (400 MHz, DMSO) 69.84 (t, J = 5.6 Hz, 1H), 8.88 (d, J = 6.9 Hz, 1H), 8.50 (s, 2H), 8.38 (d, J = 1.4 Hz, IH), 8.34 (d, J = 1.6 Hz, IH), 8.17 (d, J = 1.9 Hz, IH), 8.09 (dd, J = 8.3, 1.5 Hz, IH), 7.93 (d, J = 8.2 Hz, IH), 7.87 (s, IH), 7.82 (s, IH), 7.73 (d, J = 7.6 Hz, IH), 7.65 (d, J = 7.7 Hz, IH), 7.61 — 7.55 (m, 2H), 7.52 (d, J = 7.0 Hz, IH), 6.09 (d, J = 2.1 Hz, IH), 4.91 (s, 2H), 4.71 (d, J = 5.5 Hz, 2H), 4.10 (d, J = 5.6 Hz, 2H), 3.70 (s, 3H);MS MH+ 537.05 Example 21: Synthesis of compound 233.

[0297] 4- (( (1-(4-aminophenyl)- 1H-pyrazol-3-yl)methyl)sulfonyl)-3-( (4-fluorophenyl)ethynyl)- N- (imidazo [1,2- a]pyridin-7-ylmethyl)benzamide (4- (((1-(4-aminophenyl)— IH— pyrazol— 3— yl)methyl)sulfonyl)-3-( (4- f luoropheny 1 )ethynyl )-

[0298] Synthesis of N-( imidazo[l ,2— a]pyr idin— 7— ylmethyl )benzamide)

[0299] Reagents and conditions: (a) 1-fluoro-4-nitrobenzene, K2CO3, DMF, room temperature (rt), 16 h; (b) LiAlH4 in 1.0 M THF (L1AIH4 in THF), THF, 0°C, 7 h; (c) SOCI2, MC, 0°C, room temperature (rt); (d) methyl 3-iodo-4-mercaptobenzoate, K2CO3, DMF, room temperature (rt), 2 h; (e) mCPBA, MC, room temperature (RT), overnight: (f) 1-ethynyl-4-fluorobenzene 4- f luorobenzene), TEA, Cui, PdC12(PPh3)2, ACN, reflux (reflux), 1 h (Ih); (g) NaOH, EtOH, H2O, reflux (reflux), 1 h (Ih); (h) 1-{imidazo[1,2-a]pyridin-7-yl}methanamine hydrochloride, TBTU, TEA, MC, room temperature (rt), 7 h (7h), (i) Zn, NH4C1, 1,4-dioxane, H2O, room temperature (rt), 5 h (5h) Step 1) Ethyl 1-(4-nitrophenyl)-1H-pyrazole-3 -Synthesis of ethyl 1-(4-nitrophenyl )—lH—pyrazole— 3— carboxylate Ethyl 1H-pyrazole- 3 -carboxylate (ethyl IH-pyr azo 1 e-3-car boxy late, 1.4 g, 10 mmol, leq) was dissolved in DMF (100 ml, 0.1 M) and then K2C03 (1.66 g, 12 mmol, 1.2 eq), 1-fluoro-4-nitrobenzene (1-fluoro-4-nitrobenzene, 1.55 g, 11 mmol, l.leq) was added and stirred at room temperature overnight. After completion of the reaction, water was added, and the resulting solid was filtered and dried to obtain a crude product. (1.907 g, 73%) Step 2) Synthesis of (1-(4-nitrophenyl)-1H-pyrazol-3-yl)methanol Ethyl 1-(4-nitrophenyl)-1H-pyrazole-3-carboxylate (ethyl 1-(4-nitr opheny 1)-IH-pyr azo 1 e-3-car boxy late, 1.907 g, 7.36 mmol, 1 eq) was dissolved in anhydrous THF (73 ml, 0.1 MH], and 1.0 M LiAlH4in THF (10.9 ml, 10.9 mmol, 1.5 eq) was slowly added dropwise at 0°C and stirred for 7 hours. After completion of the reaction, water, The solid was filtered and the filtrate was concentrated to obtain a crude product. (0.468g) iH NMR (400 MHz, CDCls) 6 8.40 — 8.33 (m, 2H), 8.03 (d, J = 2.6 Hz, 1H), 7.91 — 7.86 (m, 2H), 6.59 (d, J = 2.6 Hz, IH), 4.84 (s, 2H). Step 3) Synthesis of 3-(chloromethyl)- 1-(4-nitrophenyl)- IH-pyrazole (3-(chloromethyl)- l-(4-nitr opheny 1 )- IH-pyrazole) (1-(4-nitrophenyl)- 1H-pyrazol-3 -yl)methanol ( ( 1- (4-nitr opheny 1 )— 1H— pyrazol-3-yl )methanol , 0.468 g , 2.135 mmol , leq) was dissolved in DCM (11 ml , 0.2 M), and SOC12 (0.46 ml , 6.41 mmol , 3 eq) was slowly added dropwise at 0°C and refluxed overnight.After completion of the reaction, the crude product was obtained by concentration under reduced pressure. (0.432 g, 100%) iH NMR (400 MHz, CDCls) 6 8.37 — 8.30 (m, 2H), 8.00 (d, J = 2.6 Hz, 1H), 7.87 (dd, J= 6.9, 5.0 Hz, 2H), 6.63 (d, J= 2.6 Hz, IH), 4.68 (s, 2H). Step 4) Synthesis of methyl 3-iodo-4-(((1-(4-nitrophenyl)- IH-pyrazol-3-yl)methyl)thio)benzoate.

[0300] 3-(chloromethyl)-1-(4-nitrophenyl)-1H-pyrazole (0.15g, 0.5mmol, leq) was dissolved in DMF (4ml, 0.1M), then K2CO3 (0.116g, 0.84mmol, 2eq) was added and methyl 3-iodo-4-mercaptobenzoate (0.15g, 0.5mmol, 1.2eq) dissolved in DMF (5ml, 0.1MH) was slowly added and stirred at room temperature for 2 hours. After completion of the reaction, the product was added and the resulting solid was filtered, dried, and then column chromatography (silica gel, EA / HX) was purified. (0.073 g, 29.4%) iH NMR (400 MHz, CDCls) 6 8.45 (d, J = 1.8 Hz, IH), 8.39 — 8.34 (m, 2H), 7.98 (dd, J = 4.6, 3.0 Hz, 2H), 7.89 — 7.84 (m, 2H), 7.42 (d, J = 8.4 Hz, IH), 6.60 (d, J = 2.6 Hz, IH), 4.33 (s, 2H), 3.92 (d, J = 2.9 Hz, 3H Step 5) Methyl 3-iodo-4-(((1-(4-nitrophenyl)- IH-pyrazol-3-yl)methyl)sulfonyl )benzoate (methyl 3-iodo-4-( ( (1-(4-nitrophenyl )-1H-pyrazol-3-yl )methyl )sulfonyl )benzoate) Synthesis of methyl 3-iodo-4-( ( (1-(4-nitrophenyl )-1H-pyrazol-3-yl)methyl)thio)benzoate (methyl 3- iodo-4 - (((1-( 4-nitrophenyl ) - 1H- pyr azol- 3- yl )methyl )thio)benzoate, 0.073 g, 0.147 mmol , 1 eq) was dissolved in MC (8 ml , 0.2 M) and then added to mCPBA (0.127 g, 0.735 mmol, 5 eq) was added and stirred overnight. After completion of the reaction, saturated aqueous NaHCOs was added and extracted with MC. The organic layer was dried over MgSO, filtered, concentrated, and obtained as a crude product. (0.080g, 100%) Step 6) Synthesis of methyl 3-((4-fluorophenyl)ethynyl)-4-(((1-(4-nitrophenyl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzoate (methyl 3-((4-fluorophenyl 1 )ethynyl 1 )-4- ( ( (1-(4-nitr opheny 1 )-1H-pyrazol-3-yl )methyl )sulfonyl )benzoate) Methyl 3-iodo-4-( ( (1-(4-nitrophenyl )-1H-pyrazol-3-yl )methyl )sulfonyl )benzoate )methyl )sulfonyl )benzoate benzoate (0.447 g, 0.859 mmol , 1 eq) was dissolved in ACN (8.6 ml, 0.1 M), and then TEA (0.26 ml, 1.89 mmol , 2.2 eq), PdCl2(PPh3)2 (18 mg, 0.025 mmol , 3 mol%), and Cui (6.5 mg, 0.034 mmol , 4 mol%) were added and stirred at room temperature for 5 min. 1-Ethynyl-4-f luorobenzene (0.15 ml, 1.29 mmol , 1.5 eq) was added and stirred at 90°C for 1 h. After cooling to room temperature, the residue was concentrated and purified by column chromatography (silica gel, EA / HX). (0.125 g, 28%) iH NMR (400 MHz, CDCls) 68.38 (s, 1H), 8.28 (d, J = 9.1 Hz, 2H), 8.02 (d, J= 0.8 Hz, 2H), 7.91 (d, J= 2.4 Hz, IH), 7.72 — 7.65 (m, 4H), 7.11 (t, J = 8.6 Hz, 2H), 6.56 (d, J = 2.4 Hz, IH), 4.90 (s, 2H), 3.98 (s, 3H). Step 7) Synthesis of 3-((4-fluorophenyl)ethynyl)-4-(((1-(4-nitrophenyl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid (3-((4-f luorophenyl)ethynyl)-4-( ((1-(4-nitrophenyl)-1H-pyr azo 1-3-yl)methyl)sulfonyl)benzoic acid) Methyl 3-((4-fluorophenyl)ethynyl)-4-( ((1-(4-nitrophenyl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzoate (methyl 3-((4-f luorophenyl)ethynyl 1 )-4-( ((1-(4-nitrophenyl)—lH—pyrazol— 3— yl )methyl )sulfonyl )benzoate, 0.125 g, 0.065 mmol, 1 eq) was dissolved in EtOH (1 ml, 0.05 M), and then NaOH (0.005 g, 0.13 mmol, 2 eq) dissolved in H2O (0.14 ml) was added and refluxed for 1 hour. After cooling to room temperature, the mixture was concentrated and diluted with water. After adjusting the pH to 5 to 6 with IN HC1, the resulting solid was filtered, washed with water, and dried. (0.1 g, 82%) Step 8) 3-((4-fluorophenyl)ethynyl)- N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-(4-nitrophenyl)- 1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (3-.

[0301] Synthesis of ( (4— f luorophenyl )ethynyl )— N— ( imidazo[l , 2— a]pyr idin— 7— y Imethy 1 )— 4—( ( (1—(4— nitrophenyl )— 1H— pyrazol— 3— yl )methyl )sulfonyl )benzamide)

[0302] 3-( (4-fluorophenyl )ethynyl )- 4-( ( (1-(4-nitrophenyl )- 1H-pyrazol-3-yl )methyl )sulfonyl )benzoic acid (3- ( (4- f luorophenyl )ethynyl )-4-( ( (l-(4-nitrophenyl )- IH-pyr azo 1-3-yl )methyl )sulfonyl )benzoic acid, 0.1 g, 0.2 mmol , 1 eq) was dissolved in MC (2 ml, 0.1 M), then TBTU (0.1 g, 0.3 mmol , 1.5 eq), TEA (0.06 ml, 0.44 mmol , 2.2 eq), 1-{imidazo [1,2- a]pyridin- 7 -yl}methanamine hydrochloride (1- {Imidazo[l,2—a]pyridin— 7— yLhnethanamine hydrochloride, 0.04 g, 0.22 mmol, 1.1 eq) was added and stirred at room temperature for 7 hours. After completion of the reaction, the mixture was concentrated and purified by column chromatography (silica gel, MeOH / MC). (51 mg, 40.2 %) Step 9) 4-(((1-(4-aminophenyl)- 1H-pyrazol- 3 -yl)methyl)sulfonyl)- 3-((4-fluorophenyl)ethynyl)- N- (imidazo[1,2-a]pyridin- 7 -ylmethyl)benzamide (4-

[0303] ( ( ( 1- ( 4-am i nopheny 1 )— 1H— pyrazol— 3— yl )methyl )sulfonyl )— 3—((4— f 1 uoropheny 1 )et hyny 1 ) — N— (imidazo[l,2— a] pyr idin— 7— y 1 me t hy 1 ) benz am i de ) Synthesis of 3-( (4-fluorophenyl )ethynyl )- N- (imidazo[1 , 2- a]pyridin- 7 -ylmethyl )- 4- ( ( (1- (4-nitrophenyl)- 1H-pyrazol- 3 -yl) methyl)sulfonyl)benzamide (3-((4- f luorophenyl )ethynyl )— N— ( imidazo[l , 2— a]pyr idin— 7— y Imethy 1 )—4—(((l—(4— nitrophenyl )—lH— pyrazol— 3— yl )methyl )sulfonyl )benzamide, 0.051 g, 0.080 mmol 1 , 1 eq) was dissolved in 1,4-dioxane (1,4-dioxane): 0 (3:l(v:v), 1 ml, 0.084 MH], then Zinc (0.055 g, 0.84 mmol , 10 eq) and NH4CI (0.045 g, 0.84 mmol , 10 eq) were added and stirred at room temperature for 5 hours. The reaction mixture was washed with MeOH and filtered under reduced pressure through celite. The filtrate was concentrated and purified by reverse phase column chromatography (0.1% formic acid in H2(〕 / Acetonitrile). iH NMR (400 MHz, MeOD) 6 8.48 (d, J = 7.1 Hz, 1H), 8.29 (s, 1H), 8.25 (s, IH), 7.98 — 7.94 (m, 2H), 7.88 (s, IH), 7.86 (d, J = 2.4 Hz, IH), 7.78 — 7.73 (m, 2H), 7.63 (s, IH), 7.57 (s, IH), 7.23 — 7.16 (m, 4H), 7.04 (d, J = 7.1 Hz, IH), 6.71 (d, J = 8.8 Hz, 2H), 6.41 (d, J = 2.4 Hz, IH), 4.94 (s, 2H), 4.70 (s, 2H). Example 22: Synthesis of compound 122.

[0304] Reagents and conditions: (a) tert-butyl 4-

[0305] ((methylsulfonyl)oxy)piperidine-1-carboxylate (tert-butyl)

[0306] ((methyl sulfonyl )oxy)piper idine-l-carboxylate), K2CO3, DMF, 70°C (b) 1.0 M L1AIH4 in THF, THF, 0°C, 1 h (Ih); (c) MsCl, TEA, THF, 0°C to room temperature (0°C 〜 rt), 12 h (12h); (d) methyl 3-iodo-4-mercaptobenzoate, K2CO3, DMF, room temperature (rt), overnight; (e) mCPBA, MC, room temperature (RT), overnight; (f) 1-ethynyl-4-fluorobenzene (1-ethynyl-4-f luorobenzene, ) TEA, Cui , PdC 12(PPh3 )2,

[0307] ACN, reflux (reflux), 1 h (Ih); (g) NaOH, EtOH, H2O, reflux (reflux), 1 h (Ih); (h) 1-{imidazo[1,2-a]pyridin-7-yl}methanamine hydrochloride(1-

[0308] {imidazo[l,2—a]pyridin—7—yLhnethanamine hydrochloride) , TBTU, TEA, MC, room temperature (rt), overnight, (i) 4N HC1 in dioxane, DCM, room temperature (rt), 2 h Step 1) Synthesis of tert-butyl 4-(3-(ethoxycarbonyl)-lH-pyrazol-l-yl)piperidine-l-carboxylate Ethyl IH-pyrazole-3-carboxylate, 1.4 g, 10 mmol , 1 eq) was dissolved in DMF (50 ml , 0.2 M) and K2CO3 (1.66 g, 12 mmol , 1.2 eq) and tert-butyl 4-((methylsulfonyl )oxy)piperidine-l-carboxylate (tert-butyl 4-( (methylsulfonyl )oxy)piper idine-l-carboxylate, 3.07 g, 11 mmol , 1.1 eq) were added and stirred for 70 minutes.The mixture was stirred for 16 hours in In. After the reaction was completed, it was cooled to room temperature, water was added, and extraction was performed using a sieve. The organic layer was dried over MgS04, filtered, concentrated, and purified by column chromatography (silica gel, EA / HX). (1.623 g, 50.2%) Step 2) Synthesis of tert-butyl 4-(3-(hydroxymethyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (tert-butyl 4-(3-(hydr oxymethyl)-IH-py r az 01 - 1-y 1)piper idine-1-carboxylate) (1.623 g, 5.02 mmol, 1 eq) in anhydrous After dissolving in THF (50 ml, 0.1 M), 1.0 M LiAlH4 in THF (1.0 M LiAlH4 in THF, 7.6 ml, 7.60 mmol, 1.5 eq) was slowly added dropwise at 0°C and stirred for 1 hour. After completion of the reaction, water and toluene were added, the solid was filtered, and the filtrate was concentrated to obtain a crude product. (1.5 g, 100%) Step 3) tert-Butyl 4-(3-(((methylsulfonyl)oxy)methyl)-1H-pyrazol-1-yl)piperidine-!-carboxylate (tert-butyl 4-(3-。

[0309] Synthesis of (((methylsulfonyl )oxy)methyl )— 1H— pyrazol— 1— yl )piperidine—l— carboxylate Tert-butyl 4-(3-(hydroxymethyl )- 1H- pyrazol- 1-yl )piperidine- 1-carboxylate (tert- butyl 4-(3-(hydr oxymethyl )- 1H- pyrazol- 1-yl )piperidine- 1-carboxylate, 0.2 g, 0.71 mmol, leq) was dissolved in THF (4 ml, 0.2 M), then TEA (0.12 ml, 0.852 mmol, 1.2 eq) and MsCl (0.06 ml, 0.781 mmol, 1.1 eq) were added and stirred overnight. After completion of the reaction, water was added and extracted with DCM. The organic layer was dried over MgS04, filtered, concentrated, and obtained as a crude product. (0.204 g, 100%) Step 4) tert-butyl 4- (3- (((2-iodo- 4- (methoxycarbonyl)phenyl)thio)methyl)- 1H-pyrazol- 1-yl)piperidine- 1-carboxylate (tert- butyl 4- (3- (((2- iodo- 4-

[0310] Synthesis of tert-butyl 4-(3-(((methylsulfonyl)oxy)methyl)-1H-pyrazol-1-yl)piper idine-1-carboxylate (tert-butyl 4-(3-(((methylsulfonyl)oxy)methyl)-1H-pyrazol-1-yl)piper idine-1-carboxylate, 0.204g, 0.57mmol, leq) was dissolved in DMF (5 ml, 0.1M), then K2CO3 (0.16g, 1.134mmol, 2eq) was added and dissolved in DMF (5 ml, 0.1M] methyl 3-iodo-4 -Mercaptobenzoate (methyl 3-iodo-4-mercaptobenzoate, 0.2g, 0.68mmol, 1.2eq) was slowly added and stirred at room temperature for 1 hour. After completion of the reaction, water was added, and the resulting solid was filtered and dried to obtain a crude product. (0.193g, 50.9%) iH NMR (400 MHz, CDCls) 68.50 (d, J = 1.7 Hz, 1H), 8.00 (dd, J = 8.2, 1.8 Hz, IH), 7.50 (d, J = 1.3 Hz, IH), 7.30 (s, IH), 7.28 (s, IH), 6.22 (d, J = 1.7 Hz, IH), 4.32 (dd, J = 13.2, 8.8 Hz, 3H), 4.24 (d, J = 5.9 Hz, 2H), 3.93 (d, J= 4.6 Hz, 3H), 2.89 (t, J= 12.7 Hz, 2H), 2.23 (qd, J= 12.6, 4.2 Hz, 2H), 1.95 (d, J = 12.3 Hz, 2H), 1.49 (s, 9H). Step 5) tert-butyl 4- (3- (((2 -iodo- 4-

[0311] Synthesis of tert-butyl 4-(3-(((2-iodo-4-(methoxycarbonyl)phenyl)thio)methyl)- IH-pyrazol-1-yl)piperidine-1-carboxylate (tert-butyl 4-(3-(((2-iodo-4-(methoxycarbonyl)phenyl)sulfonyl)methyl)- IH-pyrazol-1-yl)piperidine-1-carboxylate)

[0312] (methyl carboxy 1 )phenyl )thio)methyl )—lH— pyrazol— 1—yl )piper idine— 1— carboxylate, 0.193 g, 0.346 mmol , 1 eq) was dissolved in MC (2 ml, 0.2 M), mCPBA (0.3 g, 1.731 mmol, 5 eq) was added, and the mixture was stirred overnight. After completion of the reaction, saturated aqueous NaHCOs was added, and the mixture was extracted with MC. The organic layer was dried over MgSO4, filtered, and concentrated to obtain a crude product. (0.183 g, 100%) Step 6) Preparation of tert-butyl 4- (3- (((2- ((4-fluorophenyl)ethynyl)- 4-

[0313] (methoxycarbonyl)phenyl)sulfonyl)methyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (tert-butyl 4— (3—( ( (2—( (4— f luorophenyl )ethynyl )—4—

[0314] Synthesis of tert-butyl 4- (3- (((2-iodo-4-(methoxycarbonyl)phenyl)sulfonyl)methyl)- 1H-pyrazol-1-yl)piperidine-1-carboxylate (tert- butyl 4- (3- (((2-iodo-4-(methoxycarbonyl)phenyl)sulfonyl)methyl)- 1H-pyrazol-1-yl)piperidine-1-carboxylate

[0315] (methyl )phenyl )sulfonyl )methyl )-IH-pyr azo 1-1-y 1 )piper idine-1-carboxylate (0.183 g, 0.31 mmol , 1 eq) was dissolved in ACN (4 ml, 0.1 M), then TEA (0.1 ml, 0.68 mmol , 2.2 eq), PdC12(PPh3)2 (6.5 mg, 0.009 mmol , 3 mol%), and Cui (2.4 mg, 0.012 mmol, 4 mol%) were added and stirred at room temperature for 5 minutes. 1-Ethynyl-4-fluorobenzene (0.053 ml, 0.47 mmol, 1.5 eq) was added and stirred at 90°C for 1 hour. After cooling to room temperature, the mixture was concentrated and purified by column chromatography (silica gel, EA / HX). (0.1 g, 55.6%) Step 7) Synthesis of 4-(((1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzoic acid (4-(((1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzoic acid) tert-butyl 4-(3-(((2-((4-fluorophenyl)ethynyl)-4-

[0316] (methoxycarbonyl)phenyl)sulfonyl)methyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (tert-butyl 4- (3-( ( (2-( (4- f luorophenyl )ethynyl )-4-

[0317] (methoxy c ar bony 1 ) phenyl ) sulfonyl ) methyl ) -IH-pyr azo 1 -1-y 1 ) piperidine-1- carboxylate, 0.10 g, 0.172 mmol , 1 eq) was dissolved in EtOH (4 ml, 0.05 M), and then NaOH (0.014 g, 0.344 mmol, 2 eq) dissolved in H2O (0.1 ml) was added and refluxed for 1 hour. After cooling to room temperature and concentrating, the target compound was obtained as a crude product. Step 8) Preparation of tert-butyl 4- (3- (((2- ((4-fluorophenyl) ethynyl)-4-

[0318] Synthesis of ( (imidazo [1,2- a]pyridin-7-ylmethyl)carbamoyl)phenyl)sulfonyl)methyl)-lH-pyrazol-1-yl)piperidine-!-carboxylate (tert-butyl 4- (3- (((2-((4- f 1 uoropheny 1 )et hyny 1)— 4— ((imidazo[l,2— a] pyr idin-7- ylmethyl)carbamoyl )phenyl )sulfonyl)methyl ) - IH-py r az o 1 - 1-y 1 )piper idine— 1— carboxylate)

[0319] 4-(((1-(1-(tert-Butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzoic acid (4-(((1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzoic acid, 0.1 g, 0.172 mmol, 1 eq) was dissolved successively, and then TBTU (0.083 g, 0.258 mmol, 1.5 eq), TEA (0.053 ml, 0.38 mmol, 2.2 eq), 1-{imidazo[1,2-a]pyridin-7-yl}methanamine hydrochloride (1-{imidazo[1,2-a]pyridin-7-yl}methanamine hydrochloride, 0.035 g, 0.189 mmol, 1.1 eq) were added, and the mixture was stirred at room temperature overnight. After completion of the reaction, saturated aqueous NaHCO₃ was added for neutralization, and then extracted with MC. The organic layer was dried over MgSO₄, filtered, concentrated, and purified by column chromatography (silica gel, MeOH / MC). (0.112 g, 93.3%) Step 9) 3-((4-fluorophenyl)ethynyl)-N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-(piperidin-4-yl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (3-((4-fluorophenyl)ethynyl)-N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-(piperidin-4-yl)-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide

[0320] Synthesis of tert-butyl 4-(3-(((2-((4-fluorophenyl)ethynyl)-4-((imidazo[1,2-a]pyridin-7-ylmethyl)carbamoyl)phenyl)sulfonyl)methyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate tert-butyl 4-(3-( ((2-((4-fluorophenyl)ethynyl)benzamide)-4-

[0321] (( imidazo[l ,2-a]pyridi n-7-ylmethyl ) carbamoyl ) phenyl ) sulfonyl ) methyl )—lH— pyrazol— 1—yl )piperidine—l— carboxylate (0.112 g, 0.16 mmol , leq) was dissolved in DCM (1 ml, 0.2 M), 4N HC1 in dioxane (4N HC1 in dioxane, 0.4 ml, 1.6 mmol, 10 eq) was added, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, the mixture was concentrated and purified by reverse-phase column chromatography (0.1% formic acid in H2O / ACN) to obtain the title compound (0.028 g, 32.5%). iH NMR (400 MHz, MeOD) 6 8.62 (s, 1H), 8.44 (d, J = 7.0 Hz, 1H), 8.09 (dd, J = 8.1, 1.1 Hz, IH), 7.88 (d, J = 8.1 Hz, IH), 7.83 (s, IH), 7.76 (s, IH), 7.56 (s, IH), 7.38 (d, J= 1.9 Hz, IH), 7.30 (dd, J= 8.7, 5.4 Hz, 2H), 7.07 — 6.98 (m, 4H), 5.91 (d, J= 1.9 Hz, IH), 4.72 (s, 2H), 4.60 — 4.50 (m, IH), 3.22 (d, J = 12.8 Hz, 2H), 2.79 (td, J = 15.0, 4.7 Hz, 2H), 2.68 (s, 2H), 2.22 — 2.10 (m, 3H), 1.97 (d, J = 10.1 Hz, IH). Example 23: Synthesis of compound 148

[0322] 4-( (4-aminobenzyl)sulfonyl )-3-( (4-fluorophenyl)ethynyl )- N- (imidazo [ 1 , 2 - a ]pyridin -7 -ylmethyl)benzamide 4- ( ( 4- am i nobenzyl )sulfonyl )-3-( (4- f 1 uoropheny 1 )et hyny 1 ) — N— (imidazo[l,2— a] pyr idin-7-ylmethyl )benzamide

[0323] Reagents and conditions: (a) l-(chloromethyl)-4-nitrobenzene, K2CO3, DMF, room temperature (r.t), 0.5 h (0.5 h) (b) mCPBA, DCM, room temperature (rt), 16 h (16 h) (c) PdChfPPhsh, Cui, TEA, ACN, room temperature (rt), 16 h (16 h) (d) NaOH, H2O, MeOH, 55°C, 12 h (12 h) (e) l-{imidazo[l,2-a]pyridin-7-yl}methanamine hydrochloride, TBTU, TEA, DCM, room temperature (rt), 12 h (12 h) (f ) Zn, NH4CI, Dioxane, H20, room temperature (rt), 2 h (2 h) Step 1) Methyl 3-iodo- 4- ((4-nitrobenzyl)thio)benzoate methyl 3- iodo-

[0324] Synthesis of 4-((4-nitrobenzyl)thio)benzoate

[0325] 1-(chloromethyl)-4-nitrobenzene (0.24 g, 1.4 mmol, 1 eq) was dissolved in DMF (14 ml) and K2C03 (0.39 g, 2.84 mmol, 2 eq) was added. Methyl 3-iodo-4-mercaptobenzoate (0.5 g, 1.70 mmol, 1.2 eq) was added to the reaction mixture and stirred for 30 minutes. Water was added to the reaction mixture and extracted several times with EA. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure to obtain the target compound (0.6 g, 99%) as a crude product. Step 2) Synthesis of methyl 3-iodo-4-((4-nitrobenzyl)sulfonyl)benzoate Methyl 3-iodo-4-((4-nitrobenzyl)thio)benzoate (0.73 g, 1.7 mmol, leq) was dissolved in DCM (8.5 ml, 0.2 M), mCPBA (1.47 g, 8.5 mmol, 5 eq) was added, and the mixture was stirred for 16 h. The reaction was confirmed by TLC, and when the reaction was completed, water was added to dilute, and the mixture was neutralized with saturated NaHCOs aqueous solution and extracted several times with DCM. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 40% EA / HX) to obtain the target compound (0.23 g, 29.Step 3) Synthesis of methyl 3-((4-fluorophenyl)ethynyl)-4-((4-nitrobenzyl)sulfonyl)benzoate To methyl 3-iodo-4-((4-nitrobenzyl)sulfonyl)benzoate (methyl 3-iodo-4-((4-nitrobenzyl)sulfonyl)benzoate (0.23 g, 0.5 mmol, 1 eq) add MeCN (5 ml, 0.1 M) and then add TEA (0.15 ml, 1.1 mmol, 2.2 eq). PdCl^PPhzh (10.5 mg, 3 mol%) and Cui (4 mg, 3 mol%) were added to the reaction mixture, and the mixture was stirred at room temperature for 5 minutes under a nitrogen atmosphere. Then, 4-fluorophenyl-acetylene (0.09 ml, 0.78 mmol, 1.5 eq) was added. The reaction mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 40% EA / HX) to obtain the target compound (0.191 g, 84.1%). iH NMR (400 MHz, CDC13) 6 8.38 (d, J = 1.6 Hz, 1H), 8.09 (d, J = 8.7).

[0326] Hz, 2H), 7.99 (dd, J= 8.3, 1.7 Hz, IH), 7.85 (d, J= 8.3 Hz, IH), 7.67 (dd,

[0327] J = 8.9, 5.3 Hz, 2H), 7.36 (d, J = 8.7 Hz, 2H), 7.15 (t, J = 8.7 Hz, 2H),

[0328] 4.80 (s, 2H), 3.98 (s, 3H). Step 4) Synthesis of 3-((4-fluorophenyl)ethynyl)-4-((4-nitrobenzyl)sulfonyl)benzoic acid 3-((4-fluorophenyl)ethynyl)—4— ((4—nitrobenzyl)sulfonyl)benzoic acid Methyl 3-((4-fluorophenyl)ethynyl)-4-((4-nitrobenzyl)sulfonyl)benzoate

[0329] (methyl 3-( (4- f luorophenyl )ethynyl )—4— ((4— nitrobenzyl )sulfonyl )benzoate,

[0330] To (0.191 g, 0.421 mmol, 1 eq) was added MeOH (8 ml), H2O (0.3 ml), and NaOH (0.034 g, 0.842 mmol, 2 eq) and stirred at 55°C for 1 h. The reaction was confirmed by TLC and completed. The pH of the reaction mixture was adjusted to 1 with IN HC1 aqueous solution and extracted with ethanol. The organic layer was washed with water, dried over magnesium sulfate, and concentrated under reduced pressure to obtain the target compound (0.1 g, 56%). Step 5) Synthesis of 3-((4-fluorophenyl)ethynyl)-N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-((4-nitrobenzyl)sulfonyl)benzamide

[0331] 3-((4-fluorophenyl)ethynyl)-4-((4-nitrobenzyl)sulfonyl)benzoic acid (3-((4-f luorophenyl)ethynyl)—4— ((4— nitrobenzyl)sulfonyl)benzoic acid, 0.1 g, 0.228 mmol, 1 eq) was added to DCM (2.3 ml) with TBTU (0.1 g, 0.342 mmol, 1.5 eq), TEA (0.07 ml, 0.5 mmol, 2.2 eq), 1-{imidazo[1,2-a]pyridin-7-yl}methanamine hydrochloride (1-{imi daz o [ 1 , 2-a ]pyridin-7-yl 1}me t hanam i ne hydrochloride, 0.046 g, 0.25 mmol , 1.1 eq) was added and stirred for 12 hours. The reaction was concentrated under reduced pressure, and the obtained residue was purified by column chromatography (silica gel, 10% MeOH / DCM) to obtain the target compound (0.053 g, 40.8%). Step 7) 4-((4-aminobenzyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)-N-

[0332] (Imidazo [1,2-a]pyridin-7-ylmethyl)benzamide 4-((4-aminobenzyl)sulfonyl)-3-

[0333] Synthesis of ((4— f luorophenyl)ethynyl)— N— (imidazo[l,2— a]pyridin— 7— ylmethyl)benzamide

[0334] 3-((4-fluorophenyl)ethynyl)-N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-((4-nitrobenzyl)sulfonyl)benzamide (3-((4-f luorophenyl)ethynyl)-N-( imidazo[l,2-a]pyr idin-7-ylmethyl)—4— ((4— nitrobenzyl)sulfonyl) benz am ide, 0.053 g, 0.084 mmol, leq) was dissolved in 1,4-dioxane:water (1,4-dioxane:H20, 3:l(v:v), 1 ml), and then Zinc (0.023 g, 0.42 mmol, 5 eq), NH4CI (0.022 g, 0.42 mmol, 5 eq) were added. The mixture was stirred at room temperature for 2 hours. The reaction mixture was washed with MeOH and filtered under reduced pressure through Celite. The filtrate was concentrated and subjected to prep-LC (0.1% formic acid in

[0335] It was purified with H20 / Acetonitrile). (0.002 g) iH NMR (400 MHz, MeOD) 6 8.58 (s, 1H), 8.53 (s, 7H), 8.44 (d, J = 6.8 Hz, IH), 8.06 (d, J = 9.0 Hz, IH), 7.84 (d, J = 8.3 Hz, 2H), 7.70 (s, IH), 7.55 (s, 2H), 7.42 — 7.36 (m, 2H), 6.99 (dd, J= 14.3, 7.7 Hz, 5H), 6.63 (d, J = 8.6 Hz, IH), 4.71 (s, 2H).

[0336] MS(ESI) m / e MH + 539 Example 24: Synthesis of Compound 234

[0337] 4-(((1H-pyrazol-3-yl)methyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)-N-

[0338] Synthesis of (imidazo[l,2-a]pyridin-7-ylmethyl)benzamide 4-( ((IH-pyr azo 1-3- yl)methyl)sulfonyl )-3-( (4-f luoropheny 1 )ethynyl )— N— (imidazo[l,2— a]pyr idin— 7— ylmethyl )benzamide Reagents and conditions: (a) 3-(Chloromethyl)pyrazole hydrochloride, K2CO3, DMF, room temperature (rt), 0.5 h (0.5 h) (b) TsCl, pyridine, DCM, room temperature (rt), 12 h (12 h) (c) mCPBA, DCM, room temperature (rt), 16 h (16 h) (d) PdCl^PPhzh, Cui, TEA, ACN, room temperature (rt), 16 h (16 h) (e) NaOH, H2O, MeOH, 55°C, 12 h (12 h) (f) 1-{imidazo[l,2- a]pyridin- 7- yLhnethanamine hydrochloride), TBTU, TEA, DCM, 12 h (12h) Step 1) Synthesis of methyl 4-(((1H-pyrazol-3-yl)methyl)thio)-3-iodobenzoate (methyl 4-(((IH-pyr azo 1 -3-y 1 )met hy 1 )thi 0 )-3 - iodobenzoat e )

[0339] 3-(Chloromethyl)pyrazole hydrochloride (0.5 g, 1.70 mmol, 1 eq) was dissolved in DMF (14 ml) and K2C03 (0.39 g, 2.84 mmol, 2 eq) was added. Methyl 3-iodo-4-mercaptobenzoate (0.5 g, 1.70 mmol, 1.2 eq) was added to the reaction mixture and stirred for 30 minutes. Water was added to the reaction mixture, and the resulting solid was filtered and dried to obtain the target compound. Step 2) Synthesis of methyl 3-iodo-4-(((1-tosyl-1H-pyrazol-3-yl)methyl)thio)benzoate Methyl 4-(((1H-pyrazol-3-yl)methyl)thio)-3-iodobenzoate (methyl 4-(((1H— pyrazol— 3— yl)methyl )thio)— 3— iodobenzoate, 0.05 g, 0.133 mmol, leq) was dissolved in DCM (0.1 M, 1.33 ml) and pyridine (pyridine, 0.027 ml, 5.8 M), TsCl (0.030 g, 0.16 mmol, 1.2 eq) was added and stirred at room temperature for 12 hours. After concentrating the reaction mass, water was added and extracted with DCM. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 20% EA / HX) to obtain the target compound (0.041 g, 0.08 mmol, 58.6%).Step 3) Synthesis of methyl 3-iodo-4-(((1-tosyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzoate Methyl 3-iodo-4-(((1-tosyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzoate (methyl 3— iodo— 4— (((1— tosyl— 1H— pyrazol— 3— yl)methyl )thio)benzoate, 0.041 g, 0.08 mmol, leq) was dissolved in DCM (1 ml), and mCPBA (0.07 g, 0.39 mmol, 5 eq) was added and stirred for 16 hours. The reaction was confirmed by TLC, and when the reaction was completed, water was added to dilute, neutralized with saturated NaHCOs aqueous solution, and extracted several times with DCM. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure, and the obtained residue was used in the next step without separation. Step 4) Synthesis of methyl 3- ( (4- f luorophenyl )ethynyl )-4-(((l-tosyl- IH-pyr azo 1-3-yl )methyl )sulfonyl )benzoate Methyl 3-iodo- 4-( ( ( 1-tosyl- 1H-pyrazol- 3 -yl )methyl )sulfonyl )benzoate.

[0340] (methyl 3— iodo— 4— (((1— tosyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )benzoate, 0.03 g, 0.052 mmol, 1 eq) was added to MeCN (1 ml) and TEA (0.016 ml, 0.114 mmol, 2.2 eq) was added. PdC12[PPhs]2 (1 mg, 3 mol%) and CuI (0.4 mg, 3 mol%) were added to the reaction mixture and stirred at room temperature for 5 minutes under a nitrogen atmosphere. Then, 4-fluorophenyl-acetylene (0.009 ml, 0.078 mmol, 1.5 eq) was added. The reaction mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 40% EA / HX) to obtain the target compound (0.020 g, 69.7%). Step 5) Synthesis of 4-(((1H-pyrazol-3-yl)methyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzoic acid (4-(((IH-pyr azo 1-3-yl 1 )methyl )sulfonyl )-3-((4-f luorophenyl )ethynyl )benzoic acid) Methyl 3-((4-fluorophenyl )ethynyl )-4-(((1-tosyl- 1H-pyrazol-3-yl )methyl )sulfonyl )benzoate (methyl 3-((4-f luorophenyl )ethynyl )-4-(((l-tosyl- IH-pyr azo 1-3-yl )methyl )sulfonyl )benzoate, 0.020 g, 0.036 mmol , 1 Add MeOH (1 ml), H2O (1 ml), NaOH (3 mg, 0.072 mmol, 2 eq) and 55。Stir for 0 to 1 hour. The reaction was confirmed by TLC, and when the reaction was completed, the crude product was obtained by concentration under reduced pressure. Step 6) Synthesis of 4-(((IH-pyrazol-3-yl)methyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)- N-(imidazo[l,2-a]pyridin-7-ylmethyl)benzamide (4-( ((IH-pyr azo 1-3- yl)methyl)sulfonyl)-3-( (4- f luorophenyl )ethynyl )— N— (imidazo[l,2— a]pyr idin— 7— ylmethyl )benzamide)。

[0341] 4-( ( (1H-pyrazol-3-yl)methyl)sulfonyl)-3-( (4-fluorophenyl)ethynyl)benzoic acid (4- ( ( (IH-pyr azo 1-3-y 1)methyl )sulfonyl 1 )-3- ( (4- f 1 uor opheny 1 )ethynyl )benzoic acid, 0.022 g, 0.057 mmol, 1 eq) was added to DCM (1 ml) and TBTU (0.027 g, 0.09 mmol, 1.5 eq), TEA (0.02 ml, 0.125 mmol, 2.2 eq), 1—{imidazo[1,2— a]pyridin— 7— yl}methanamine hydrochloride (1-{imidazo[l,2- a]pyridin- 7- yLhnethanamine hydrochloride, 0.012 g, 0.063 mmol, 1.1 eq) was added and stirred for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue obtained was purified by column chromatography (silica gel, 10% MeOH / DCM) to obtain the target compound. iH NMR (400 MHz, MeOD) 6 8.42 (d, J = 7.0 Hz, 1H), 8.24 (s, 1H), 7.89 (t, J = 6.4 Hz, 2H), 7.82 (s, IH), 7.74 (dd, J = 8.6, 5.4 Hz, 2H), 7.54 (d, J = 7.0 Hz, 2H), 7.48 (s, IH), 7.22 (t, J = 8.7 Hz, 2H), 6.96 (d, J = 7.1 Hz, IH), 6.25 (s, IH), 4.65 (s, 2H).

[0342] MS(ESI) m / e MH + 514 Example 25: Synthesis of Compound 235

[0343] Synthesis of N- (3- (1H-pyrazol-4-yl)propyl)-3-( (3-methoxy-4-methylphenyl)ethynyl)-4- ( ( (1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide Reagents and conditions: (a) NaOH, H2O, MeOH, 60°C, 2 h (2 h); (b) 3-(1H-pyrazol-4-yl)propan—l— amine dihydrochloride, TBTU, TEA, DCM, 12 h (12 h); (c) PdC12[PPh3]2, Cui, TEA, ACN, room temperature (rt), 1 h (1 h) Step 1) Preparation of 3-iodo— 4- (((1-methyl- IH-pyrazol- 3 -yl)methyl)sulfonyl)benzoic acid Synthetic methyl 3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzoate

[0344] (methyl 3— iodo— 4— (((1— methyl— IH— pyrazol— 3— yl )methyl )sulfonyl )benzoate,

[0345] To (1.216 g, 2.9 mmol, 1 eq) was added MeOH (15 ml, 0.2 M), H2O (2 ml), and NaOH (0.23 g, 5.79 mmol, 2 eq) and stirred at 60。In for 2 hours. The reaction was confirmed by TLC and completed. The pH of the reaction was adjusted to 1 with IN HC1 aqueous solution and extracted with Toyo. The organic layer was washed with water, separated, dried over magnesium sulfate, and concentrated under reduced pressure to obtain the target compound (1.18 g, 100%). iH NMR (400 MHz, DMSO) 6 13.74 (s, IH), 8.57 (d, J = 1.3 Hz, IH), 8.04 (dd, J = 8.2, 1.4 Hz, IH), 7.93 — 7.88 (m, IH), 7.59 (d, J = 2.0 Hz, IH), 6.06 (d, J = 2.1 Hz, IH), 4.83 (s, 2H), 3.69 (s, 3H). Step 2) Synthesis of N-(3-(IH-pyrazol-4-yl)propyl)-3-iodo-4-(((l-methyl-IH-pyrazol-3-yl)methyl)sulfonyl)benzamide

[0346] 3 -iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid (3-iodo-4-

[0347] To (((1— methyl— IH— pyrazol— 3— yl )methyl )sulfonyl )benzoic acid, 0.4 g, 1 mmol , 1 eq) were added DCM (10 ml), TBTU (0.48 g, 1.5 mmol , 1.5 eq), TEA (0.3 ml, 2.2 mmol , 2.2 eq), 3-(1H-pyrazol- 4 -yl)propan—l— amine dihydrochloride (0.22 g, 1.1 mmol , 1.1 eq) and stirred for 12 h. The resulting residue was concentrated and purified by column chromatography (silica gel, 10% MeOH / DCM) to obtain the target compound. (0.16g, 31.3%) iH NMR (400 MHz, MeOD) 68.56 (d, J= 1.4 Hz, 1H), 7.92 (d, J= 8.2 Hz, 1H), 7.87 (dd, J = 8.2, 1.5 Hz, IH), 7.51 — 7.45 (m, 3H), 6.18 (d, J = 2.2 Hz, IH), 4.83 (s, 2H), 3.77 (s, 3H), 3.43 (t, J = 7.1 Hz, 2H), 3.37 (s, IH), 2.83 (s, IH), 2.61 (t, J = 7.5 Hz, 2H), 1.91 (p, J = 7.3 Hz, 2H). Step 3) Synthesis of N-(3-(IH-pyrazol-4-yl)propyl)-3-((3-methoxy-4-methylphenyl)ethynyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide)N-(3-(IH-pyrazol-4-yl)propyl)—3—((3—methoxy—4—methylphenyl)ethynyl)—4—(((1—methyl—IH—pyrazol—3-yl)methyl)sulfonyl)benzamide)

[0348] To N-(3-(IH-pyrazol-4-yl)propyl)-3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (N-(3-(IH-pyrazol-4-yl)propyl)-3-iodo-4-(((l-methyl— IH— pyrazol— 3— yl)methyl)sulfonyl)benzamide (0.03 g, 0.058 mmol, leq) was added MeCN (1 ml, 0.1 M) and TEA (0.018 ml, 0.128 mmol, 2.2 eq). PdC12[PPh3]2 (1.22 mg, 3 mol%) and Cui (0.44 mg, 3 mol%) were added to the reaction mixture, and the mixture was stirred at room temperature for 5 minutes under a nitrogen atmosphere. Then, 4-ethynyl-2-methoxy-1-methylbenzene (13 mg, 0.088 mmol, 1.5 eq) was added. The reaction mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 10% MeOH / DCM) to obtain the target compound (27 mg, 87.7%). iH NMR (400 MHz, CDCls) 68.16 (s, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.84 (d, J = 8.2 Hz, IH), 7.50 (s, 2H), 7.44 (s, IH), 7.19 (d, J = 4.8 Hz, 3H), 6.16 (s, IH), 4.86 (s, 2H), 3.89 (s, 3H), 3.72 (s, 3H), 3.44 (t, J = 7.0 Hz, 2H), 2.62 (t, J = 7.5 Hz, 2H), 2.24 (s, 3H), 1.97 — 1.88 (m, 2H). Compounds 44, 45, 46, and 75 to 82 can be synthesized by changing the reactants in substantially the same manner as in Example 25. Example 26: Synthesis of Compound 236

[0349] N- (3- (1H-pyrazol- 4 -yl )propyl )-4-( ( (1-methyl- 1H-pyrazol- 3 -yl )methyl)sulfonyl )- 3- ((4- (trifluoromethoxy )phenyl) ethynyl)benzamide (N- (3- (IH- pyrazol- 4- yl )propyl )— 4— (((1— methyl— IH— pyrazol— 3— yl )methyl )sulfonyl )— 3—((4—

[0350] Compound 236 was prepared in substantially the same manner as the synthesis of compound 235 of Example 25, except that 1-ethynyl-4-(trifluoromethoxy)benzene was used instead of 4-ethynyl-2-methoxy-1-methylbenzene in step 3). iH NMR (400 MHz, CDCls) 68.18 (s, 1H), 7.89 (q, J = 8.2 Hz, 2H), 7.80 (d, J = 8.7 Hz, 2H), 7.48 (s, 2H), 7.44 (s, IH), 7.39 (d, J = 8.2 Hz, 2H), 6.16 (d, J = 2.0 Hz, IH), 4.82 (s, 2H), 3.72 (s, 3H), 3.44 (t, J = 7.0 Hz, 2H), 2.61 (t, J = 7.4 Hz, 2H), 1.97 — 1.85 (m, 2H). Example 27: Synthesis of compound 237

[0351] N-(3-(1H-pyrazol-4-yl)propyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-

[0352] Compound 237 was prepared in substantially the same manner as the synthesis of compound 235 in Example 25, except that 4-ethynylpyridine was used instead of 4-ethynyl-2-methoxy-1-methylbenzene in step 3), compared to the synthesis of compound 235 in Example 25, 3-(pyridin-4-ylethynyl)benzamide. iH NMR (400 MHz, MeOD) 6 8.67 (d, J = 5.9 Hz, 2H), 8.25 (s, IH), 7.96 (s, 2H), 7.71 (d, J = 6.1 Hz, 2H), 7.50 (s, 2H), 7.46 (d, J = 2.1 Hz, IH), 6.20 (d, J = 2.2 Hz, IH), 4.82 (s, 2H), 3.73 (s, 3H), 3.46 (t, J = 7.1 Hz, 2H), 2.63 (t, J= 7.5 Hz, 2H), 1.99 — 1.89 (m, 2H), 1.33 (t, J= 7.3 Hz, 1H). Example 28: Synthesis of Compound 238

[0353] 3- ((4-fluorophenyl)ethynyl)- N- (imidazo [1,2- a]pyrimidin-6-ylmethyl)- 4-

[0354] Synthesis of (((1-methyl- 1H-pyrazol- 3 -yl)methyl)sulfonyl)benzamide (3-((4- f luorophenyl )ethynyl )— N— (imidazo[l,2— a]pyr imidin— 6— ylmethyl )—4—(((l—methyl— IH-pyr azo 1-3-yl )methyl )sulfonyl ) benz am ide) Reagents and conditions: (a) {imidazo[l,2-a]pyrimidin-6-yl}methanamine dihydrochloride, TBTU, TEA, DCM, room temperature (rt), overnight; (b) 1-Ethynyl-4-f luorobenzene, PdC12(PPh3)2, Cui, TEA, ACN, 60 °C, 1 h Step 1) N-(Imidazo[1,2-a]pyrimidin-6-ylmethyl)-3-iodo-4-(((1-methyl-

[0355] Synthesis of N-( imidazo[l ,2- a]pyr imidin- 6- ylmethyl )— 3— iodo— 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )benzamide)

[0356] 3-iodo-4-(((1-methyl- 1H-pyrazol- 3-yl)methyl)sulfonyl)benzoic acid (3-iodo-4-(((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )benzoic acid, 0.27 g, 0.67 mmol , 1 eq) was dissolved in DCM (6.7 ml, 0.1 M), and {imidazo[l,2— a]pyr imidin-6-yl}methanamine dihydrochloride (0.147 g, 0.8 mmol , 1.2 eq), TBTU (0.257 g, 0.8 mmol , 1.2 eq), TEA (0.37 ml, 2.68 mmol, 4 eq) was added and stirred at room temperature overnight. The reaction mixture was diluted with DCM, and the organic layer was extracted with aqueous NaHC03 solution, H2O, and brine. The organic layer was dried over MgSO, filtered, concentrated, and purified by reverse-phase column chromatography (0.1% formic acid in H2O / ACN) to obtain the target compound (0.092 g, 25.6%). Step 2) Synthesis of 3-((4-fluorophenyl)ethynyl)-N-(imidazo[1,2-a]pyrimidin-6-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (3-((4-f luorophenyl)ethynyl)—N—(imidazo[l,2—a]pyrimidin— 6— ylmethyl)—4—(((l—methyl—IH-pyr azo 1-3-yl)methyl)sulfonyl)benzamide)

[0357] N-(imidazo[l,2-a]pyrimidin-6-ylmethyl)-3-iodo-4-(((1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (N-( imidazo[l,2-a]pyr imidin- 6- ylmethyl )-3- iodo— 4— (((1— methyl— 1H— pyrazol— 3— yl)methyl )sulfonyl ) benz am ide, 0.046 g, 0.08 mmol, 1 eq) was dissolved in ACN (1 ml, 0.1 M), and 1-ethynyl-4-fluorobenzene (1-ethynyl-4-f luorobenzene, 0.014 g, 0.12 mmol, 1.5 eq), PdC12(PPh3)2 (0.001 g, 0.002 mmol, 0.03 eq), Cui (0.00045 g, 0.002 mmol, 0.03 eq), TEA (0.016 g, 0.16 mmol, 2 eq) were added and degassed with nitrogen gas (N2 gas). The reaction mixture was heated to 60。0 and stirred for 1 hour. After completion of the reaction, it was filtered through celite and extracted with Toyo. The organic layer was washed with water, separated, dried over MgS04, filtered, concentrated, and purified by column chromatography (silica gel, MeOH / DCM) to obtain the target compound (0.016 g, 37.8%). iH NMR (400 MHz, DMSO) 6 9.45 (s, 1H), 8.96 (d, J = 2.2 Hz, 1H), 8.57

[0358] (d, J = 2.4 Hz, IH), 8.28 (d, J = 1.4 Hz, IH), 8.01 (dd, J = 8.3, 1.6 Hz,

[0359] IH), 7.92 (dd, J = 6.6, 4.8 Hz, 2H), 7.76 (dd, J = 8.7, 5.5 Hz, 2H), 7.71 (d, J = 1.1 Hz, IH), 7.58 (d, J = 2.1 Hz, IH), 7.37 (t, J = 8.9 Hz, 2H),

[0360] 6.07 (d, J = 2.1 Hz, IH), 4.85 (s, 2H), 4.55 (d, J = 4.1 Hz, 2H), 3.69 (s,

[0361] 3H). Example 29: Synthesis of compound 239

[0362] Synthesis of 4-( (3-aminobenzyl)sulfonyl )-3-( (4-fluorophenyl)ethynyl )- N- (imidazo[1,2- a]pyridin-7-ylmethyl)benzamide ( 4- ( (3- am i nobenzyl )sulfonyl )-3-( (4- f 1 uoropheny 1 )et hyny 1 ) — N— (imidazo[l,2— a] pyr idin— 7— y 1 me t hy 1 ) benz am i de )

[0363] Reagents and conditions: (a) 3-nitrobenzyl chloride, K2CO3, DMF, room temperature (rt), 2 h (b) m-CPBA, DCM, 0 °C to rt, overnight; (c) 1-Ethynyl-4-fluorobenzene, PdCl2(PPh3)2, Cui, TEA, ACN, 60 °C, 1 h; (d) Zn, NH4CI, 1,4-dioxane, H20, room temperature (rt), 0.5 h (0.5 h); (e)

[0364] IN NaOH(aq), THF, 70 °C, overnight; (f) 1-{imidazo[l,2-a]pyridin-7-yl}methanamine dihydrochloride, TBTU, TEA, DCM, room temperature (rt), overnight Step 1) Synthesis of methyl 3-iodo-4-((3-nitrobenzyl)thio)benzoate

[0365] 3-nitrobenzyl chloride (0.291 g, 1.7 mmol, 1 eq), K2CO3 (0.469 g, 3.4 mmol, 2 eq) were dissolved in DMF (3.4 ml, 0.5 MH), and methyl 3-iodo-4-mercaptobenzoate (0.5 g, 1.7 mmol, leq) was added dropwise and stirred at room temperature for 2 hours. Water was added to the reaction mixture and extracted with a solvent. The organic layer was dried over MgS04, filtered, concentrated, and purified by column chromatography (silica gel, EA / HEX) to obtain the target compound (0.661 g, 90.5%). Step 2) Methyl 3-iodo-4- ((3 Synthesis of methyl 3-iodo-4-((3-nitrobenzyl)sulfonyl)benzoate Methyl 3-iodo-4-((3-nitrobenzyl)thio)benzoate (methyl 3-iodo-4-((3-nitrobenzyl)thio)benzoate, 0.661 g, 1.54 mmol, 1 eq) was dissolved in DCM (15.4 ml, 0.1 M), and m-CPBA (1.063 g, 6.16 mmol, 4 eq) was added dropwise at 0 。(2). The reaction mixture was slowly warmed to room temperature and stirred overnight. After completion of the reaction, NaHC03 aqueous solution was added and extracted with DCM. The organic layer was dried over MgSO, filtered, and concentrated to obtain the target compound as a crude product. Step 3) Synthesis of methyl 3-((4-fluorophenyl)ethynyl)-4-((3-nitrobenzyl)sulfonyl)benzoate (methyl 3-((4-fluorophenyl)ethynyl)-4-((3-nitrobenzyl)sulfonyl)benzoate)

[0366] (methyl 3— iodo— 4— ((3— nitrobenzyl )sulfonyl )benzoate, 0.1 g, 0.22 mmol , 1 eq) was dissolved in ACN (2.2 ml, 0.1 MH], and 1-ethynyl-4-fluorobenzene (1- ethynyl-4-fluorobenzene, 0.039 g, 0.33 mmol , 1.5 eq), PdC12(PPhs)2 (0.005 g, 0.007 mmol , 0.03 eq), Cui (0.001 g, 0.007 mmol , 0.03 eq), TEA (0.045 g, 0.44 mmol , 2 eq) were added and degassed with nitrogen gas (late gas). The reaction solution was heated to 60 。(2 Stirred for 1 hour. After completion of the reaction, filtered through celite and extracted with a toyo. The organic layer was washed with water, separated, dried over MgS04, filtered, concentrated, and purified by column chromatography (silica gel, MeOH / DCM) to obtain the target compound (0.083 g, 83%). Step 4) Synthesis of methyl 4-((3-aminobenzyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzoate Methyl 3-((4-fluorophenyl)ethynyl)-4-((3-nitrobenzyl)sulfonyl)benzoate

[0367] (methyl 3-( (4- f luorophenyl )ethynyl ) -4 - ( ( 3-nitr obenzy 1 )sulfonyl )benzoate,

[0368] 0.083 g, 0.18 mmol, 1 eq) was dissolved in 1,4-dioxane:H2(〕(3:1, v / v) (1.8 ml, 0.1 MH], and then Zn (0.058 g, 0.9 mmol, 5 eq) and NH4C1 (0.048 g, 0.9 mmol, 5 eq) were added and stirred at room temperature for 0.5 h. After completion of the reaction, the target compound was obtained as a crude product by filtration and concentration. Step 5) Synthesis of 4-((3-aminobenzyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzoic acid Methyl 4-( (3 -aminobenzyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzoate

[0369] (methyl 4- ( ( 3-am i nobenzy 1 )sulfonyl )-3-( (4-f luoropheny 1 )ethynyl )benzoate,

[0370] After dissolving 0.076 g, 0.18 mmol, 1 eq) in THF (1.8 ml, 0.1 M), IN NaOH aqueous solution (0.36 ml, 0.36 mmol, 2 eq) was added, heated to 70。In and stirred overnight. After completion of the reaction, the reaction solution was concentrated to obtain the target compound as a crude product. Step 6) 4-((3-aminobenzyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)-N-

[0371] Synthesis of (imidazo[1,2-a]pyridin-7-ylmethyl)benzamide (4-((3-am i nobenzyl)sulfonyl)-3-((4-f 1 uoropheny 1)et hyny 1) — N— (imidazo[l,2— a]pyridin-7-ylmethyl)benzamide)

[0372] 4—((3-aminobenzyl)sulfonyl)-3-((4-fluorophenyl)ethynyl)benzoic acid (4-((3-aminobenzyl )sulfonyl )-3-( (4-fluorophenyl )ethynyl )benzoic acid, 0.040 g, 0.098 mmol, 1 eq) was dissolved in DCM (1 ml, 0.1 M), 1—{imidazo[1,2— a]pyridin— 7— yl}methanamine dihydrochloride (1-{imidazo[l,2- a]pyridin- 7- yLhnethanamine dihydrochloride, 0.019 g, 0.108 mmol , 1.1 eq), TBTU (0.047 g, 0.147 mmol, 1.5 eq), TEA (0.019 g, 0.196 mmol, 2 eq) was added and stirred at room temperature overnight. After completion of the reaction, water was added to the reaction solution and extracted with DCM. The organic layer was washed with water, separated, dried over MgSO4, filtered, concentrated, and purified by reverse phase column chromatography (0.1% formic acid in H2O / ACN) to obtain the target compound.

[0373] (0.005g, 9.47%) was obtained.

[0374] 1H NMR (400 MHz, MeOD) 6 8.38 (d, J = 7.1 Hz, 1H), 8.20 (d, J = 1.4 Hz, 1H), 7.86 — 7.75 (m, 3H), 7.69 (dd, J = 8.8, 5.4 Hz, 2H), 7.50 (s, 1H), 7.44 (s, 1H), 7.19 (t, J = 8.8 Hz, 2H), 6.95 — 6.84 (m, 2H), 6.57 — 6.49 (m, 2H), 6.40 (d, J = 7.6 Hz, 1H), 4.65 (s, 2H), 4.61 (s, 2H). Example 30: Synthesis of compound 240

[0375] 3_((4—aminophenyl)ethynyl)— N— (imidazo [heart 2- a]pyridin-6-ylmethyl)-4- (((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide ( 3- ( (4-aminopheny 1 )ethynyl )-N-

[0376] Synthesis of (imidazo[l,2— a]pyr idin— 6— ylmethyl )-4-( ((l-methyl-lH-pyrazol-3- yl )methyl )sulfonyl )benzamide) Reagents and conditions: (a) Imidazo[l,2-a]pyridin-6-ylmethanamine dihydrochloride, TBTU, TEA, DCM, room temperature (rt), overnight; (b) 4-ethynylaniline, PdCl2(PPh3)2, Cui, TEA, ACN, 60°C, 3 h Step 1) N-(Imidazo[l,2-a]pyridin-6-ylmethyl)-3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide )-3 - iodo- 4- (((1- methyl- 1H- pyrazol- 3- yl ) methyl ) sulfonyl ) benz am ide)

[0377] 3-iodo-4-(((1-methyl- 1H-pyrazol- 3-yl)methyl)sulfonyl)benzoic acid (3-iodo-4-(((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )benzoic acid, 0.1 g, 0.246 mmol , 1 eq) was dissolved in DCM (2.5 ml, 0.1 M), and imidazo[1,2- a]pyridin-6-ylmethanamine dihydrochloride (Imidazotl , 2-a]pyridin-6-ylmethanamine dihydrochloride, 0.065 g, 0.295 mmol , 1.2 eq), TBTU (0.158 g, 0.492 mmol , 2 eq), TEA (0.074 g, 0.739 mmol, 3 eq) was added and stirred at room temperature overnight. After completion of the reaction, water was added and extracted with DCM. The organic layer was separated by washing with water, dried over MgSO, filtered, concentrated, and purified by column chromatography (silica gel, MeOH / DCM) to obtain the target compound (0.033 g, 25%). Step 2) Synthesis of 3-((4-aminophenyl)ethynyl)- N-(imidazo[1,2-a]pyridin-6-ylmethyl)- 4-(((1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl)benzamide

[0378] N-(imidazo[l,2-a]pyridin-6-ylmethyl)-3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (N-( imidazo[l,2-a]pyr idin-6- ylmethyl )-3-iodo-4- (((1— methyl— 1H— pyrazol— 3— yl )methyl)sulfonyl ) benz am ide, (0.033 g, 0.062 mmol , 1 eq) was dissolved in ACN (1 ml , 0.1 M), and 4-ethynylaniline (4-ethynylani 1 ine) (0.0087 g, 0.074 mmol , 1.2 eq), PdC12(PPh3)2 (0.001 g, 0.002 mmol, 0.03 eq), Cui (0.0003 g, 0.002 mmol, 0.03 eq), TEA (0.0125 g, 0.124 mmol, 2 eq) were added and degassed with nitrogen gas. The reaction solution was heated to 60 °C and stirred for 3 hours. After completion of the reaction, it was filtered through celite and extracted with ethanol. The organic layer was washed with water, separated, dried over MgSO4, filtered, concentrated, and purified by column chromatography (silica gel, MeOH / DCM) to obtain the target compound (0.0089 g, 27.4%). iH NMR (400 MHz, MeOD) 6 8.53 (s, 1H), 8.10 (d, J = 1.4 Hz, 1H), 7.91 (s, IH), 7.79 (dt, J = 8.3, 5.0 Hz, 2H), 7.65 (s, IH), 7.61 (d, J = 9.4 Hz, IH), 7.50 (d, J = 9.3 Hz, IH), 7.38 (d, J = 2.2 Hz, IH), 7.35 (d, J = 8.6 Hz, 2H), 6.65 (d, J = 8.6 Hz, 2H), 6.09 (d, J = 2.2 Hz, IH), 4.82 (s, 2H),

[0379] 4.59 (s, 2H), 3.68 (s, 3H). Example 31: Synthesis of compound 241. Reagents and conditions: (a) PdCMPPhyh, Cui, TEA,

[0380] ACN, room temperature (rt), 16 hours (16h)

[0381] Synthesis of 3-((4-amino-3-fluorophenyl)ethynyl)-N-(imidazo[1,2-a]pyridin-7-ylmethyl)—4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide

[0382] N-(Imidazo[l,2-a]pyridin-7-ylmethyl)-3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzimide (N-( imidazo[l,2-a]pyr idin-7-ylmethyl)-3-iodo-4- (((1— methyl— IH—pyrazol— 3— yl)methyl)sulfonyl)benzamide, 0.1 g, 0.2 mmol, 1 eq) was added MeCN (1 ml, 0.2 M) and TEA (0.08 ml, 0.6 mmol, 3 eq). PdCl^PPhyh (4 mg, 3 mol%) and Cul (l mg, 3 mol%) were added to the reaction mixture and stirred at room temperature under a nitrogen atmosphere for 5 min. Then, 4-ethynyl-2-fluoroaniline (4-ethynyl-2-f luoroani line, 35 mg, 1.2 eq) was added. The reaction mixture was stirred at room temperature for 16 hours and concentrated under reduced pressure. The resulting residue was purified by reverse phase chromatography (water / acetonitrile) to obtain the target compound. iH NMR (400 MHz, DMSO) 69.43 (t, J = 5.8 Hz, 1H), 8.51 (d, J = 7.1 Hz, 1H), 8.23 ​​(d, J = 1.5 Hz, IH), 7.89-7.98 (m, 3H), 7.61 (d, J = 2.1 Hz, IH), 7.54 (d, J = 1.0 Hz, IH), 7.46 (s, IH), 7.39 (dd, J = 12.0, 1.7 Hz, IH), 7.25 (dd, J = 8.2, 1.6 Hz, IH), 6.89 (dd, J = 7.0, 1.5 Hz, IH), 6.85 — 6.78 (m, IH), 6.10 (d, J = 2.2 Hz, IH), 5.88 (s, 2H), 4.87 (s, 2H), 4.54 (d, J = 5.7 Hz, 2H), 3.73 (s, 3H). Example 32: Synthesis of compound 242

[0383] Reagents and conditions: (a) PdChtPPhsh, Cui, TEA,

[0384] ACN, room temperature (rt), 16 h (16 h) (b) NaOH, H20, MeOH, 55°C, 2 h (2 h) (c) 1-

[0385] {Imidazo[l,2-a]pyridin-7-yl}methanamine dihydrochloride (l-{imidazo[l,2-a]pyridin-7-yl}methanamine dihydrochloride), TBTU, TEA, DCM, 12 h (12 h) Step 1) Synthesis of 3-iodo-4-(((1-methyl- 1H-pyrazol- 3 -yl)methyl)sulfonyl)benzoic acid Methyl 3-iodo-4-(((1-methyl- 1H-pyrazol- 3 -yl)methyl)sulfonyl)benzoate

[0386] (methyl 3— iodo— 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )benzoate, 0.42 g, 1 mmol, 1 eq) was added MeOH (10 ml, 0.1 M), H2O (5 ml, 0.2 M), NaOH (0.1 g, 2.5 mmol, 2.5 eq) and stirred at 80°C for 2 hours. The reaction was confirmed by TLC and completed. The pH of the reaction product was adjusted to 1 with IN HC1 aqueous solution and extracted with distilled water. The organic layer was washed with water, dried over magnesium sulfate and concentrated under reduced pressure to obtain the target compound (0.35 g, 86%). Step 2) Synthesis of N-(imidazo[l,2-a]pyridin-7-ylmethyl)-3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide

[0387] 3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzoic acid (3-iodo-4-

[0388] To (((1— methyl— IH— pyrazol— 3— yl )methyl )sulfonyl )benzoic acid, 0.35 g, 0.86 mmol , 1 eq) were added DCM (10 ml) and TBTU (0.42 g, 1 mmol, 1.5 eq) and stirred at room temperature for 50 min. Then, TEA (0.45 ml, 1.3 mmol, 3.7 eq) and 1-{imidazo[1,2-a]pyridin-7- yl}methanamine dihydrochloride (l-{imidazo[l,2-a]pyridin-7- yl}methanamine dihydrochloride) (92 mg, 0.42 mmol , 1.2 eq) were added and stirred for 12 h. The solid formed from the reaction was filtered to obtain the target compound (0.3 g, 65%). Step 3) N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-3-((4-((2-(piperidin-1-yl)ethyl)carbamoyl)phenyl)ethynyl)benzamide (N-( imidazo[l ,2— a]pyr idin— 7— ylmethyl )-4- (((1-methyl-1H-pyrazol-3-yl )methyl )sulfonyl )-3- ((4-((2-

[0389] Synthesis of (piper idin-l-yl )ethyl )carbamoyl )phenyl )ethynyl )benz am ide)

[0390] N-(Imidazo[1,2-a]pyridin-7-ylmethyl)-3-iodo-4-(((1-methyl-1H-pyrazole-

[0391] 3-(imidazo[l,2-a]pyridin- 7-ylmethyl)-3-iodo-4- (((1— methyl— 1H— pyrazol— 3— yl)methyl)sulfonyl)benzamide, 0.15 g, 0.28 mmol, 1 eq) was added MeCN (1.4 ml, 0.2 M) and TEA (0.12 ml, 0.84 mmol, 3 eq). PdC12[PPh3]2 (6 mg, 3 mol%) and CuI (1.6 mg, 3 mol%) were added to the reaction mixture and stirred at room temperature under a nitrogen atmosphere for 5 minutes. Then, 4-ethynyl- N- (2- (piperidin- 1-yl) ethyl) benzamide (4-ethynyl- N- (2- (piperidin- 1- yl) ethyl) benzamide, 86 mg, 1.2 eq) was added. The reaction mixture was stirred at room temperature for 16 h and concentrated under reduced pressure. The obtained residue was purified by prep-LC to obtain the target compound. iH NMR (400 MHz, MeOD) 6 8.46 (d, J = 6.1 Hz, 2H), 8.29 (s, 1H), 7.97 (s, 4H), 7.88 — 7.78 (m, 3H), 7.56 (m, 2H), 7.46 (s, IH), 7.01 (d, J = 6.5 Hz, IH), 6.19 (s, IH), 4.86 (s, 2H), 4.69 (s, 2H), 3.80 (s, 2H), 3.74 (m, 3H), 3.31 — 3.25 (m, 2H), 2.68 (s, 3H) , 1.90 (s, 4H), 1.71 (s, 2H), 1.31 (s, IH). Example 33: Synthesis of compound 243

[0392] Synthesis of 3-((6-aminopyridin-3- yl)ethynyl)-N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide

[0393] Reagents and conditions (a) 5-ethynylpyridin-2-amine, TEA, Cui, PdC12(PPhs)2, ACN, reflux, 3 h

[0394] N-(imidazo[l,2-a]pyridin-7-ylmethyl)-3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide N-(imidazo[l,2-a]pyr idin-7-ylmethyl)-3-iodo-4-

[0395] (((1— methyl— IH— pyrazol— 3— yl )methyl )sulfonyl )benzamide (50 mg, 0.09 mmol , 1 eq) was dissolved in ACN (1 ml, 0.1 MH], then TEA (0.025 ml, 0.18 mmol , 2 eq), PdC12(PPhs)2 (1.89 mg, 0.0027 mmol , 3 mol%), and Cui (0.51 mg, 0.0027 mmol , 3 mol%) were added and stirred at room temperature for 5 minutes. 5-ethynylpyr idin- 2-amine (22 mg, 0.186 mmol , 2 eq) was added and stirred under reflux for 3 hours. After cooling to room temperature, the mixture was concentrated and purified by reversed-phase column chromatography. Purification with (0.1% formic acid in H2O / ACN) gave the title compound (0.004 g, 8.4%). iH NMR (400 MHz, MeOD) 68.38 (d, J = 7.0 Hz, 1H), 8.21 (d, J = 2.0 Hz, 1H), 8.15 (d, J = 0.9 Hz, IH), 7.86 (dd, J = 8.9, 4.8 Hz, 2H), 7.78 (s, IH), 7.66 (dd, J = 8.7, 2.2 Hz, IH), 7.51 (s, IH), 7.46 (s, IH), 7.41 (d, J = 2.1 Hz, IH), 6.92 (dd, J = 7.0, 1.2 Hz, IH), 6.58 (d, J = 8.7 Hz, IH), 6.12 (d,

[0396] J = 2.2 Hz, IH), 4.80 (s, 2H), 4.62 (s, 2H), 3.70 (s, 3H). Example 34: Synthesis of compound 244

[0397] Synthesis of N-(3-(1H-pyrazol-4-yl)propyl)- 3-((4-(dimethylamino)phenyl)ethynyl)- 4-(((1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl)benzamide Compound 244 was prepared in substantially the same manner as the synthesis of compound 235 of Example 25, except that 4-ethynyl-N,N-dimethylaniline was used instead of 4-ethynyl-2-methoxy-1-methylbenzene in step 3). iH NMR (400 MHz, MeOD) 68.11 (d, J= 1.5 Hz, 1H), 7.87 (d, J= 8.3 Hz, 1H), 7.77 (dd, J= 8.3, 1.7 Hz, IH), 7.54 (d, J= 8.9 Hz, 2H), 7.50 (s, 2H), 7.45 (d, J= 2.1 Hz, IH), 6.79 (d, J= 8.9 Hz, 2H), 6.15 (d, J= 2.2 Hz, IH), 4.88 (s, 2H), 3.75 (s, 3H), 3.45 (t, J= 7.1 Hz, 2H), 3.05 (s, 6H), 2.63 (t, J = 7.5 Hz, 2H), 1.97 — 1.88 (m, 2H). Example 35: Synthesis of compound 162

[0398] Synthesis of N-(3-(1H-pyrazol-4-yl)propyl)-3-(2-(4-fluorophenyl)thiazol-5-yl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide Reagents and conditions: (a)NBS, DMF, room temperature (rt),

[0399] 1 hour (lh )(b) Bis(pinacolato)diboron, KOAc,

[0400] PdC12(dppf) , 1,2—Dimethoxyethane, 80°C, 1.5 h (c) N- (3- (1H-pyrazol-4-yl)propyl)-3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide, PdC12(dppf) , K2CO3, 1,4-dioxane, H2O, 100°C, 1 h (lh) Step 1) Synthesis of 5-bromo-2-(4-fluorophenyl)thiazole

[0401] 2-(4-fluorophenyl)thiazole (2-(4-f luorophenyl ) thiazole, 0.27 g, 1.5 mmol, leq) was dissolved in DMF (3 ml), N-Bromosucc inimi de (0.402 g) was added, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, water was added, filtered, and dried to obtain the target compound as a crude product. Step 2) Synthesis of 2-(4-fluorophenyl)-5-(4,4,5,5-tetramethyl- 1,3,2- dioxaborolan- 2-yl) thiazole

[0402] 5-Bromo-2-(4-fluorophenyl)thiazole (0.05g, 0.194mmol, leq) was dissolved in 1,2-Dimethoxyethane (0.2M, 1ml), Bis(pinacolato)diboron (0.058g, 0.23mmol, 1.2eq), KOAc (0.057g, 0.582mmol, 3eq), PdCl2(dppf) (0.014g, 0.0194mmol, 0.1eq) were added, and the mixture was stirred at 80°C for 1 hour and 30 minutes. After completion of the reaction, the crude product was obtained by filtration through celite and concentration. Step 3) Synthesis of N-(3-(1H-pyrazol-4-yl)propyl)-3-(2-(4-fluorophenyl)thiazol-5-yl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide

[0403] N-(3-(1H-pyrazol-4-yl)propyl)-3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (0.03 g, 0.058 mmol, 1 eq), 2-(4-fluorophenyl)-5-(4, 4, 5, 5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole (0.059 g, 0.194 mmol, 1.5 eq), PdCl2(dppf) (8.5 mg, 0.011 mmol, 0.2 eq), K2CO3 (17.6 mg, 0.128 mmol, 2.2 eq) were dissolved in 1,4-dioxane:H2O (3:1 (v / v)) (0.1 M, 0.6 ml) and stirred at 100 °C for 1 hour. After completion of the reaction, it was filtered through celite and concentrated, and purified by column chromatography (silica gel, MeOH / DCM) to obtain the target compound.

[0404] 1H NMR (400 MHz, MeOD) 6 8.11 — 8.05 (m, 2H), 8.03 (s, 1H), 7.99 (d, J = 1.8 Hz, 1H), 7.62 (d, J = 3.3 Hz, 2H), 7.45 (d, J = 2.2 Hz, 1H), 7.32 — 7.27 (m, 2H), 7.27 — 7.23 (m, 2H), 6.13 (d, J = 2.2 Hz, 1H), 4.41 (s, 2H), 3.74 (s, 3H), 3.43 (t, J = 7.2 Hz, 2H), 2.61 (t, J = 7.5 Hz, 2H), 1.95 — 1.86 (m, 2H). By changing the reactants in substantially the same manner as in Example 35, compounds 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 151, 152, 159, 160, 161, 162, 163, 164, 165, 166, 167, and 168 can be synthesized. Example 36: Synthesis of compound 246

[0405] 3-(3-(2-aminoethyl)-2-methyl-4-oxo-3,4-dihydroquinazolin-7-yl)-N-

[0406] (Imidazo [1,2- a]pyridin-7-ylmethyl)-4-( ((1-methyl- 1H-pyrazol-3-yl)methyl)sulfonyl)benzamide 3- (3- (2-aminoethyl)-2-methyl- 4-oxo- 3,4- dihydr oquinazol in-7-yl) — N— (imidazo[l,2— a] pyr idin-7-ylmethyl )-4-( (( 1-methyl-

[0407] Synthesis of IH-pyr azo 1-3-yl )methyl )sulfonyl )benzamide

[0408] Reagents and conditions: (a) Bis(pinacolato)di boron, KOAc, Pd(dppf)C12, 1,4-dioxane, reflux, 0.5 h; (b) N-(imidazo[l,2-a]pyridin-7-ylmethyl)-3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide, PdC12(dppf)2, K2CO3, 1,4-dioxane, H20, reflux, overnight; (c) tert-butyl (2-bromoethyl)carbamate, CS2CO3, DMF, 80°C, overnight; (d) 4N HC1 in dioxane, 4N HC1 in dioxane, room temperature (rt), overnight Step 1) 2-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-4(3H)-one Synthesis of tetramethyl- 1,3,2- di oxaboro lan- 2- yl )quinazol in- 4(3H)- one

[0409] 7-Bromo-2-methylquinazolin-4(3H)-one (0.5 g, 2.1 mmol, 1.0 eq) was dissolved in 1,4-dioxane (21 ml, 0.1 M), and then bis(pinacolato)diboron (1.06 g, 4.2 mmol, 2 eq), Pd(dppf)C12 (0.307 g, 0.42 mmol, 0.2 eq), and KOAc (0.412 g, 4.2 mmol, 2 eq) were added. The reaction mixture was heated to reflux and stirred for 0.5 h. After completion of the reaction, the mixture was cooled to room temperature and concentrated to obtain the target compound as a crude product. Step 2) N-(Imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-3-(2-methyl-4-oxo-3,4-dihydroquinazolin-7-yl)benzamide N-

[0410] ( imidazo[l,2— a]pyr idin— 7— ylmethyl )— 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )— 3— (2— methyl— 4— oxo— 3,4— dihydroquinazol in— 7— yl ) synthesis of benz am ide

[0411] N-(imidazo[l,2-a]pyridin-7-ylmethyl)-3-iodo-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide (N-(imidazo[l,2-a]pyr idin-7-ylmethyl)-3-iodo-4-

[0412] (((1— methyl— 1H— pyrazol— 3— yl)methyl)sulfonyl)benzamide, 0.2g, 0.374 mmol , 1 eq) was dissolved in 1,4-dioxane:water (1,4-dioxane: H20, 3:l(v:v), 3 ml, 0.1 MH], and 2-methyl-7-(4, 4, 5, 5-tetramethyl- 1,3, 2-dioxaborolan- 2-yl)quinazolin- 4(3H)-one (2-methyl— 7— (4,4,5,5— tetramethyl— 1,3,2— di oxaboro lan— 2— yl )quinazol in— 4(3H)— one, 0.214 g, 0.747 mmol , 2 eq), PdC12(dppf)2 (0.054 g, 0.075 mmol , 0.2 eq), K2CO3 (0.114 g, 0.822 mmol, 2.2 eq) was added. The reaction mixture was stirred overnight while heating under reflux. After completion of the reaction, the mixture was filtered through Celite and extracted with Toyo. The organic layer was washed with water, separated, dried over MgSO4, filtered, concentrated, and purified by reverse phase column chromatography (0.1% formic acid in H2O / ACN) to obtain the target compound (0.019 g, 8.9%). Step 3) Preparation of tert-butyl (2- (7- (5- ((imidazo[1,2-a]pyridin-7-ylmethyl)carbamoyl)-2-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)phenyl)-2-methyl-4-oxoquinazolin-3 (4H)-yl)ethyl)carbamate Synthesis of a]pyridin- 7- ylmethyl ) carbamoyl )— 2— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl ) phenyl )- 2- methyl- 4- oxoquinazol in- 3(4H)- yl )ethyl )carbamate

[0413] N-(Imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)-3-(2-methyl-4-oxo-3,4-dihydroquinazolin-7-yl)benzamide (N-

[0414] (imidazo[l,2— a] pyri din— 7— ylmethyl )— 4— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )— 3— (2— methyl— 4— oxo— 3,4— dihydroquinazol in— 7— yl ) benz am ide, 0.019 g, 0.03 mmol, 1.0 eq) was dissolved in DMF (1 ml, 0.03 M), and tert-butyl (2-bromoethyl ) carbamate, 0.008 g, 0.036 mmol , 1.2 eq), and CS2CO3 (0.019 g, 0.06 mmol, 2 eq) were added. The reaction mixture was heated to 80 °C and stirred overnight. After completion of the reaction, it was cooled to room temperature and extracted with ethanol. The organic layer was washed with water, separated, dried over MgSO, filtered, and concentrated to obtain the target compound as a crude product. Step 4) Synthesis of 3-(3-(2-aminoethyl)-2-methyl-4-oxo-3,4-dihydroquinazolin-7-yl)-N-(imidazo[1,2-a]pyridin-7-ylmethyl)-4-(((1-methyl-1H-pyrazol-3-yl)methyl)sulfonyl)benzamide 3—(3—(2—aminoethyl)—2—methyl—4—0x0—3,4—dihydroquinazol in—7—yl)-N—(imidazo[l,2—a]pyri din—7—ylmethyl)—4—(((1—methyl—1H—pyrazol—3—yl)methyl)sulfonyl)benz am ide tert-butyl (2-(7- (5-((imidazo [1,2- a]pyridin- 7 -ylmethyl)carbamoyl)- 2-

[0415] (((1-methyl- 1H-pyrazol- 3-yl)methyl)sulfonyl)phenyl)- 2-methyl- 4-oxoquinazolin- 3(4H)-yl)ethyl)carbamate (tert- butyl (2- (7- (5- ((imidazo[l,2- a]pyridin- 7- ylmethyl )carbamoyl )— 2— (((1— methyl— 1H— pyrazol— 3— yl )methyl )sulfonyl )phenyl )- 2— methyl— 4— oxoquinazol in— 3(4H)— yl )ethyl )carbamate, 0.019 g, 0.03 mmol , leq) was dissolved in 1,4-dioxane (1 ml, 0.03 M) and then added to 4N HC1 in dioxane (4N HC1 in Dioxane, 0.05 ml, 0.2 mmol, 6.6 eq) was added and stirred at room temperature overnight. After completion of the reaction, the residue was concentrated and purified by reverse phase column chromatography (0.1% formic acid in H2O / ACN) to obtain the title compound (0.001 g, 5.4%). iH NMR (400 MHz, MeOD) 5 8.75 (s, 1H), 8.29 (d, J = 8.1 Hz, 1H), 8.18 (s, IH), 8.12 (s, IH), 8.08 (d, J = 8.0 Hz, IH), 8.03 (d, J = 8.1 Hz, IH) , 7.99 (s, IH), 7.92 (s, IH), 7.85 (s, IH), 7.69 (s, IH), 7.59 (d, J = 7.9 Hz, IH), 7.48 (d, J = 10.3 Hz, 2H), 6.10 (s, IH), 4.78 (s, 2H), 4.72 (s, 2H), 4.34 - 4.29 (m, 2H), 3.76 (s, 3H), 3.41 (d, J = 6.0 Hz, 2H), 2.73 (s, 3H).

[0416] MS(ESI) m / e MH+ 611.08 Example 37: Synthesis of compound 247

[0417] Synthesis of N-(3-(1H-pyrazol-4-yl)propyl)-3-((4-fluorophenyl)ethynyl)-4-((oxazol-5-ylmethyl)sulfonyl)benzamide

[0418] Reagents and conditions: (a) oxazol-5-ylmethanol, SOCI2, DCM, 2 h (2 h) (b) methyl 3-iodo-4-mercaptobenzoate, K2CO3, DMF, room temperature (rt), 1 h (1 h) (c) mCPBA, DCM, room temperature (rt), 16 h (16 h) (d) PdChfPPhsh, Cui, TEA, ACN, room temperature (rt), 16 h (16 h) (e) NaOH, H2O, MeOH, room temperature (rt), 4 h (4 h) (f) 3-(1H-pyrazol-4-yl)propan-1-amine dihydrochloride 4- yl )propan—l— amine dihydrochloride) , TBTU, TEA, DCM, 12 h (12 h). Step 1) Synthesis of 5-(chloromethyl )oxazole Dissolve oxazol-5-ylmethanol (1 g, 10 mmol, 1 eq) in DCM (20 ml) and add 1.0 M thionyl chloride in dichloromethane (11 ml,

[0419] 11 eq) was slowly added dropwise. The temperature of the reaction mixture was raised to room temperature and stirred for 2 hours. The reaction mixture was concentrated under reduced pressure to obtain the target compound as a crude product. Step 2) Synthesis of methyl 3-iodo-4-((oxazol-5-ylmethyl)thio)benzoate

[0420] 5-(chloromethyl)oxazole (1 g, 6.5 mmol, 1 eq) was dissolved in DMF (13 ml) and K2C03 (1.79 g, 13 mmol, 2 eq) was added. Methyl 3-iodo-4-mercaptobenzoate (1.9 g, 6.5 mmol, 1 eq) was added to the reaction mixture and stirred for 1 hour. Water was added to the reaction mixture and extracted several times with a distilled water bath. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 40% EA / HX) to obtain the target compound (0.22 g, 9%). Step 3) Synthesis of methyl 3-iodo-4-((oxazol-5-ylmethyl)sulfonyl)benzoate Methyl 3-iodo-4-((oxazol-5-ylmethyl)thio)benzoate (0.22 g, 0.59 mmol, leq) was dissolved in DCM (5 ml), mCPBA (0.3 g, 1.17 mmol, 2 eq) was added, and the mixture was stirred for 16 h. The reaction was confirmed by TLC, and when the reaction was completed, water was added to dilute, and the mixture was neutralized with saturated NaHCOs aqueous solution and extracted several times with DCM. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The obtained residue was concentrated under reduced pressure to obtain the target compound as a crude product.Step 4) Synthesis of methyl 3-((4-f luorophenyl)ethynyl)-4-((oxazol-5-ylmethyl)sulfonyl)benzoate To methyl 3-iodo-4-((oxazol-5-ylmethyl)sulfonyl)benzoate (0.17 g, 0.41 mmol, 1 eq) was added MeCN (2 ml, 0.2 M) and TEA (0.074 ml, 0.53 mmol, 0.53 eq). PdC12[PPh3]2 (8.4 mg, 3 mol%) and CuI (2.3 mg, 3 mol%) were added to the reaction mixture and stirred at room temperature for 5 minutes under a nitrogen atmosphere. Then, 4-fluorophenyl-acetylene (0.06 g, 0.49 mmol, 1.2 eq) was added. The reaction mixture was stirred at room temperature for 16 hours and concentrated under reduced pressure. The obtained residue was purified by column chromatography (silica gel, 30% EA / HX) to obtain the target compound (0.05 g, 30.5%). Step 5) Synthesis of 3-((4-fluorophenyl)ethynyl)-4-((oxazol- 5-ylmethyl)sulfonyl)benzoic acid Methyl 3-((4-fluorophenyl)ethynyl)-4-((oxazol- 5-ylmethyl)sulfonyl)benzoate (0.05 g, 0.125 mmol, 1 eq) was added to MeOH (0.6 ml), H2O (0.3 ml), NaOH (0.012 g, 0.31 mmol, 2.5 eq) was added and stirred for 4 hours.The reaction was confirmed by TLC, and when the reaction was completed, the pH of the reaction product was adjusted to 1 with IN HC1 aqueous solution and extracted with Toyo. The organic layer was washed with water, dried over magnesium sulfate, and concentrated under reduced pressure to obtain the target compound. Step 6) N-(3-(1H-pyrazol-4-yl)propyl)-3-((4-fluorophenyl)ethynyl)-4-.

[0421] Synthesis of ((oxazol- 5 -ylmethyl)sulfonyl)benzamide (N- (3- (1H- pyrazol- 4- yl) propyl)-3-( (4- f luorophenyl)ethynyl)—4— ((oxazol— 5— ylmethyl)sulfonyl)benzamide)

[0422] 3-((4-fluorophenyl)ethynyl)-4-((oxazol-5-ylmethyl)sulfonyl)benzoic acid (0.05 g, 0.125 mmol, 1 eq) was added to DCM (2 ml) with TBTU (0.06 g, 0.19 mmol, 1.5 eq), TEA (0.064 ml, 0.46 nmol, 3.7 eq), 1-{imidazo[l,2— a]pyridin— 7-yl}methanamine hydrochloride (0.03 g, 0.15 mmol, 1.2 eq) was added and stirred for 12 hours. The reaction mixture was concentrated under reduced pressure, and the residue obtained was purified by column chromatography (silica gel, 5-10% MeOH / DCM) to obtain the target compound (0.053 g, 40.8%). iH NMR (400 MHz, DMSO) 6 12.55 (s, 1H), 8.89 (t, J= 5.6 Hz, 1H), 8.32 (s, IH), 8.27 (d, J = 1.2 Hz, IH), 8.06 — 8.00 (m, IH), 7.96-7.94 (m, IH), 7.74 (dd, J= 8.6, 5.5 Hz, 2H), 7.53 (s, IH), 7.39 (t, J= 8.8 Hz, 2H), 7.09 (s, IH), 5.19 (s, 2H), 3.34 — 3.28 (m, 2H), 2.48 (m, 2H), 1.80 (p, J = 7.2 Hz, 2H).

[0423] MS(ESI) m / e MH + 493.08

[0424] <Experimental Example> Experimental Example 1: NAMPT enzyme inhibition assay The NAMPT enzyme activity inhibition ability of the compound of the present invention was evaluated using the NAMPT Inhibitor Screening Assay Kit (# 7176-1) from BPS bioscience. Recombinant NAMPT protein was added to each well of a black 96-well 11-plate, and dilution buffer was added instead of NAMPT protein to blank wells. After adding a 5-fold concentrated compound solution, the mixture was pre-incubated at room temperature (approximately 22° C) for 30 minutes before starting the reaction to allow the compound and protein to bind before the enzyme reaction. At this time, the concentration of NAMPT protein was adjusted according to the enzyme activity of each protein lot within the range of 4-10 ng / u 1 for the final concentration, and the test compound was serially diluted at a ratio of 1:3 from 1000 nM to 3 nM, and experiments were conducted with n=2 for about 7 concentrations. A 2x concentrated assay buffer containing ATP (final concentration 20 yM), Nicot inamide (final concentration 20 uM), Phosphoribosyl pyrophosphate (PRPP, final concentration 40 |iM), and Ethanol (final concentration 1.5%) was added and the plate was incubated at 30°C for 2 h. The fluorescence of the resulting reactant was measured at excitation 340 nm and emission 460 nM. NAMPT enzyme activity (%) was calculated by subtracting the measurement of the blank well without NAMPT protein from the measurement of all wells and then taking the measurement of the control well without compound as 100%. IC50 was calculated using GraphPad Prism 9 software, and the results are shown in Table 2.

[0425] <Experimental Example 2> Cellular NAD measurement assay

[0426] The reduction of intracellular NAD+ and NADH levels due to the inhibition of NAMPT enzyme activity by compounds in HCT-116 cells was evaluated using the NAD / NADH-Glo™ Assay (Promega, G9072) from Promega. Cells were cultured in DMEM (Gibco, 11995-065) containing 10% FBS. Cells were dispensed at a density of 2,500 cells per well in a 96-well plate, and HCT-116 cells were cultured for 24 hours, and then treated with drugs using serum-free DMEM. First, the compounds were dissolved in 100% DMSO (Dimethyl sulfoxide), and then the compounds were diluted in the culture medium to a final concentration of 0.5% in DMSO for drug treatment. The final concentration of the compounds was 0.1 nM - 100 nM. Afterwards, it was cultured for an additional 24 hours at 37°C and CO25% conditions. NAD / NADH-

[0427] To perform the Glo™ Assay, the culture medium of drug-treated cells was removed, and 50 uL of DPBS was added per well and left at room temperature for 5 minutes. The required amount of NAD / NADH-Glo™ Detection Reagent (Reconstituted Luciferin Detection Reagent 1 mL, Reductase 5 u L, Reductase Substrate 5 u L, NAD Cyc 1 i ng Enzyme 5 u L, NAD Cyc 1 i ng Substrate 25 uL) was prepared according to the manufacturer's manual, and 50 uL was added per well. For cell lysis, the plate was incubated for 2 minutes at 400 rpm on a plate shaker, and then incubated for 30 minutes at room temperature and luminescence was measured. NAD+ / NADH levels were calculated by subtracting the measurement value of a cell-free blank well from the measurement value of all wells, and then using the 0.5% DMS0 treatment control as the 100% standard. IC50 was calculated using GraphPad Prism 9 software, and the results are shown in Table 2 below.

[0428] [Table 2]

[0429] In the above table, A, B, and are as follows.

[0430] NAMPT IC50 A: <0.5uM (less than 0.5uM) / B: <1UM (more than 0.5UM and less than lyM) /

[0431] C: >luM (greater than luM)

[0432] NAD IC50 A: <10 nM (Less than 10 nM) / B: <1 11M (More than 10 nM, Less than 1 yM) /

[0433] C: >1 11M (Exceeding 1 11M) As can be seen in the table above, the compounds of the present invention exhibit excellent inhibitory activity against NAMPT, and sufficient inhibitory activity even at low concentrations. Therefore, the compounds of the present invention may have excellent preventive or therapeutic effects on NAMPT-related diseases. As can be seen in the table above, the compounds of the present invention significantly inhibited NAD production in the HCT-116 cell line, and sufficiently suppressed the concentration of intracellular NAD even at low concentrations. Therefore, the compounds of the present invention inhibit NAMPT, and can sufficiently lower the concentration of NAD in cells even at low concentrations, and thus may have excellent preventive or therapeutic effects on diseases that can be treated by inhibiting NAMPT (e.g., cancer).

[0434] <Experimental Example 3> Tumor cytotoxicity assay

[0435] The anticancer efficacy of the compound of the present invention was evaluated in HCT116 colon cancer cell line using the MTT assay method. Cells were cultured using DMEM medium containing 10% FBS. HCT116 cells were distributed at a density of 2,500 cells per well in a 96-well plate, cultured for 24 hours, and then treated with drugs using serum-free DMEM. First, the compound was prepared in 100% DMSO (Dimethyl sulfoxide) at a concentration of 0.02 iiM - 200 iiM, and then the compound was diluted in the culture medium so that the final DMSO concentration was 0.5% and treated with the drug. The final concentration of the compound was 0.1 nM - 1000 nM. After incubation for an additional 72 hours under conditions of 37 °C and C025%, MTT (Sigma-Aldrich, M2128) was treated to confirm cytotoxicity. Formazan, which was produced by the reduction of mitochondria in living cells, was measured using a Spark® Multimode Microplate Reader TECAN instrument. Cell viability (%) was determined relatively by subtracting the reference 650 nm absorbance from the 570 nm optical density (OD) and taking the 0.5% DMSO-treated control as the standard (100%). The results were plotted as a function of compound concentration using GraphPad Prism 9 software to calculate the CC5o (50% cytotoxic concentration rat ion) value, and the results are shown in Table 3.

[0436] [Table 3]

[0437] In Table 3 above, A, B, and C are as follows.

[0438] A: CC 50 <30 nM (less than 30 nM)

[0439] B: 30 nM < CC5o <100 nM (more than 30 nM and less than or equal to 100 nM)

[0440] C: lOOnM

Claims

【Scope of Claims】 【 Claim 11 A benzamide derivative compound represented by the following Chemical Formula I, its stereoisomers, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof: <화학식 1> In the Chemical Formula I, 日 is aryl having 6 to 14 members; C2-C8 heterocycloalkenyl; or heteroaryl having 5 to 12 members, and the Ri inside may be unsubstituted or substituted with one or more 보 being halogen, NRaRb, N02 or 0H; Li is C1-C6 alkylene; L2 is a single bond; or C2-C6 alkynylene; 오 is arylene having 6 to 14 members; C2-C8 heterocycloalkenylene; or heteroarylene having 5 to 12 members, wherein one or more of the 오 inside may be unsubstituted or one or more of the 보 may be substituted with C1-C6 alkyl, CF3, halogen, - Cl-C6 alkoxy, or 0H, and the - CH2 - of the 오 may be unsubstituted or one or more of the - CH2 - may each independently be substituted with - (C=0)-, L3 is a single bond; C1-C6 alkylene; C2-C6 alkenylene; C=0; (C=O)NRc; (C=O)NRd- (C1-C6 alkylene); NRy(C=0)-(Cl-C6 alkylene); or 0(C=0)- (Cl-C6 alkylene); R2 is H, halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, C1-C8 heterocycloalkyl, - NRZIRZ2, aryl having 6 to 14 members or heteroaryl having 5 to 12 members, and the Ri inside may be unsubstituted or one or more of the inside may be substituted with C1-C6 alkyl, OH, COOH, (C1-C6 alkylene)- NReRf, NRgRh, N02, CF3, (C=O)NRiRj or halogen; lx is a single bond, C1-C6 alkylene, - NRm- (Cl-C6 alkylene)- or NRn; R3 is H, C1-C6 alkyl, C3-C8 cycloalkyl, 6-14 membered aryl, C1-C8 heterocycloalkyl, C2-C8 heterocycloalkenyl, 5-12 membered heteroaryl, 6-14 membered arylene-Cl-C8 heterocycloalkyl, 6-14 membered arylene-5-12 membered heteroaryl, 5-12 membered heteroarylene-6-14 membered aryl, 5-12 membered heteroarylene-Cl-C8 heterocycloalkyl or 5-12 membered heteroaryl, wherein the inside of R3 is unsubstituted or one or more of the insides are C1-C6 alkyl, C1-C6 alkoxy, phenoxy, OH, (C1-C6 alkylene)- OH, COOH, (C1-C6 alkylene)- COOH, (C1-C6 alkylene)- CN, NRoRp, (C1-C6 alkylene)- NRqRr, (C=0)-(Cl- C6 alkyl), (C=0)-(C3- C8 cycloalkyl), (C=0)-(6- to 14-membered aryl), 6- to 14-membered aryl, 6- to 14-membered heteroaryl, 6- to 14-membered heterocycloaryl, (C=O)NRsRt which may be substituted with halogen, (C=O)-(C1- C6 alkylene)- NRuRv, NRwRx, (C=0)0-(Cl- C6 alkyl), N02, CHF2, CF3, 0CF3 or halogen may be substituted, and the -CH2- of the heterocycloalkenyl of R3 may be unsubstituted or substituted with -(C=0)-, and Ra to Rj, Rm to Ry, Rzi and Rz2 are each independently H or C1-C6 alkyl. 【Claim 1, wherein the aryl is C6 - C14 aryl; C2 - C8 heterocycloalkenyl containing one or more heteroatoms or hetero functional groups selected from the group consisting of N, O, S, S(=O), and S(=O)2; or 5 - 12 membered heteroaryl containing one or more heteroatoms selected from the group consisting of N, O, and S, and wherein the Ri moiety is unsubstituted or one or more substituents may each independently be substituted with halogen, -NRaRb, -NO2 or -OH, Li is C1 - C6 alkylene, L2 is a single bond; or C2 - C6 alkenylene, and L3 is C6 - C14 arylene; C2 - C8 heterocycloalkenylene containing one or more heteroatoms or hetero functional groups selected from the group consisting of N, O, S, S(=O), and S(=O)2; or 5 - 12 membered heteroarylene containing one or more heteroatoms selected from the group consisting of N, O, and S, and wherein the X moiety is unsubstituted or, when the X moiety is C6 - C14 arylene or C2 - C8 heterocycloalkenylene, one or more substituents may each independently be substituted with C1 - C6 alkyl, -CF3, halogen, -C1 - C6 alkoxy or OH, and when the X moiety is C2 - C8 heterocycloalkenylene, -CH2 - is unsubstituted or at least one -CH2 - may be substituted with -(C=O)-, L3 is a single bond; C1 - C6 alkylene; C2 - C6 alkenylene; -C=O; -C(=O)NRc; -C(=O)NRd-(C1 - C6 alkylene); -NRyC(=0)-(C1 - C6 alkylene); -NHC(=O); or -OC(=O)-(C1 - C6 alkylene), R2 is H; halogen; -NRZ1RZ2; C1 - C6 alkyl; C1 - C6 alkoxy; C3 - C8 cycloalkyl; C1-C8 heterocycloalkyl containing one or more heteroatoms or hetero functional groups selected from the group consisting of N, 0, S, SO and S02; 6-14 membered aryl or 5-12 membered heteroaryl containing one or more heteroatoms selected from the group consisting of N, 0 and wherein the inside of said R2 is unsubstituted or one or more insides of R2 may be independently substituted with -C1-C6 alkyl, -C1-C6 alkoxy, -OH, -COOH, -(C1-C6 alkylene)- NReRf, -NRgRh, -N02, -CF3, - C(=O)NRiRj or halogen, L4 is a single bond; -C1-C6 alkylene-; -NRm-(Cl-C6 alkylene)-; or -NRn-, wherein the inside of L4 is unsubstituted or one or more insides of R2 may be independently substituted with -C1-C6 alkyl, R3 is H; C1-C6 alkyl; C3-C8 cycloalkyl; 6-14 membered aryl; C1-C8 heterocycloalkyl containing one or more heteroatoms or heterofunctional groups selected from the group consisting of N, 0, S, S0 and S(》; C2- containing one or more heteroatoms or heterofunctional groups selected from the group consisting of N, 0, S, S0 and S02 C8 heterocycloalkenyl; 5-12 membered heteroaryl comprising at least one heteroatom selected from the group consisting of N, 0 and ; 6-14 membered arylene-C1-C8 heterocycloalkyl (wherein said heterocycloalkyl comprises at least one heteroatom or hetero functional group selected from the group consisting of N, 0, S, S0 and S02); 6-14 membered arylene-5-12 membered heteroaryl (wherein said heteroaryl comprises at least one heteroatom selected from the group consisting of N, 0 and ; 5-12 membered heteroarylene-6-14 membered aryl (wherein said Heteroarylene comprises one or more heteroatoms selected from the group consisting of N, 0 and ); 5- to 12-membered heteroarylene-Cl-C8 heterocycloalkyl (wherein the heteroarylene may comprise one or more heteroatoms selected from the group consisting of N, 0 and , and the heterocycloalkyl comprises one or more heteroatoms or heterofunctional groups selected from the group consisting of N, 0, S, SO and S02);Or 5 to 12 membered heteroarylene-5 to 12 membered heteroaryl (wherein said heteroarylene or heteroaryl includes one or more heteroatoms selected from the group consisting of N, 0 and S), wherein the inside of R3 is unsubstituted or one or more of R3 is each independently - Cl- C6 alkyl, -C1- C6 alkoxy, -phenoxy, -OH, -(C1-C6 alkylene)- OH, -COOH, -(C1-C6 alkylene)- COOH, (C1-C6 alkylene) - CN, -NRoRp, (C1-C6 alkylene)- NRqRr, - C(=0)-(Cl- C6 alkyl), - C(=0)-(C3-C8 cycloalkyl), - C=(0)-(6 to 14 membered aryl), - N(》, -CHF2, -CF3, -OCFs, 6-14 membered aryl, 6-14 membered heteroaryl comprising at least one heteroatom selected from the group consisting of N, 0 and S, 6-14 membered heterocycloaryl comprising at least one heteroatom or heterofunctional group selected from the group consisting of N, 0, S, S0 and S02, - C(=O)NRsRt (wherein, the inside of - C(=O)NRsRt may be unsubstituted or one or more of the insides may be independently substituted with halogen), -C(=O)-(C1-C6 alkylene)- NRuRv, -NRwRx, or may be substituted with halogen, and when said R3 is heterocycloalkenyl, - CH2 - may be unsubstituted or one or more of - CH2 - may be independently substituted with -(C=0)-, and said Ra to Rj, Rm to Ry, Rzi and Rz』 are respectively in each case; 239 A benzamide derivative compound represented by the above formula I, which may independently be H or C1-C6 alkyl, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof. 【

3. In claim 1, the day is A benzamide derivative compound represented by the above formula I, wherein the innermost group of Ri may be unsubstituted or one or more of the outermost groups of Ri may be independently substituted with halogen, -NRaRb, -N02 or -0H, wherein Ra or Rb is each independently -H or Cl-C6 alkyl, a stereoisomer thereof, a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof. 【

4. In claim 3, the inner side of Ri is unsubstituted or one or more inner sides of Ri can be independently substituted with -NH2, -NO2, -NHCHs, -MOfeh or -0H. A benzamide derivative compound represented by the above chemical formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof. 【

5. In claim 1, Li is methylene (- CH『 ), ethylene (- CH2CH2- ), n-propylene (- CH2CH2CH2- ), isopropylene (- CHCH3 CH2 ), n-butylene (- CH2CH2CH2CH2- ), sec-butylene (- CHCH3CH2CH2- ), isobutylene (- CH2CHCH3CH2- ), n-butylene (- CH2CH2CH2CH2- ), sec-butylene (- CHCH3CH2CH2 - ), tert-butylene (- CCH3CH3CH2 - ), n-pentylene (- CH2CH2CH2CH2CH2 - ), or n-hexylene (- CH2CH2CH2CH2CH2CH2CH2- ), represented by the chemical formula I. Benzamide derivative compounds, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof. 【

6. In claim 1, M2 is a single bond or ethynylene (ethynylnene, Namely, the benzamide derivative compound represented by the above Chemical Formula I, its stereoisomers, their pharmaceutically acceptable salts, or their hydrates or solvates. 【

7. In claim 1 or 2, In case of , the inner may be unsubstituted or one or more inner may be independently substituted with C1-C6 alkyl, halogen, -C1-C6 alkoxy, -0H, or - CF3, and the inner may be substituted with 5 or more In the case where -CH2- is unsubstituted or at least one -CH2- can be independently substituted by - (C=0)- respectively, the benzamide derivative compound represented by the above Chemical Formula I, its stereoisomers, their pharmaceutically acceptable salts, or their hydrates or solvates. 【 Claim 8 According to claim 1, L3 is a single bond; C1-C6 alkylene; C2-C6 alkenylene; - (C=0)-; - (C=O)-NRc-; -C(=0)NRd-(C1-C6 alkylene)-; - NRyC(=O)- (C1-C6 alkylene); -NHC(=O): or - 0(C=0)-(C1-C6 alkylene), where Rc, Rd or Ry are each independently -H or C1-C6 alkyl. The benzamide derivative compound represented by the above Chemical Formula I, its stereoisomers, their pharmaceutically acceptable salts, or their hydrates or solvates. According to claim 8, L3 is a single bond; - (CH2)-; - (CH2)2; - (CH2)3; - (CH2)4-; - (CH2)5-; -(C=0)-NH(CH2)n; -NH(C=O)-; -NH(C=0)-(CH2)m; -(C=O)NH-; -(CH=CH)-CH2-; -0(C=0)CH2; or - (C=0)-, where n and m are each independently 1, 2, 3 or 4. The benzamide derivative compound represented by the above Chemical Formula I, its stereoisomers, their pharmaceutically acceptable salts, or their hydrates or solvates.

10. In claim 1, R2 is H; halogen; C1-C6 alkyl; C1-C6 alkoxy; -0H; 243 At this time, the inside of R2 is unsubstituted or one or more of the insides of R2 are each independently halogen, -C1-C6 alkoxy, -NH2, -OH, -CF3, -NO2, -C1-C6 alkyl, -(CH2) -NH2, -(CH2)2-NH2, -(CH2)3-NH2, -(C=O)NH2, -NHCH3, -NHCH(CH3)2, or -COOH, and the benzamide derivative compound represented by the above formula I, its stereoisomers, their pharmaceutically acceptable salts or their hydrates or solvates.

11. The benzamide derivative compound represented by the above formula I, its stereoisomers, their pharmaceutically acceptable salts or their hydrates or solvates according to claim 1 or 2, wherein L4 is a single bond; -C1-C6 alkylene-; -NRm-(C1-C6 alkylene)-; or -NRn-, where Rm and Rn are each independently -H or C1-C6.

12. The benzamide derivative compound represented by the above formula I, its stereoisomers, their pharmaceutically acceptable salts or their hydrates or solvates according to claim 11, wherein L4 is a single bond; - (CH2)-; - (CH2)2-; - (CH2)3-; - (CH2)4-; - (CH2)5-; -NH-; -NHCH2-; -NH(CH2)2-; -NH(CH2)3-; -CH(CH3)-; -CH2NH-; -(CH2)2NH-; or - (CH2)3NH-, and the inside of L4 is unsubstituted or at least one of the insides of L4 is each independently substituted with -C1-C6 alkyl.

13. According to claim 1, R3 is 244 and at this time, the inside of R3 is unsubstituted or one or more of the insides of R3 are each independently -C1-C6 alkyl, -C1-C6 alkoxy, -phenoxy, -OH, - (C1-C6 alkylene)-OH, - COOH, -(C1-C6 alkylene)-COOH, (C1-C6 alkylene)-CN, -NRoRp, (C1-C6 alkylene)-NRqRr, -C(=O)-(C1-C6 alkyl), -C(=O)-(C3-C8 cycloalkyl), -C(=O)-(aryl of 6 to 14 members), -W-CHF2, -CFs, -OCFs, —C(=O)NRsRt (wherein the — of —C(=O)NRsRt may be unsubstituted or each of one or more — may be independently substituted with halogen), -C(=O)-(C1-C6 alkylene)-NRuRv, -NRwRx, or may be substituted with halogen, and when R3 is heterocycloalkenyl, -CH₂ may be unsubstituted or at least one of —CH₂— may be independently substituted with -C(=O)-, wherein Ro, Rp, Rq, Rr, Rs, Rt, Ru, Rv, Rw or Rx is in each case independently H or C1-C6 alkyl, the benzamide derivative compound represented by the above formula I, its stereoisomers, its pharmaceutically acceptable salts or their hydrates or solvates.

14. According to claim 13, the inside of R3 is unsubstituted or at least one -H of R3 is independently -C1-C6 alkyl -C1-C6 alkoxy, -phenoxy, -OH, -CH2F, 246 -CHF2, -CFs, -OCFs, 할로겐, -(C=0)0CH2CH3, -(C=0)CH3, -(C=0)CH(CH3)2, - (C=0)CHCH3NH2, -NH2, -NHCHS, -N(CH3)2, -COOH, _(C=O)NH2, _(C=O)NHCH3, - (C=0)N(CH3)2, -N0 2I _(C=0)NHCH2CF3, -CH(CH3)OH, -CH2(CH3)OH, -CH2CN, -CH(CH3)CN, -C(CH3)CH2CN, -(CH2)2NH2, -(CH2)NH2, -(CH2)3NH2, -(CH2)4NH2, -(CH2)20H, — (CH2)0H, can be, and the above R3 In the case, -CH2- may be unsubstituted or at least one of -CH₂- may be substituted with -C(=O)-, the benzamide derivative compound represented by the above formula I, its stereoisomers, its pharmaceutically acceptable salts or their hydrates or solvates.

15. According to claim 1, the above formula I is a compound represented by the following formula 1-1, the benzamide derivative compound represented by the above formula I, its stereoisomers, its pharmaceutically acceptable salts or their hydrates or solvates: <Formula 1-1> In the above chemical formula 1-1, Ri, Li, X, L3, R2, L4, and R3 are as defined in claim 1.

16. At this time, the benzamide derivative compound represented by the above chemical formula I, wherein the inner part of Ri is unsubstituted or one or more of the groups can be independently substituted with halogen, - NH2, -N02, -NHCHS, - N(CH3)2 or -OH, a stereoisomer thereof, a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof.

17. In claim 15, Li is methylene (- CH2-), ethylene (- CH2CH2-), n-propylene (- CH2CH2CH2-), isopropylene (- CHCH3 CH'), n-butylene (- CH2CH2CH2CH2-), sec-butylene (- CHCH3CH2CH2-), isobutylene (- CH2CHCH3CH2-), tert-butylene (-CCH3CH3CH2-), n- Pentylene (- CH2CH2CH2CH2CH2-), or n-hexylene (- CH2CH2CH2CH2CH2CH2CH2-), etc., and specifically, methylene (- CH2-), ethylene (- CH2CH2-), n-propylene (- CH2CH2CH2-), isopropylene (- CHCH3 CH2), n-butylene (- CH2CH2CH2CH2-), n-pentylene (- CH2CH2CH2CH2CH2-), or n-hexylene (- CH2CH2CH2CH2CH2CH2CH2-), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, represented by the above chemical formula I.

18. or A benzamide derivative compound represented by the above formula I, wherein the above-described compound is unsubstituted or may be independently substituted with one or more -C1-C6 alkyl, halogen, -OH, -C1-C6 alkoxy, or -CF3, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof. 【Claim 1 is in claim 15, wherein the above In the case where, the is not substituted or one or more of the is each independently C1-C6 alkyl, halogen, -C1-C6 alkoxy, - 0H, or -CF3 which may be substituted, the benzamide derivative compound represented by the above formula I, its stereoisomers, their pharmaceutically acceptable salts or their hydrates or solvates. 【

20. The compound according to claim 15, wherein L3 is a single bond, -(CH2)-, -(CH2)2-, -(CH2)3-, -(CH2)4-, - (CH2)5-, -(C=0)-NH(CH2)n, -(C=O)NH-, or _(C=0)-, where n is 0, 1, 2, 3 or 4, the benzamide derivative compound represented by the above formula I, its stereoisomers, their pharmaceutically acceptable salts or their hydrates or solvates. 【

21. In claim 15, R2 is H; halogen; C1-C6 alkyl; C1-C6 alkoxy; - NH2; Wherein the is of the R2 is not substituted or one or more of the R2 is each independently halogen, -C1-C6 alkoxy, -NH2, or -C1-C6 alkyl which may be substituted, the benzamide derivative compound represented by the above formula I, its stereoisomers, their pharmaceutically acceptable salts or their hydrates or solvates 【

2. The compound according to claim 15, wherein 匕4 is a single bond; -(CH2)-; -(CH2)2-; -(CH2)3-; -(CH2)4-; - (CH2)5-; -NH-; -NHCH2-; -NH(CH2)2-; or -NH(CH2)3 -, 250 Wherein the is of the L4 is not substituted or at least one of the L4 is each independently -C1-C6 alkyl which may be substituted, the benzamide derivative compound represented by the above formula I, its stereoisomers, their pharmaceutically acceptable salts or their hydrates or solvates.

23. At this time, the inner side of R3 is unsubstituted or at least one of - of R3 is independently -C1-C6 alkyl, - Cl- C6 alkoxy, - NH2, -CFs, -OCFs, halogen, or Which may be substituted, the benzamide derivative compound represented by the above formula I, its stereoisomers, their pharmaceutically acceptable salts or their hydrates or solvates.

24. In claim 1, the chemical formula I is a compound represented by the following chemical formula 1-2, a benzamide derivative compound represented by the chemical formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof: <Chemical Formula 1-2> 251 In the above chemical formula 1-2, Ri, Li, X, L3, R2, L4, and R3 are as defined in claim 1. 【

25. In claim 24, in the chemical formula 1-2 The inner side of the above Ri is unsubstituted or one or more of the outer side is independently halogen (F, Cl, Br, or I), -NH2, -N0 2I -NHCHs, -N(CH3)2 or - 0H, wherein Li is C1-C6 alkylene, and the above , and at this time, the inner part of the above is not substituted or one or more inner parts are each independently C1-C6 alkyl, halogen (F, Br, Cl, or I), -OH, -C1-C6 alkoxy, or - CF3, which may be substituted with the above five 10th day of the lunar calendar, ... 、If it is 'that', — CH2 _ is not substituted or at least one - CH2 - can be independently substituted with - (C=0)-, and the above L3 is a single bond or C1-C6 alkylene, and X FJ R2 is H, halogen, - NH2, or . In this case, the - of R2 is not substituted or one or more of R2 is independently halogen (F, C1, Br or I), -C1-C6 alkoxy, - NH2, or -C1-C6 alkyl, L4 is a single bond, -C1-C6 alkylene-, - s ,N ☆r NH L / The R3 may be '우''', and in this case, the inside of the R3 may be unsubstituted or at least one inside of the R3 may be independently substituted with -C1-C6 alkyl, -C1-C6 alkoxy, or halogen, a benzamide derivative compound represented by the above formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

26. Compounds of Table A below, stereoisomers thereof, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof: [Table A] 【

27. ​​A pharmaceutical composition comprising a compound represented by the chemical formula I according to claim 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof. 304 【

28. A pharmaceutical composition according to claim 27, wherein the pharmaceutical composition exhibits NAMPT inhibitory activity. 【Claim 2: The pharmaceutical composition according to claim 28, wherein the pharmaceutical composition is a pharmaceutical composition for preventing or treating cancer. 【

30. A pharmaceutical composition according to claim 29, wherein the cancer is a solid cancer or a blood cancer. 【

31. The pharmaceutical composition of claim 30, wherein the cancer is one selected from the group consisting of skin cancer, melanoma, lymph node cancer, breast cancer, cervical cancer, uterine cancer, gastrointestinal cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, colon cancer, rectal cancer, oral cancer, brain cancer, head and neck cancer, throat cancer, testicular cancer, kidney cancer, pancreatic cancer, bone cancer, spleen cancer, liver cancer, bladder cancer, laryngeal cancer, nasal cancer, AIDS-related cancer, esophageal cancer, stomach cancer, gastric cancer, pancreatic cancer, colorectal cancer, virus-related cancer, nasopharyngeal cancer, vaginal cancer, vulvar cancer, penile cancer, Kaposi's sarcoma, Burkitt's lymphoma, T-cell lymphoma and Merkel cell cancer, multiple myeloma, acute and chronic leukemia, lymphoblastic leukemia, myelogenous leukemia, lymphocytic leukemia and myelocytic leukemia. 【Claim 3: A method for preventing or treating cancer by administering to a subject a compound represented by the chemical formula I according to claim 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, or a pharmaceutical composition according to claim 27.

33. 305 Use of a compound represented by the above formula I according to claim 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, or a pharmaceutical composition according to claim 27, for preventing or treating cancer.

34. Use of a compound represented by the above formula I according to claim 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, or a pharmaceutical composition according to claim 27 for use in the manufacture of an agent for preventing or treating cancer. 306

Citation Information

Patent Citations

  • Screening Methods of a Substance for Preventing or Treating a Joint Disease Using Nampt

    KR1020150014250A

  • Pyrrolopyrimidine compounds with anti-tumor activity as well as application thereof

    CN110078735A

  • Chemokine receptor modulators

    WO2008109154A1

  • Inhibitors of ion channels

    WO2008118758A1

  • Amide compounds, compositions and uses thereof

    WO2009110985A2